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1.1 INTRODUCTION 
 
Solid state chemistry, in its many facets, is the guiding principle for different projects 
carried out in this thesis. Most of the projects discussed here involve organic and 
pharmaceutical materials and some projects are based on metal-organic clusters and 
frameworks. All projects focus on the design, synthesis and characterization of these 
compounds in the solid state and emphasize the pharmaceutical applications of the 
methods developed and materials prepared. The objective of this introductory chapter is 
to discuss various condensed phases of matter used in pharmaceutical processing,1 and 
point to areas where the contents of this thesis make some contributions. Our work 
involves oriented crystal growth on surfaces that offer complementary functional groups, 
control of polymorphism using fluorous substrates that inhibit heterogeneous nucleation, 
preparation of binary cocrystals that use single- and multi-point hydrogen bonds, and 
synthesis of multicomponent solid solutions that contain a target molecule and several 
isosteric components. Crystals, polymorphs, solvates, neutral cocrystals, ionic cocrystals, 
and solid solutions are the various phases that we specifically prepared or fortuitously 
encountered in this work.2-6 In the following sections we highlight the properties of these 
phases and discuss their relevance in pharmaceutical development.  
 
1.2 MOLECULES AND MOLECULAR AGGREGATES 
 
Molecules are a collection of atoms bound together by covalent bonds. The assembly of 
molecules depends on their size, chemical composition, and three-dimensional structure. 
Molecules, when aggregate into macroscopic state, can adopt different structures and 
have different energies. The macroscopic forms that are homogeneous in chemical 
composition and physical state and that exhibit defined boundaries are called phases. 
Molecules exist as phases and the bulk properties of a given compound are defined by its 
phase structure and composition.  
 
In different phases, molecules are at different separations and orientations and participate 
in intermolecular interactions of different strength and geometry. These interactions, 
though weak, influence the material properties of a given compound; in the 
pharmaceutical realm, they determine the important traits such as solubility, 
bioavailability and long-term stability. Controlling the phase structure and composition is 
therefore an essential part in drug development. 
 
1.3 THE FOUR PHASES OF MATTER 
 
We generally consider matter to adopt one of the four possible phases: gases, liquids, 
mesophases and solids. In gases, molecules are far apart and their relative orientation and 
separation do not significantly affect macroscopic properties. In liquids, though the 
molecules are closer to each other than they are in gases, the relative orientation and 
separation of the components hardly affects the bulk properties of the liquids. In 
crystalline solids, molecules are locked into specific orientations and separations and 
changes in orientations and separations between components lead to different solid 
phases (polymorphs) with different macroscopic properties.  
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Mesophases possess some characteristics of liquids and some of solids. In liquids 
molecules have positional, orientational, conformational and vibrational freedom. In 
crystalline solids all freedoms but the vibrational one are absent. Mesophases are formed 
when certain freedoms are introduced into the solid state. For example, solids in which 
the components have (a) positional freedom result in liquid crystals, (b) orientational 
freedom result in plastic crystals, and (c) conformational freedom result in condis 
crystals. Together, liquid crystals, plastic crystals and condis crystals are called 
mesophases.7  
 
1.4 PHARMACEUTICALLY RELEVANT CONDENSED PHASES 
 
It is essential to understand the structures and energetics of phases to master their 
synthesis and control their properties. In previous section, we discussed the structural 
aspects of the phases. As the molecular motion and intermolecular separation decrease 
when one goes from gases, to liquids, to mesophases, and to solids, the packing order and 
intermolecular attraction increase in the same order. Thus, the more condensed the phases 
get the lower is their free energy. Crystalline solids are energetically the most stable of 
the phases and are most often used in drug development.8 Figure 1.1 shows some of the 
macroscopic forms used in pharmaceutical formulations. In addition to the phases 
discussed above, it contains the amorphous solid phase and multicomponent phases such 
as salts, solvates and cocrystals. Below we will discuss the properties of these distinct 
forms and their relevance in dosage design and our work.  
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Figure 1.1 Schematic representations of different forms that can be generated form an 
active pharmaceutical ingredient (API). Solid forms indicated in blue are traditionally used 
in pharmaceutical industry. Forms in yellow and pink have been proposed as new types of 
phases for drug formulations.  
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1.5 AMORPHOUS SOLIDS 
 
Amorphous solids, also called glasses, are condensed phases of matter that lack long 
range molecular order, but possess some short range order.9 Though amorphous solids are 
widely studied, little is known about their structure. Most of this structural information is 
obtained on inorganic glasses and that information is extended to organic amorphous 
materials. Amorphous solids are formed by kinetic pathways; they are metastable with 
respect to their crystalline counterparts. Glasses are generally prepared by cooling a 
material below its melting point and arresting the positions of molecules within this super 
cooled liquid. Pharmaceutical amorphous solids are prepared by methods such as spray 
drying, rapid solvent evaporation, temperature quenching, lyophilization, and mechanical 
compaction.9  
 
Amorphous solids have lower packing efficiency, higher molecular disorder and higher 
potential energy than crystals. Higher energy of amorphous solids leads to their lower 
stability but also to higher solubility, bioavailability and reactivity.10 The differences in 
energy between the two solid states often results in the transformation of the amorphous 
solid to the crystalline solid. This transformation is dictated by the kinetic barrier; higher 
the barrier the greater the stability of amorphous solids. The path to crystallization is 
often induced by humidity, temperature, pressure or some other external factor. The 
processes in the early development, lyophilization for example, often produce solids that 
are more amorphous than crystalline, and exhibit superior solubilities and 
bioavailabilities. In late stage development, however, purer and larger quantities of the 
drugs readily yield crystalline solids that exhibit inferior dissolution properties. 
Recognition and control of the solid phases are thus crucial in drug development. Figure 
1.2 shows different forms an API can adopt for use in formulations.  
 
cocrystal
(two-component)
crystal
(single-component)
amorphous solid
(single component)
molecular SS
(two-component)
supramolecular SS
(four-component)
solvate
(two-component)
 
Figure 1.2 Schematic representations of various solid state forms API (grey object). Pink 
circles represent solvent molecules and blue objects represent molecule that are isosteric 
with API. White, green and orange ovals represent molecules that can form hydrogen bonds 
with API to yield cocrystals or solid solutions. The term SS stands for solid solution. 
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1.6 CRYSTALLINE SOLIDS 
 
Crystalline solids, the most widely used condensed phases in pharmaceutical practice,8 
exhibit short range and long range molecular order. Short range order in crystals arises 
from specific, directional, and attractive interactions between complementary portions of 
molecules. Long range order results in a macroscopic phase with lowest potential energy. 
Crystals, with their periodic structures, lend themselves well to diffraction analysis and 
allow the determination of three-dimensional structures of molecules and intermolecular 
packing. From this data, one can glean information about molecular composition, 
conformation, and stereochemistry, and intermolecular interactions, packing patterns, and 
packing efficiency.11-13 Crystals are the most stable condensed phases and are most 
sought after targets in drug development. Extensive research has been done in areas of 
crystal growth, structure determination, and the design of crystal structures. In Chapter 2 
we discuss the importannce of heterogeneous nucleation in crystal growth and how it 
may impact the oriented growth of carbamazepine. The fields of crystal engineering5 and 
supramolecular chemistry13 enhanced our understanding that properties of a compound 
are dependent on molecular and supramolecular structure. In the following sections, we 
discuss various forms in which the single or multicomponent crystals can be obtained and 
how these forms affect the properties of the target compound.  
 
1.7 POLYMORPHS 
 
The ability of a chemical entity to crystallize in more than one solid state structures is 
known as polymorphism.2 An oft quoted statement asserts that every compound has 
different polymorphic forms, and the number of forms known for a given compound is 
proportional to the time and money spent in research on that compound.14 A well known 
example is ROY, a pharmaceutical intermediate that at the moment has seven reported 
polymorphs.15 It is estimated that about 30% of the pharmaceuticals exhibit 
polymorphism.3  
 
Polymorphs can exhibit different lattice structures or different molecular conformations 
or both. Conformational polymorphism refers to structures in which molecules exist in 
different conformations but retain the same packing arrangement. Packing polymorphism, 
exhibited by many rigid molecules, refers to crystals in which the components retain the 
same conformation but show different packing arrangements. Different polymorphs of 
the same molecule often exhibit very different properties and behave as different 
materials. They may show different thermodynamic, kinetic, spectroscopic, mechanical 
and physicochemical properties. This awareness is very important in fields where 
products are commercialized as crystalline solids (such as drugs, food additives, 
pigments, explosives). 
 
In pharmaceutical industry, thermodynamically most stable polymorphs are often chosen 
as final drug products because they are less likely to convert to other macroscopic phases. 
The disadvantage of this approach is that usually the most stable polymorph is the least 
soluble therefore shows the lowest bioavailability. When the most stable form is not 
indentified during the initial polymorph screening it may have devastating consequences 
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on the marketed drug. A well known example is the case of ritanovir (Norvir).16 During 
the formulation process only form I was discovered. After about two years on the market 
capsules containing ritanovir drug failed to dissolve due to the precipitation of new, 
thermodynamically more stable form of the drug (form II).  The difference in solubility 
of form I and form II is about five fold. The original drug formulation had to be taken 
back from the market and the new formulation had to be developed. This extreme 
example shows the importance of extensive work in the early development to identify all 
possible forms and their stabilities. We show in Chapters 3 and 4 a unique method that 
promotes the crystallization of more stable polymorphs under conditions that are 
favorable for the growth of less stable polymorphs. 
 
1.8 SOLVATES 
 
Besides single component polymorphs, organic compounds can also exist as solvates, 
salts and other multicomponent materials such cocrystals or solid solutions. Of practical 
interest are solid forms containing solvents, where solvent molecule is incorporated in the 
crystal lattice in a stoichiometric or a non-stoichiometric ratio. They are generally known 
as solvates but sometimes also called as pseudopolymorphs. Solvates are capable of 
bringing significant changes in properties compared to polymorphs of the API 
molecule.17-19  
 
During the drug development process pharmaceutical solids are exposed to solvents or 
solvent vapors. The most common solvent-based processes that lead to the formation of 
solvates in pharmaceutical industry are precipitation, crystallization, wet granulation or 
dissolution. The tendency of an API molecule to form solvates is highly related with its 
molecular structure, ability to form hydrogen bonds, and overall size and shape. A 
molecule that possesses greater number of hydrogen bond donors than acceptors (or vice 
versa) will show higher tendency to form solvates. In addition, the tendency of solvation 
increases with the size of the molecule and ionization.  
 
Nucleation of unsolvated crystals from solvent requires solute-solvent interactions to be 
replaced by solute-solute interactions. Relatively stable solute-solvent interactions may 
lead to formation of solvated crystals. An analysis of the Cambridge Structural Database 
(CSD) showed that water is most frequently met as solvate former due its abundance in 
atmosphere, its small size and its ability to behave as both hydrogen bond donor and 
acceptor.20 In general, more than 57% of drug molecules form polymorphs or solvates.6 
The antibacterial drug sulfathiazole forms an incredibly high number of solvates, over 
one hundred of them.21  
 
Solvates can be attractive candidates for drug development especially when they exhibit 
higher solubility compared to other solid state forms. In contrast, unintended hydrate 
formation can lead to decreased solubility in blood and failure of an otherwise potent 
drug. Solvates are common among drug substances and a better knowledge of solvent-
API interactions will help to understand and control complex behavior of molecules. 
Solvents, most often than not, included into crystal lattice by chance, not by choice. The 
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intended incorporation of a foreign chemical entity into a drug substance can lead to a 
neutral cocrystal, an ionic cocrystal or a salt. 
 
1.9 SALTS 
 
Drug discovery has gone through significant changes in the last decade. The increased 
use of combinatorial chemistry, computational modeling in drug discovery as well as the 
recent change in the in vitro biology screening method from manual screening of aqueous 
soluble drugs to high-throughput screening of compounds soluble in DMSO led to 
compounds with very low solubility. Newly proposed drugs typically tend to have larger 
molecular size and a greater number of hydrogen bonding groups, leading to a significant 
decrease in solubility. Consequently, targeted compounds have low aqueous solubility 
limiting their use for oral absorption.  
 
Polymorphs and solvates offer limited variation of solid forms of a given API. In case of 
insoluble drugs, crystal engineering approaches allow us to design new solid forms 
without altering the chemical activity of the compound. The most common method 
involves salt formation.22 To create a salt, a drug candidate must possess ionizable (acidic 
or basic) functional group. Typically, a stable salt is formed when the difference in pKa 
values between the acid and base is at least two units. Usually, preparation of drug salts 
significantly improves its aqueous solubility and bioavailability compared to the 
corresponding uncharged molecule making salts suitable choice for drug formulation. 
 
1.10 COCRYSTALS 
 
When a drug molecule is weakly basic or acidic, cocrystals (Figure 1.2) can be used as 
new alternatives to salts.23 There are many views on what constitutes a cocrystal.24 
According to one definition, at least two components of the crystal should interact 
through hydrogen bonding or other noncovalent interactions. An additional constraint 
proposed is that all components should be solids at room temperature.25 Cocrystals are 
described in literature under different names such as organic molecular compounds or 
complexes.26 Widely known examples of molecular complexes were reported a century 
ago, where derivatives of hydroquinone complexed with quinine were used to produce 
photographic films.  The term cocrystal itself was used for the first time in a 1963 
patent,27 where adducts of different phenols and amines were examined as photosensitive 
compositions to create colored images.  
 
Cocrystals can be designed by crystal engineering approaches.12 Typically molecules 
containing complementary functional groups that can form specific heteromeric synthons 
can crystallize together to give a cocrystal. Cocrystals significantly change the 
intermolecular interactions and modify crystal packing. Thus, cocrystals can be used to 
alter the physical and pharmaceutical properties of the drugs. Most of the small molecule 
drugs possess functional groups capable of forming hydrogen bonds, making them 
suitable candidates for cocrystallization. Formation of drug cocrystal provides new 
opportunity to design different solid forms with enhanced pharmaceutical properties 
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while the activity of the API is unchanged.28 In Chapter 5 we discuss the preparation of 
cocrystals and their utility in preparing supramolecular solid solutions.  
 
There are several recent examples that illustrate the utility of cocrystals in pharmaceutical 
phases.29-37 For example, nicotinamide (form of vitamin B-3) in the pure form of drug 
shows high hygroscopicity and deliquescent behavior under humidity. Crystalline adducts 
of nicotinamide and fatty acids in 1:1 ratio significantly improve the hygroscopic 
behavior of the drug.38 In the solid state nicotinamide molecules interact with each other 
through hydrogen bonding associated with amide groups, while fatty acids form 
heterosynthons with the pyridyl N-atoms of the drug. The acid-pyridyl synthon reduces 
the affinity of the drug towards water and hence improves its hygroscopicity.  
 
1.11 IONIC COCRYSTALS 
 
The distinction between salts and ionic cocrystals is related more to the way they are 
made than the charges on the components within them.32 Salts, traditionally, are formed 
by mineral acids or alkaline or other metal hydroxide bases.22 The counter ions in these 
traditional salts are spherical and often their location within a crystal is determined by 
close packing than specific directional interactions. Ionic cocrystals on the other hand are 
made with the specific objective of bringing together the participating molecules into 
particular local geometries. The components within these ionic cocrystals are typically 
connected by charge-assisted hydrogen bonds.  
 
O
OHN
(a)
O
OHN
δ−δ+
(b)
O
ON H
+ -
(c)
 
Figure 1.3 Representation of the molecular complexes where (a) proton transfer is absent, 
(b) proton is partially transferred, and (c) where proton is fully transferred. 
 
Ionic cocrystals can be distinguished by the location of proton between cocrystallized 
acid and base, where complete proton transfer occurs. Such proton transfer is absent in 
neutral cocrystals. It is generally proven that ionic cocrystals are formed if ∆pKa (pKabase 
– pKaacid is greater than 3, neutral cocrystals will mostly result if ∆pKa is less than 0, and 
if ∆pKa  is between 0 and 3 both can be obtained or cocrystals with partial proton transfer 
are formed. The extent of proton transfer is strongly influenced by ∆pKa values as well as 
crystalline environment (crystal structure). For the practical use in drug development both 
cocrystals and ionic cocrystals can be valuable. Ionic cocrystals are desirable in case 
where API solubility is an issue; solubility of ionized complex in water is generally 
higher. In cases where the dissolution rate is more important than solubility, cocrystals of 
API can be more beneficial. However, in some cases both cocrystals and ionic cocrystals 
may show almost identical physical properties. 
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1.12 SOLID SOLUTIONS 
 
Crystalline materials where the lattice sites are occupied with the random population of 
two or more components are called solid solutions (Figure 1.2).39 Most molecular 
complexes are prepared as cocrystals; to date only a small number of molecular solid 
solutions are reported. Traditionally, organic alloys are formed by molecules with similar 
shapes and sizes. Creation of an alloy of an arbitrary organic compound is extremely 
difficult because most organic molecules possess intricate shapes and participate in 
directional intermolecular interactions. 
 
Solid solutions can be interstitial or substitutional. The former are obtained when a 
second component is incorporated into the voids present in the crystals of the first 
component. In this work, we are interested in substitutional solid solutions, where the 
second component replaces the first component at random sites within its crystal. 
Extensive work carried out by Kitaigorodskii showed that organic substitutional solid 
solutions can be made when the participating components have the same shape, same size 
and adopt similar crystal structures.39 Owing to these restrictions, not every compound 
can form solid solutions; the restrictions are particularly stringent for pharmaceutical 
molecules. In Chapter 5 we present a new approach to prepare supramolecular solid 
solutions of any compound that is capable of forming cocrystals.40  
 
1.13 SUMMARY AND CONCLUSION 
 
Condensed phases of matter can exist as crystals, amorphous solids or mesophases. The 
differences in the molecular separations and orientations within these phases result in 
their different macroscopic properties. Controlling the phase obtained is therefore an 
important step in drug development. Polymorphs are crystalline materials of the same 
chemical entity with different structures. Our work in Chapters 3 and 4 describes 
suppression of nucleation as a new technique to control the crystal growth and enhance 
the yield of stable polymorphs. Crystalline solids can be single or multicomponent, and 
among the latter, salts and solvates have been studied for a long time and used 
extensively in marketed drugs. New forms of multicomponent phases include cocrystals 
and solid solutions; the utility of these phases in pharmaceutical formulations is slowly 
emerging in current research. Our work in Chapter 5 discusses a new method for the 
preparation of supramolecular solid solutions in which the properties of the resultant 
materials are finely tuned based on the nature and relative content of the components.  
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2  PARITY DEPENDENT FACE-SELECTIVE CRYSTAL GROWTH OF CARBAMAZEPINE ON SELF-ASSEMBLED MONOLAYERS 
 
 
 
 
 
 
 
 
n = even
{012}
n = odd
{101}
S
C
n
 
OO
H
Au
N
O
N
N
O
N
H
H
H
H
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
TH
IS
 P
AG
E 
LE
FT
 IN
TE
NT
IO
NA
LL
Y 
BL
AN
K
PARITY DEPENDENT FACE-SELECTIVE CRYSTAL GROWTH ON SAMS  17 
 
2.1 INTRODUCTION 
 
Most pharmaceuticals are developed and marketed as solids. Crystalline solids, owing to 
their long term stability, are used in pharmaceutical formulations in preference to 
amorphous solids.1 Consequently, fundamental understanding of crystallization and the 
control of crystal growth are critical in the early development of pharmaceuticals and 
their manufacturing. Much effort in pharmaceutical crystallization is centered on the 
manipulation of crystal size and shape, to control the chemical properties such as 
dissolution and mechanical properties such as flowability. Many pharmaceutical 
molecules, however, crystallize as polymorphs; that is, they adopt more than one solid 
state structure.2-3 Polymorphs exhibit different physicochemical properties and harnessing 
polymorphism is a prerequisite in establishing the control over crystal size, shape and 
other properties.4 In the next chapter, we will describe the methods that are currently used 
in the selective growth of polymorphs. In this chapter, we wish to explore heterogeneous 
nucleation as a means to control the crystal growth of polymorphic drugs.5 Crystals often 
grow on foreign substrates such as dust particles and the driving force for this 
heterogeneous attachment is best appreciated by an understanding of nucleation.6  
 
2.2 NUCLEATION  
 
We begin with an intuitive picture of nucleation occurring in solution. In a crystallization 
solution, solute molecules either as monomers or as small discrete assemblies act as 
crystal growth units. For simplicity, we assume that the molecules are spherical and that 
they assemble into progressively larger cubic clusters and ultimately into a crystal with 
simple cubic topology (Figure 2.1a). In these clusters, each spherical molecule assumes 
octahedral geometry and forms six noncovalent bonds with neighboring solute or solvent  
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Figure 2.1 (a) Schematic representation of nucleation. Molecules are represented as 
spheres. The numbers below the clusters show the number of bonds formed by the spheres; 
the numbers on the left indicate bonds within a cluster (volume contribution) and the 
numbers on the right indicate the interfacial bonds (surface contribution). The 3×3×3 
cluster represents a critical nucleus with radius r*. (b) Free energy of clusters as a function 
of the size of the cluster showing the volume and surface contributions, critical radius (r*), 
and nucleation barrier. This figure is adopted from reference 6. 
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molecules. An isolated solute molecule forms six bonds with solvent molecules and a 
2×2×2 cluster with eight molecules exhibits 12 solute-solute bonds and 24 solute-solvent 
bonds. The bonds between solute molecules hold the cluster together and the bonds 
between solute and solvent molecules tend to break the cluster apart. The former bonds 
represent the volume contribution in Figure 2.1b and the latter represent the surface 
contribution. As the cluster grows, the number of bonds within a cluster increase and 
after some critical size, these intra-cluster bonds dominate the bonds between cluster and 
the solvent molecules. In the hypothetical model depicted in Figure 2.1a, the 3×3×3 
cluster with 27 molecules represents the critical size in which the surface and volume 
contributions are equal (assuming that solute-solute and solute-solvent bonds are of equal 
strength). The cluster with this critical size is called the critical nucleus; clusters smaller 
than this nucleus are likely to dissolve back into solution and clusters larger than the 
nucleus are likely to grow into a crystal. 
 
Nucleation is the process of overcoming the critical nucleus and the energy required to 
overcome this critical size is represented as the nucleation barrier in Figure 2.1b. 
Homogeneous nucleation, therefore, does not ensue until the solution reaches a certain 
supersaturation that is enough to surpass the nucleation barrier. Another path to 
nucleation is to lower the nucleation barrier; this lowering can be achieved by decreasing 
the surface free energy of the nucleus at the cluster-solvent interface. Thus, clusters, 
when attached to foreign surfaces, can readily reach the critical size and grow beyond the 
critical nucleus. This phenomenon is termed as heterogeneous nucleation. 
 
2.3 CRYSTAL GROWTH BY HETEROGENEOUS NUCLEATION  
 
Biomineralization, the growth of minerals such as calcite and hydroxyapatite in living 
organisms, is mediated by specific interfacial interactions between proteins and growing 
crystal nuclei.7 The understanding that barrier to nucleation is lowered by foreign 
surfaces and that biomineralization involves specific interfacial chemical 
complementarity, inspired the idea of designer interfaces for crystal growth.8 A well-
known illustration of the engineered interfaces as templates for crystal growth is given by 
nucleation of ice at the Langmuir monolayers formed by long chain alcohols.9 Related 
work showed that oriented crystal growth of glycine on Langmuir monolayers formed by 
α-amino acid amphiphiles is mediated by chemical and geometric epitaxy at the 
interface.10 Several other substrates, Langmuir-Blodgett monolayers,8 silane mono-
layers,11-12 self-assembled monolayers (SAMs),13-25 and polymer and single crystal 
surfaces,26-29 have been extensively used for the crystal growth of organic and inorganic 
compounds. These studies showed that it is possible to control the orientation, size, and 
polymorphism of the growing compounds using interfacial molecular recognition. In this 
chapter, we are interested in using the thiol SAMs formed on gold as templates for the 
crystal growth of pharmaceutical compounds. Specifically, we will discuss the 
crystallization of carbamazepine on SAMs with –COOH groups at the interface and the 
dependence of growth orientation on even or odd number of methylene groups in the 
alkyl spacers within the SAMs.30 
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2.4 SELF-ASSEMBLED MONOLAYERS  
 
Long chain alkanethiol derivatives form structured two-dimensional monolayers (SAMs) 
when brought into contact with metal substrates such as gold and silver.31-32 Figure 2.2 
shows the two step process of the fabrication of thiol SAMs on gold. Thiol groups and 
gold atoms have high affinity for each other; they form strong Au–S bonds at the exposed 
gold surfaces. Formation of these bonds is the first step in the fabrication of SAMs; the 
Au–S bonds lower the surface free energy of the gold. In the second step, the long alkyl 
chains reorganize on the surface such that they establish an energy-minimized inter-
grooved packing. It is the self-organization of these alkyl chains that imparts the adjective 
self-assembled to the monolayers formed by alkanethiol derivatives. For the most part, 
{111} faces are exposed at the exterior surfaces of gold substrates because of their lower 
surface free energy compared to the other possible growth faces. Figure 2.3 shows a 
schematic illustration of the two-dimensional order of thiol SAMs formed on {111} faces 
of gold substrates. We can consider SAMs as two-dimensional crystals with their lattice 
parameters being determined by the lattice of underlying metal substrate. We will use 
these lattice parameters in our epitaxy calculations discussed in Section 2.12.  
 
adsorbatesubstrate
adsorption organization
(a) (b) (c)
 
Figure 2.2 Preparation of thiol SAMs on gold substrates (yellow rectangles). The 
adsorbates contain thiol groups (orange circles) for binding to gold substrates, alkyl or aryl 
spacers (grey strings) for self-assembly, and terminal groups (red circles) for desired 
surface chemistry. The process involves (a) immersion: submerging the substrate in a 
solution of adsorbates, (b) adsorption: formation of Au–S bonds at the surface of gold, and 
(c) self-assembly: organization of adsorbates to expose terminal groups at the interface.  
 
 
Figure 2.3 Cross-sectional diagram of a thiol SAM on the {111} face of gold. White 
circles represent the top layer of Au atoms in the substrate and the grey circles represent the 
S atoms of the SAM. Notice the periodic arrangement of grey circles (thiol molecules).  
 
20 CHAPTER 2  
 
The fabrication of thiol SAMs is simple and fast (Figure 2.2) and they offer a convenient 
way to tailor the surface properties. It is possible to manipulate the property of the surface 
by modifying the terminal functional groups while leaving the rest of the molecule 
unchanged. For example, hydrophobic or hydrophilic surfaces can be achieved by 
changing the terminal group of the monolayer from –CH3 to –COOH. 
 
malonic acid
HS(CH2)15CO2H on Au
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calcite
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calcite
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4-iodo-4'-nitrobiphenyl
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4-iodo-4'-nitrobiphenyl
HS-C6H4-C6H4-I on Au
nucleating plane (00-1)
200 µm
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Figure 2.4 Crystal growth on SAMs. (a) Oriented growth of calcite on micropatterned 
substrates that contain islands of protic SAMs surrounded by SAMs terminated with methyl 
groups.15 Note that different –COOH and –OH terminal groups promote the nucleation on 
different crystal planes. (b) Malonic acid crystallization on hydrogen bonding and 
hydrophobic SAMs. Note the higher nucleation density on SAMs exposing –COOH 
groups.25 (c) Oriented growth of a polar crystal based on –NO2⋅⋅⋅I– interactions on aryl 
SAMs exposing –NO2 or –I groups.21  
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2.5 SAMS AS TEMPLATES FOR CRYSTAL GROWTH  
 
The periodic structure, a high degree of order, and tailorable surface chemistry of SAMs 
made them attractive templates for crystal growth in many studies.13-25 Figure 2.4 shows 
some representative examples. Thiol SAMs containing alkyl spacers and exposing protic 
functional groups such as –OH, –COOH, –SO3H promoted the growth of calcite crystals 
on specific planes (Figure 2.4a).15 This growth is mediated by deprotonation at the 
interface, binding of Ca2+ ions to carboxylate or other anionic terminal groups, and 
growth of crystals by sequential attachment of Ca2+ and CO32- ions. The planes on which 
the nucleation took place are determined by the underlying geometry (Au, Ag or Pd) and 
the exposed functionalities (–COO-, –O- or –SO3-). Crystallization of malonic acid on 
thiol SAMs with alkyl spacers and –COOH, –CH3, or ester terminal groups showed that 
the nucleation density and growth orientation depend on the interfacial functional groups 
(Figure 2.4b).25 The –COOH groups, owing to their polar character and hydrogen 
bonding ability, showed higher rates of nucleation and promoted the growth of malonic 
acid crystals on {001} faces. 4-Iodo-4'-nitrobiphenyl crystallizes in an acentric space 
group and is an example of a polar crystal.33 Crystallization of this compound on thiol 
SAMs with aryl spacers revealed that oriented growth occurs on SAMs exposing –I or –
NO2 groups (Figure 2.4c).21 Goniometry and Beilstein tests for halogens revealed that 
crystal faces exposing –NO2 groups attach to the SAMs with terminal –I groups and vice 
versa. These examples illustrate that SAMs provide simple and versatile means for the 
templated growth of crystals and that heterogeneous nucleation of crystals can be 
mediated by ionic bonds, hydrogen bonds or other noncovalent bonds such as –NO2⋅⋅⋅I– 
interactions. 
 
2.6 PARITY OF ALKYL CHAINS AND ORIENTATION OF TERMINAL GROUPS  
 
The emergence of thiol SAMs formed on metal substrates as templates for heterogeneous 
crystal growth can be related to, among other things, their structural modularity. Figure 
2.5a shows the modular structure of a SAM. We and others have explored the variations 
in the nature of the terminal groups (e.g. NH2, SO3H), spacers (e.g. alkyl, aryl), and the 
metal substrates (e.g. Au, Ag) towards applications such as control of nucleation, 
formation of micropatterned crystals, interfacial enantioselectivity, and selective growth 
of polymorphs and semiconducting materials.25, 13-24 In this chapter we report the effect of 
another variable, the parity of alkyl chain, on the face-selective crystal growth of a drug 
polymorph.30 In general, the parity of an alkyl chain denotes whether the number of C-
atoms in that chain is odd or even. In Au-SAMs based on alkyl spacers, the terminal 
groups adopt two different orientations with respect to the SAM surface depending on 
whether the alkyl chain contains an even or odd number of methylene groups (Figures 
2.5b and 2.5c).34-35 While exploring the effect of synthetic surfaces on the polymorphism 
of pharmaceutical drugs (Chapter 3),24 we discovered that SAMs made of mercaptoun-
decanoic acid (1) and mercaptohexadecanoic acid (2) nucleate different faces of the P-
monoclinic polymorph (PMP) of carbamazepine (Section 2.7). These two SAMs have the 
same terminal groups; they differ in the parity of the alkyl chain. The SAMs with an even 
number of methylene groups between the thiol and terminal X groups, project the  
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Figure 2.5 (a) Schematic representation of a thiol SAM showing its structural modularity: 
different parts of the SAM (terminal group, spacer and the metal substrate) can be varied 
independent of each other. Idealized structures of thiol SAMs containing (b) even and (c) 
odd number of methylene groups. Notice the difference in the angles between C−X bonds 
and the SAM surface.  
 
terminal C–X bonds at ~45° with respect to the surface horizontal (Figure 2.5b).34 When 
the SAMs are made of alkyl chains with an odd number methylene groups (Figure 2.5c) 
the C–X bonds are projected at a steeper angle (~73°) with respect to the surface 
horizontal. We show here that the difference in the orientation of terminal groups is 
instrumental in determining the faces on which the PMP crystals grow on the SAMs.  
 
2.7 AMIDE DIMERS IN CARBAMAZEPINE POLYMORPHS 
 
Carbamazepine, a drug used in the treatment of epilepsy, trigeminal neuralgia, and other 
diseases, has been used as a model pharmaceutical in the preparation of cocrystals, 
prediction of crystal structures, and investigation of polymorphism and phase 
transitions.36-39 Of the four known polymorphs of this drug, the PMP and trigonal 
polymorphs can be crystallized from solutions, the former being more stable than the 
latter. In addition, carbamazepine readily forms a dihydrate (in the presence of water) and 
several solvates. One of the distinct features of the four polymorphs of carbamazepine is 
that they all contain amide hydrogen bonded dimers.38 Our hypothesis in this work is that 
the growth units (Figure 2.1a) for nucleation and growth of these polymorphs are dimeric 
assemblies of carbamazepine. The structures of PMP and the trigonal polymorph shown 
in Figure 2.6 reveal that these polymorphs are built from the packing of amide dimers. 
These two polymorphs have distinct morphologies; PMP crystallizes as blocks (see 
Figure 2.8 below) and the trigonal polymorph as needles. 
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(a) (b)
 
Figure 2.6 Crystal structures (a) P-monoclinic and (b) trigonal polymorphs of 
carbamazepine. Notice amide dimers formed by hydrogen bonds and the differences in the 
mutual packing of these dimers.  
 
2.8 PREPARATION AND CHARACTERIZATION OF SAMS 
 
We fabricated thiol SAMs on gold coated glass slides by immersing the slides in 1-3 mM 
ethanolic solutions of thiols 1 and 2, and 1-undecanethiol (3) and 1-hexadecanethiol (4) 
(Figure 2.7). Gold coated glass slides purchased from Evaporated Metal Films had two 
layers of metal coating: a ~50 Å thick chromium adhesive layer and a ~1000 Å thick gold 
layer. The slides had a thickness of 1 mm; we cut them into ~15 mm × 25 mm pieces and 
treated them with oxygen plasma for 30 sec in a plasma etcher. This plasma treatment 
helped in the removal of any organic contaminants adsorbed on the surface. After soaking 
the substrates for 8-16 hours in ethanolic solutions of SAMs, we removed the substrates, 
rinsed them with copious amounts of ethanol and dried them with a stream of nitrogen. 
We used freshly prepared SAM substrates for characterization and crystal growth 
experiments. We characterized the SAMs by contact angle goniometry, ellipsometry and 
grazing incidence IR spectroscopy; the results we obtained are in agreement with those 
reported in the literature. The measured contact angles had a maximum error of 2.5°: 
SAM-1 (28.2°); SAM-2 (26.4°); SAM-3 (94.3°); SAM-4 (98.6°); and bare gold (76.2°). 
The heights of SAMs measured with ellipsometry had a maximum error of 1.2 Å: SAM-1 
(13.1 Å); SAM-2 (22.2 Å); SAM-3 (18.5 Å); and SAM-4 (21.7 Å). 
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Figure 2.7 Schematic structures of the SAMs 1-4 showing two different terminal groups.  
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2.9 CRYSTALLIZATION OF CARBAMAZEPINE ON SAMS 
 
We used SAMs 1-4 as templates, and untreated gold slides (5), bare glass slides (6) and 
plasma treated glass slides (7) as controls. Substrates 6 and 7 are hydrophilic (contact 
angles 19.3±5.2 and 13.9±2.6° respectively) and they are expected to mimic the hydrogen 
bonding nature of the SAMs 1 and 2, but without the structural and orientational 
specificity of the SAMs. We dissolved carbamazepine in benzene and kept the solution at 
60 °C for about 20 minutes until its volume is reduced to reach a concentration of 25 
mM. We cooled the solution to room temperature and filtered it into 50 mL beakers (that 
contained the SAM substrates) such that each beaker is filled with ~15 mL of the 
solution. We covered the beakers with perforated aluminum foils and kept them in a 
desiccator. Inside the desiccator, freshly baked drierite (97% CaSO4 and 3% CoCl2) 
maintained the relative humidity at ~ 0%. Higher humidity levels (30-100%) can cause 
the crystallization of dihydrate in preference to the anhydrous forms. 
 
The solvent evaporated slowly under equilibrium conditions in the desiccator and crystals 
appeared on SAMs 1 and 2 in three to four days. We allowed the solvent to evaporate for 
three to four more days and carefully extracted the substrates from the solution. A small 
fraction of crystals (~5% on SAMs 1 and 2) fell off the surface during this withdrawal; 
these crystals did not bond strongly to the substrate and we assumed that they grew in 
solution and not on the substrate. We noticed a small number of crystals on hydrophobic 
SAMs 3 and 4; these crystals fell off during the withdrawal of the substrate. At the time 
of the withdrawal, the remaining solution in the beakers is fairly concentrated 
(supersaturated); removal of substrates from this solution led to the precipitation of a thin 
layer of carbamazepine on the slides and also on the crystals. 
 
We washed the substrates with small volumes of benzene to partially remove this 
precipitate and also to detach any weakly bound crystals. In the case of hydrophobic 
SAMs 3-4 and bare gold substrate, this washing removed one or two crystals that still 
remained on the substrates. On SAMs 1 and 2, however, this washing dissolved small 
portions (~ 2-5%) of the crystals and left trace amounts of precipitate around the crystals. 
We characterized this precipitate to be the trigonal polymorph (needle shaped crystals) by 
powder X-ray diffraction (PXRD) analysis. A small peak (at 2θ ≈ 9°) corresponding to 
this precipitated polymorph can be seen in the PXRD patterns of samples grown on 
SAMs 1-2 (see Figure 2.13 below). We confirmed from independent experiments that 
crystals of trigonal polymorph grow exclusively when supersaturated benzene solutions 
are subjected to rapid evaporation.  
 
2.10 ORIENTED CRYSTAL GROWTH 
 
We repeated the crystal growth experiments at least five times and in all the trials, 
crystals of PMP grew on SAMs 1-2 and little or no crystal growth occurred on substrates 
3-5. We will discuss the crystallization on glass substrates in Section 2.13. Examination 
of the SAM substrates under an optical microscope (Figure 2.8) revealed that crystals 
grow on different faces on SAMs 1 and 2. In order to test the facial selectivity across the 
whole surface, we analyzed the crystals with PXRD while they were still intact on the 
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substrate. We modified the sample holder for the PXRD such that the SAM substrate can 
be subjected to X-ray diffraction directly (Figure 2.9a). We collected the X-ray data in θ-
2θ mode; in this mode the diffraction is observed only from those planes that are parallel 
to the SAM substrate. 
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SAM-1 
(a) (b) (c)
 
Figure 2.8 (a) Morphology of the PMP calculated using the Bravais-Friedel-Donnay-
Harker theory. Symmetry independent faces are shaded with different colors. (b) 
Microscopic images of the crystals grown on SAMs 1 and 2. Scale bars = 1 mm. (c) View 
down (101) and (012) showing the relative orientation of crystal faces with respect to the 
growth planes. Color scheme is the same as in (a).  
 
The PXRD patterns of crystals grown on SAMs 1 and 2 show one strong diffraction peak 
in each case (Figures 2.9b and 2.9c). In the case of SAM-2, this peak corresponds to 
(101) indicating that crystals grow on their {101} faces on this SAM (Figure 2.9c). The 
only other peak at 2θ = 27.4° corresponds to the related higher index plane (202). In the 
case of SAM-1 the most intense peak corresponds to (012) suggesting that crystals grow 
on {012} faces on this SAM. Closer inspection of Figures 2.9b shows peaks 
corresponding to the related higher index plane and planes that are nearly parallel to 
(012) (see Figure 2.11 below). The rationale for the observed facial selectivity in crystal 
growth is discussed in Section 2.14. In the next section, we describe the PXRD method 
used in the analysis given above. 
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Figure 2.9 (a) Sample holder for the onboard diffraction analysis of crystals grown on 
SAMs. Experimental powder X-ray diffraction patterns of PMP crystals grown on (b) 
SAM-1 and (c) SAM-2. In (b) and (c), the hump at 2θ ≈ 17° is due to the diffraction from 
background; the circled peaks at 2θ ≈ 9° arise from the diffraction of trigonal polymorph 
precipitated during the handling of substrates.  
 
2.11 CALIBRATION OF POWDER X-RAY DIFFRACTION PATTERNS 
 
As shown in Figure 2.9a we developed a modified sample holder that can hold the SAM 
substrate such that the diffraction is observed only from those planes that are parallel to 
the SAM surface. We calibrated the diffraction from the new sample holder by 
comparing the X-ray diffraction patterns PMP powders spread on regular sample holder 
as well as on the gold slide of the new sample holder (Figure 2.10). 
  
The X-ray data collected on PMP powders spread on gold slides (with the modified 
sample holder) showed strong diffraction peaks from Au(111) at 2θ ≈ 38°. We used this 
Au(111) peak to calibrate the diffraction patterns obtained from the crystals grown on 
SAMs 1 and 2. This internal calibration allowed us to identify the peak positions with 
certainty. The sole peak from the trigonal polymorph (at 2θ ≈ 9°; Figure 2.11) also acted 
as a second, independent peak with which we could calibrate the diffraction patterns of 
crystals grown on SAMs 1 and 2. The images on the left in Figure 2.11 show the full-
scale diffraction patterns of crystals grown on SAMs 1-2. The images on the right in 
Figure 2.11 show the same patterns with the y-scale (intensity scale) expanded. 
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Figure 2.10 (a) Calculated and (b-c) experimental PXRD patterns of PMP crystals. The 
pattern in (b) is taken by placing the powdered PMP samples on a regular sample holder 
and the one in (c) by placing the sample on a gold slide in the modified holder. The peaks 
belonging to the Au substrate can be seen at 2θ ≈ 36.5, 38 and 44°. 
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Figure 2.11 Full-scale (a-b) and expanded (c-d) powder diffraction patterns of crystals 
grown on SAM-1 (top) and SAM-2 (bottom). The peaks labeled ‘trigonal’ correspond to 
the trigonal polymorph.  
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Crystals grown on SAM-2 show diffraction peaks from (101) and the corresponding 
higher index plane (202). No other peaks are seen even at this level of expansion 
indicating a very high degree of face-selective crystal growth on this SAM. Crystals 
grown on SAM-1 show diffraction peaks from (012) and the corresponding higher index 
plane (024); it also shows peaks related to several other planes that are nearly parallel to 
(012). This may indicate lesser degree of order in SAM-1, partial misalignment of the 
crystals during the growth, or during the benzene wash, imperfections in the substrate, or 
growth of crystals on these other planes. In any event, the intensity of the (012) peaks is 
much higher (100%) than the other peaks (4-8%) and SAM-1 indeed shows a high degree 
of selectivity for the growth of crystals on their {012} faces. It should be noted that 
occasionally (in two of the nine experiments) a small fraction of PMP crystals grew on 
their {101} faces on SAM-1 substrates. We will discuss the nature of chemical epitaxy at 
the growth interface in Section 2.14. In the following section, we explore the geometric 
epitaxy based on the lattice parameters of the growth planes and the underlying SAMs.  
 
2.12 GEOMETRIC EPITAXY BETWEEN SAMS AND GROWTH FACES 
 
We used the lattice matching program EpiCalc to determine geometric epitaxy.40 EpiCalc 
determines the lattice registry by rotating an overlayer lattice (b1, b2, β) on a substrate 
lattice (a1, a2, α) through a series of azimuthal angles (θ) (Figure 2.12).41 For each 
azimuthal angle, the program calculates a dimensionless potential V/Vo, whose value 
depends on the type of epitaxy between the two lattices (Table 2.1). 
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Figure 2.12 Schematic representation of (a) commensurate and (b) coincident epitaxy. 
Substrate lattice (a1, a2, α) is drawn in blue; overlayer lattices (b1, b2, β) are drawn in 
magenta or red. In (a) all the lattice points of overlayer reside on the lattice points of 
substrate. In (b) the vertices of a 3×3 supercell, not the basic cell, of the overlayer lattice 
reside on vertices of the substrate lattice.  
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Table 2.1 Relationship between the values of V/Vo and the type of epitaxy.41  
V/Vo Epitaxy Symmetry of Substrate Lattice  
1 incommensurate any 
0.5 coincident any 
0 commensurate non-hexagonal 
-0.5 commensurate hexagonal 
 
Commensurate epitaxy, an ideal form of epitaxy, involves the matching of every lattice 
point of the overlayer with the substrate lattice points (Figure 2.12a). Coincident epitaxy, 
less ideal but more common form of epitaxy, involves the matching of some lattice points 
of the overlayer with substrate lattice points. One way to look at coincident epitaxy is that 
a supercell (an integral multiple of basic unit cell; e.g., 3×3 supercell in Figure 2.12b) of 
the overlayer exhibits commensurate epitaxy with the substrate. It follows then that the 
smaller the size of the supercell greater is the epitaxial match between two lattices. If the 
two lattices do not exhibit commensurate or coincident epitaxy, they are said to be 
incommensurate. Table 2.1 shows the relationship between the values of V/Vo and the 
type of epitaxy. 
 
Table 2.2 Parameters for geometric epitaxy. Basic cell represents the unit cell of the 
crystal planes corresponding the macroscopic face under consideration. Supercell 
represents a nonprimitive cell obtained by extending the basic cell along b1 and b2 axes. 
The numbers in the multipliers column refer to the number of times b1 and b2 are 
multiplied to generate the supercell.  
basic cell super cell face b1 b2 β multipliers area (Å2) θ(°) V/Vo 
{002} 7.54 11.16 90.00 1×3 252.44 51.46 0.50 
{011} 7.54 17.83 92.23 2×1 268.67 58.90 0.50 
{101} 11.16 16.15 90.00 2×1 360.47 14.55 0.51 
{110} 13.46 13.91 91.60 3×1 561.47 46.41 0.50 
{012} 7.54 26.29 91.51 1×3 594.47 51.25 0.50 
{10-1} 11.16 15.49 90.00 4×1 691.47 41.22 0.68 
{11-1} 13.46 15.49 104.32 4×1 808.07 45.71 0.56 
 
All the SAMs have the same 2D lattice (a1 = a2 = 4.97 Å and α = 120°; Figure 2.3). We 
determined the 2D lattice parameters for all possible growth faces of PMP and listed 
them as basic cell parameters in Table 2.2. We performed epitaxy calculations for each of 
these faces against the substrate SAM lattice with a 0.01° increment in θ, and allowed 
each overlayer lattice vector (b1 and b2) to be multiplied four times at the most. We 
analyzed the results to obtain the values of θ corresponding to the best lattice match along 
with other related parameters (Table 2.2). These results indicate that five of the seven 
possible faces of PMP exhibit coincident epitaxy. The {101) and {012} faces on which 
the PMP crystals grew on SAMs 1 and 2 are part of the five faces, suggesting that crystal 
growth on these faces is not hampered by geometric incommensurate epitaxy.  
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2.13 CARBOXY TERMINATED SAMS VERSUS PLASMA TREATED GLASS SLIDES 
 
Figure 2.13a shows a microscopic image of the crystals grown on SAM 2. As mentioned 
above, washing of the substrates with benzene led to the partial dissolution of the 
crystals; this is the reason some of the crystal faces are not as well defined as expected. 
This image is selected to show the precipitation of trigonal polymorph around the PMP 
crystals grown on the SAMs. We also carried out crystallizations of carbamazepine on 
glass slides and plasma treated glass slides placed in 50 mL beakers. The plasma treated 
slides are highly hydrophilic and expose silanol groups at the interface. We wished to test 
if surface hydrophilicity or hydrogen bonding groups without the orientational specificity 
and geometric structure can lead to face selective crystal growth. As can be seen from 
Figure 2.13b face-selective crystal growth is not observed on glass slides, at least to the 
exclusive extent seen on SAMs 1 and 2. Powder X-ray diffraction also revealed that the 
crystals grown on glass slides or plasma treated glass slides gave multiple diffraction 
peaks with no consistency between different trials. 
 
(a) (b)
 
Figure 2.13 Optical microscopic images of crystals grown on (a) SAM-2 and (b) plasma 
treated glass slide. Notice in (a) smaller, needle like crystals that belong to the trigonal 
polymorph. This image was taken from the experiment where the number of trigonal 
polymorph crystals precipitated was high. Notice in (b) various growth orientations of PMP 
crystals. Scale bars = 2 mm. 
 
2.14 PARITY DEPENDENT FACE-SELECTIVE CRYSTAL GROWTH 
 
The major difference between SAMs 1 and 2 is the parity of alkyl chains. As shown in 
Figure 2.5 the terminal groups in these two SAMs adopt different orientations with 
respect to the growth surface. The carboxy groups on SAM-2 are nearly perpendicular to 
the surface; in SAM-1 they are at a shallower inclination with respect to the surface. Why 
do PMP crystals nucleate from different faces on SAMs 1 and 2? The relative orientation 
of the amide group of PMP with respect to the (012) and (101) planes suggests a possible 
answer to this question. 
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Figure 2.14 Relative orientation of carbamazepine dimers with respect to (012) and (101) 
planes. Notice the shallow inclination of amide dimer in (a) and near perpendicular 
arrangement in (b). 
 
In the crystal structure of PMP, molecules assemble into dimers through hydrogen 
bonding between the amide groups. It is reasonable to assume that molecules form 
hydrogen bonded dimers in solution and that these dimers assemble further into nuclei 
and crystals. The amide H-atom not involved in the formation of dimer and the second 
lone pair of amide O-atom are capable of participating in hydrogen bonds with the 
carboxy groups at the SAM interface. The angle between the amide dimers and (012) 
plane is 43°; the corresponding anlge for (101) plane is 73° (Figure 2.14).42 It is 
instructive to compare these angles (43° and 73°) with the angles at which the carboxy 
groups are projected at the surface of SAMs 1 and 2 (~45° and ~73°; Figure 2.5). The 
carboxy groups on SAM-1 are coplanar with the amide groups at (012) planes, whereas 
the carboxy groups on SAM-2 are coplanar with the amide groups at (101) planes. Given 
that hydrogen bonding between carboxy and amide groups is greatly facilitated when the 
two groups are coplanar, it is likely that PMP crystal nuclei interact with SAM-1 through 
their {012} faces and with SAM-2 through their {010} faces.  
 
2.15 CONCLUSION 
 
The parity of alkyl chains is rarely used as a tool to control interfacial phenomena.43-44 In 
this work, we showed that the parity of alkyl chains does play a determining role in the 
face-selective nucleation of organic compounds. Further work showed that this oriented 
growth can be extended to other carboxy terminated SAMs with even or odd number of 
metheylene groups. Thiol SAMs containing hydroxy terminal groups did not show this 
level of specificity; often these SAMs showed peaks corresponding to (101), (012) and 
some other planes irrespective of the parity of the alkyl chains. These results suggest that 
the two-point hydrogen bond recognition between the carboxy groups and the amide 
dimers exert greater influence over interfacial molecular recognition compared to the 
hydrogen bonds formed by hydroxy groups.  
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3.1 POLYMORPHISM 
 
Polymorphs are crystalline materials that have the same chemical composition but 
different solid state structures. The differences in structures of polymorphs lead to 
differences in their properties.1 Though polymorphism affects a range of compounds, 
control of polymorphism is acutely important in pharmaceuticals because changing the 
polymorph can alter the dissolution rate, bioavailability, shelf-life and other properties of 
a drug.2-4 Consequently, early discovery of polymorphs is vital to drug development, both 
to avoid late-stage manufacturing problems5 and to protect intellectual property.1 In this 
chapter, we describe a generic method that directs the growth of thermodynamically 
stable polymorphs under conditions that favor the formation of kinetic polymorphs. Our 
method uses an iconoclastic concept – suppression of nucleation at xenophobic interfaces 
– to hamper the nucleation of kinetic polymorphs and promote the growth of 
thermodynamic polymorphs.   
 
Extensive research on polymorphism has resulted in (a) classification of different types of 
polymorphs, (b) development of analytical methods for characterization of polymorphs, 
(c) understanding of the physics and chemistry underlying phase transitions, (d) 
computational approaches for the prediction of polymorphism, and (d) control of bulk 
properties of crystals. Very little work, however, has been done in the area of selective 
growth of polymorphs.6 Below, we will give various methods that are being developed 
and practiced in the crystallization of polymorphs. Some of these methods are advanced 
to the extent that they are commercialized and some are still in the conceptual stage. 
These methods illustrate the current interest in studying the polymorphism. More 
broadly, these methods recognize polymorphism as an opportunity and a challenge to 
develop new concepts that are relevant to crystal growth and solid state chemistry.7  
 
3.2 HIGH-THROUGHPUT SCREENING  
 
Changing solvents, solvent mixtures, temperature, rate of evaporation and rate of cooling 
are the traditional approaches towards the discovery of polymorphs.8 These classical 
methods have recently been automated into a high-throughput screening (HTS) system.9 
Most pharmaceutical industries now use the HTS routinely and several recent examples 
illustrate the success of this approach. For example, a study involving a number of 
different solvent combinations and local temperature conditions resulted in the discovery 
of an elusive third polymorph of acetaminophen.10 The principal advantage of HTS 
method is that it is generic. It can be applied to any compound with limited or no 
knowledge of its molecular or crystal structures and properties. Further, it uses small 
quantities of compounds to carry out a large number of experiments in a short time 
period. Yet, the HTS is a trial and error method and relies mostly on the probability of 
finding a target polymorph rather than following a designed approach. 
 
3.3 ISOMORPHIC ADDITIVES  
 
Remarkable examples of polymorphic control are offered by marine organisms that can, 
for example, selectively grow a specific polymorph of CaCO3 (calcite or aragonite).11-12 
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These examples demonstrate the specific recognition between growing crystal planes and 
macromolecules in biological matrices. Extending these ideas to synthetic systems, tailor-
made auxiliaries have been prepared to intervene in the kinetics of crystallization so as to 
control crystal morphology and polymorphism.13 A small percentage of additives that are 
structurally similar to the target material can incorporate preferentially into specific 
growth planes and impede the growth in particular directions. Similarly, isomorphic 
additives can be designed such that they block the growth of the stable polymorph and 
promote the growth of a metastable polymorph.14-15 Though harnessing crystallization 
through additives is an attractive area of research, only a few examples have been studied 
so far.16-17 One limitation in the design of additives is that it requires prior knowledge of 
the crystal structures of the polymorphs. 
 
3.4 MONOLAYERS AS SUBSTRATES  
 
Crystallization is often mediated by heterogeneous nucleation, which can occur on the 
surfaces of dust particles, glass vials, or foreign templates.18 Biomineralization inspired a 
number of studies to explore the nucleation and crystal growth at interfaces. Monolayers 
of amphiphilic molecules at air-water interface,19-20 monolayers of organosilane 
derivatives,21-23 and thiol self-assembled monolayers (SAMs)24-25 on metal substrates 
have all been used in the past twenty years to examine and control the early stages of 
crystal growth.26-28 These studies showed that face selective crystal growth is 
predominant in many systems, indicating that molecular level interactions between 
substrate and growing nucleus are responsible for such selectivity. The results of these 
studies suggested the possibility of controlling the growth of polymorphs using tailor-
made surfaces. Polymorphs have different crystal structures and it may be possible to 
glean crystal planes specific to one polymorph and provide surface templates that 
promote the nucleation of these planes. Some recent reports, published by our group and 
others, showed that SAMs can indeed nucleate polymorphs based on specific interfacial 
interactions.29-33 
 
3.5 SINGLE CRYSTALS AS SUBSTRATES 
 
Freshly cut single crystal surfaces are best examples of two-dimensional templates. 
Recent research using faces of freshly grown single crystal substrates showed that a 
multimorphic pharmaceutical intermediate grows as a metastable polymorph on certain 
faces of pimelic acid crystals.34 Crystalline substrates lend themselves well to the 
geometry matching programs that can be used to find close matches between 
crystallographic planes of the substrate and polymorphic crystals.35 Nucleation of one 
crystal on another36-40 has important implications in the growth kinetics of polymorphs.38 
For example, it is possible that a fast growing polymorph can nucleate on a slow growing 
(but fast nucleating) polymorph.39 Such outcomes point to the importance of control of 
nucleation and growth of desired polymorphs. The practical limitation of these substrates 
is that it is difficult to identify and prepare crystals that can act as templates and that do 
not tend to dissolve in solutions. 
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3.6 POLYMERS AS SUBSTRATES 
 
Polymer chemistry, one of the most matured fields in chemical sciences, affords the 
ready availability of different types of polymers with a variety of functionalities 
incorporated into the backbone. Recently, polymer chunks are used in a high throughput 
setting to screen for polymorphism in pharmaceuticals and other compounds.41-43 For 
example, when acetaminophen is crystallized from solutions containing 84 different 
polymers, about one third nucleated the metastable orthorhombic form, one third the 
stable monoclinic polymorph, and the rest a mixture of both forms.41 These studies 
indicate that a one-to-one matching of complementary molecular units at the interface 
may not be necessary for templated growth, but more likely profusion of a set of 
functional groups and certain charge density can nucleate specific polymorphs. These 
results provide us with the impetus to explore the use of silane monolayers crafted on 
glass slides and vials as substrates for polymorph discovery and selection. 
 
3.7 CRYSTALLIZATION INSIDE CAPILLARIES 
 
Crystallization in confined spaces can also lead to the selective growth of polymorphs. In 
bulk solutions (of volume mL to L) density fluctuations and impurities such as dust 
particles lower the nucleation barrier for crystallization, and thermodynamically stable 
polymorph can grow at the expense of other metastable polymorphs. When solutions are 
confined to volumes as small as nanoliters the fluctuation and contamination effects are 
minimized and the solution can continue to evaporate under quiescent conditions to reach 
high supersaturations. Under these conditions the nuclei of kinetic polymorphs have 
greater chances of survival, that is, they do not dissipate and convert to the 
thermodynamically stable polymorph. Recent work using glass capillaries for crystal 
growth showed that it is indeed possible to grow the kinetically stable polymorphs of 
pharmaceutical compounds in reproducible manner.44-45 
 
3.8 CRYSTALLIZATION INSIDE NANOSCALE CHAMBERS 
 
Often, but not always, different polymorphs have different morphologies. One can 
assume that crystal nuclei of such polymorphs have morphologies similar to the fully 
grown crystals. Crystallization of the corresponding compounds in confined nanospaces 
can lead to the growth of one polymorph over the other based on its fit with respect to the 
nanochamber. Initial proof for this concept came from a recent work, which showed that 
crystallization of anthranilic acid in nanoporous glass results in polymorph selection 
based on the shape of the nanocavities.46 Further work showed that this approach can be 
extended to other systems as well.47 
 
3.9 LASER INDUCED NUCLEATION 
 
Supersaturated solutions of certain organic compounds yield different polymorphs when 
they are illuminated with intense pulses of lasers.48 The type of polymorph obtained is 
determined by the nature of the polarization of the laser. This laser induced nucleation 
depends on the level of supersaturation but not on the wavelength used. It is argued that 
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the interaction of the laser with pre-nucleation clusters is different for linearly and 
circularly polarized lights.49 Linear alignment of molecules occurs in the presence of 
linearly polarized light and circularly polarized light results in the planar alignment of 
molecules in the clusters. Though laser induced nucleation is still in its infancy, it is an 
attractive alternative to other methods discussed here because it offers a generic, 
contaminant-free nonchemical approach to influence the crystallization of polymorphs.  
 
3.10 SONOCRYSTALLIZATION 
 
Sonocrystallization refers to the crystallization under the influence of ultrasonic sound in 
a pulsed or continuous format, typically in the range of 20 kHz to 5 MHz. Ultrasound 
assisted crystallization has been practiced for several decades. Ultrasound imparts 
nonchemical disturbances to the sample; it is found to increase the rate of nucleation and 
decrease the metastable zone width.50 In the past, ultrasound is often used to induce 
nucleation, reduce the crystal size and narrow the particle size distribution. Recent results 
suggest that it is possible to influence the crystallization of polymorphs using 
ultrasound.51-53 In addition, the homogenizing effect of ultrasound can be used to promote 
the formation of cocrystals and solid solutions where multiple components are required to 
be brought together at a molecular level.  
 
3.11 CONTACT LINE CRYSTALLIZATION 
 
It is common observation that precipitation occurs at the solvent front when a saturated 
solution is evaporated in a vessel. Recent work showed that, kinetic polymorphs that have 
lower nucleation barrier can crystallize at this solvent front.54-55 Once formed, crystals of 
the metastable polymorph can stay stable and not transform to the stable polymorph 
because they are not in touch with the solution. This process of crystal growth at the 
evaporating solvent front is termed as contact line crystallization.  
 
3.12 HIGH PRESSURE CRYSTALLIZATION 
 
Different polymorphs have different densities and it should, in principle, be possible to 
influence the polymorphism by changing the applied pressure on crystallization solution. 
Indeed, recently it has been shown that new polymorphs and solvates of acetaminophen, 
piracetam and other compounds can be grown in high pressure (up to 100 GPa) 
chambers.56-59 While some high pressure polymorphs are not stable at standard 
conditions, the ability to grow crystals at high pressures and determine their structures is 
relevant to the understanding of phase transitions that can occur during pharmaceutical 
processes such as comminution and compression.60 
 
3.13 DISAPPEARING POLYMORPHS 
 
In previous sections, we discussed different methods that are being explored for 
polymorph selection. To underscore the importance of the method discussed in this 
chapter, it is important to recall one of the well-known but strange phenomena of 
crystallization, the disappearing of polymorphs.61 In most cases, the reason for the 
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vanishing of an existing crystal form is attributed to the formation of a new, 
thermodynamically more stable polymorph. The most devastating effect of this 
phenomenon is seen in ritanovir, an anti-retroviral drug used in the treatment of AIDS. 
This drug had to be recalled after being on the market for two years because a more 
stable form with markedly lower dissolution rate started to crystallize at the 
manufacturing sites. The initial formulations contained the now metastable, but then only 
known, modification that readily transformed to the more stable polymorph. Fortunately, 
a new formulation of the drug that contains the stable polymorph could be developed and 
marketed, but only after much work and time.5 The phenomenon of disappearing 
polymorphs and the case of ritanovir illustrate the importance of the discovery of all 
possible, and especially the stable, polymorphs of a given drug at an early stage in the 
discovery. We show in this chapter that fluorous surfaces can act as nucleation inhibitors 
of kinetic polymorphs and thereby allow the growth of stable polymorphs through the 
process of Ostwald ripening.  
 
3.14 FLUOROUS SURFACES 
 
The term fluorous is coined, as an analogue of aqueous, to represent fluorinated media 
with hydrophobic and oleophobic properties.62 Today, the adjective fluorous refers to 
species that are highly or completely fluorinated saturated organic molecules or 
molecular fragments. Fluorous species are immiscible with their organic and aqueous 
counterparts and as such they offer new avenues for chemical synthesis. There is 
immense interest in fluorous species towards applications in separations, scavenging, 
catalysis, passivation, and biomaterials.63 We are interested in fluorous surfaces in this 
work and we prepare them in the form of silane monolayers bearing polyfluoroalkyl 
chains, -(CH2)2-(CF2)n-CF3. Exposure of substrates with hydroxy groups (such as 
hydrolyzed glass slides with Si–OH groups) to silanizing reagents (such as X3SiR; X = Cl 
or alkoxy) results in nucleophilic displacement reactions at the surface. These reactions 
lead to Si–O–Si bonds at the interface and to a monolayer of molecules connected to each 
other as well as to the surface (Figure 3.1).24  
 
R-SiCl3
silanizationglass
OH
Si
OH
Si
OH
Si
(a) (b)
R = -(CH2)2(CF)7CF3
R = -(CH2)2(CF)5CF3
glass
Si
O
O
Si
O
O
Si
O
Si Si Si
R RR
 
Figure 3.1 Schematic structures of (a) a hydroxylated surface showing silanol groups and 
(b) fluorous surface showing silane monolayers.  
 
Silanizing reagents are brought into contact with the substrates either in the vapor phase 
or in solution.64 The amount of water in the solution affects the reaction on the surface 
and excess amounts of water leads to bulk polymerization in the solution. Generally, only 
small amount of water is required for reactions at the interface. We assume in this work 
that the trace amounts of water adsorbed on the hydrophilic glass surface is enough to 
42 CHAPTER 3  
 
promote the reaction. Compared to thiol SAMs formed on gold, silane monolayers are 
not well-packed and less ordered but display greater chemical and thermal stability (up to 
125 °C). They are stable in organic solvents and in acidic media but slowly degrade in 
basic media. In this work, we used trichlorosilanes because of their high reactivity 
compared to the trialkoxysilanes. As the -R groups, we used the fluorous chains -(CH2)2-
(CF2)5-CF3 and -(CH2)2-(CF2)7-CF3; these polyfluoroalkyl (or perfluoroalkyl if we 
consider the fluorous part) groups are more reactive than their alkyl counterparts and they 
can form silane monolayers even in the absence of water.65 The perfluoroalkyl chains 
afford fluorous surfaces that are xenophobic, making them good candidates for testing the 
inhibition of nucleation at the interfaces. 
 
3.15 PROMOTION VERSUS INHIBITION 
 
It is important to distinguish our work with fluorous surfaces from the previous work 
carried out with other types of surfaces. Both methods attempt to influence the 
polymorphism by controlling the heterogeneous nucleation. Previous work with different 
kinds of surfaces (Langmuir and silane monolayers, thiol SAMs, and single crystal and 
polymer surfaces) attempted the growth of polymorphs by promoting the nucleation 
through complementary functional groups and attractive interfacial interactions. In most 
of these cases, the selective growth of polymorphs is based on serendipity or prior 
knowledge of the crystal structures or a high-throughput approach. Save for the high 
throughput method, these approaches are highly specific to a given compound.   
 
Our work with fluorous surfaces attempts to grow the stable polymorphs by inhibiting the 
nucleation (of kinetic polymorphs) through xenophobic functional groups and 
unattractive interfacial interactions. Our approach does not require prior knowledge of 
the crystal structures of polymorphs and it is generic and applicable to any compound that 
itself is not fluorous or does not contain fluorous fragments. Interfacial repulsion is a 
well-practiced phenomena in nature (e.g., Lotus leaf) and domestic and commercial 
products (e.g., Teflon). The fluorous surfaces we use have the same amorphous structure 
and the xenophobic characteristics as Teflon. Our fluorous surfaces are optically 
transparent, thermally stable, and inexpensive; they can be made on any glass substrate.  
 
3.16 NITROFURANTOIN 
 
We chose nitrofurantoin, an antibiotic active against many urinary tract pathogens, as a 
model pharmaceutical to demonstrate the unique ability of the fluorous surfaces in the 
selective growth of stable polymorphs. Earlier work from our group showed that among 
eight different silane monolayers (with different head groups and spacers) perfluoroalkyl 
monolayers showed a high degree of selectivity in the crystal growth of indomethacin 
polymorphs.66 The two polymorphs of indomethacin have completely different structures, 
morphologies, and densities; the difference between their lattice energies is large so 
differentiating the stable polymorph from the metastable form using fluorous surfaces is 
relatively easy. In this work, we wished to select a system that is dimorphic in which the 
two polymorphs have practically similar lattice energies. We surmised that such a system 
will test the true efficacy of the method discussed here.  
SUPPRESSION OF NUCLEATION AT FLUOROUS INTERFACES  43 
 
 
O
N
N NH
O
O
O2N
α-polymorph β-polymorph
stable
space group: P1
m.p.: 275 °C
density: 1.656 g.cm-3
Ulatt: -8771 kJ.mol-1
metastable
space group: P21/n
m.p.: 270 °C
density: 1.648 g.cm-3
Ulatt: -8733 kJ.mol-1
_
 
Figure 3.2 Molecular structure of nitrofurantoin and the important solid state properties of 
its two polymorphs. Density, melting point and crystal structure data for the polymorphs 
are taken from reference 67. We calculated the lattice energies using the Universal Force 
Field incorporated in the GULP module of the program Materials Studio. 
 
Nitrofurantoin is a planar molecule (Figure 3.2) and derives its name from the two five-
membered rings it contains, furan and hydantoin. It crystallizes in two solid state 
structures;67 α-polymorph is slightly more stable than the β-polymorph. Both polymorphs 
are reported to have near similar densities and melting points; both adopt layered crystal 
structures (Section 3.22) and have near similar lattice energies (Figure 3.2).68 Most 
crystallization conditions produce the β-polymorph readily and it is this less stable form 
that is used in the marketed products. Yet, the α-polymorph is reported to have better 
dissolution characteristics (Figure 3.3) which can decrease the side effect emesis seen in 
some patients.69 These findings amplified our interest in developing a method that yields 
the stable α-polymorph exclusively under conditions favorable for the growth of 
metastable β-polymorph. Nitrofurantoin absorbs light in the visible region (λmax: 366 nm) 
and gives pale-yellow to orange-red solutions depending on concentration. The intensity 
of the solution color is proportional to its concentration and we follow the changes in 
concentration visually, gravimetrically, and spectroscopically to assess the rate of 
crystallization in vials exposing highly hydrophilic or xenophobic surfaces. 
 
 
Figure 3.3 Mean powder dissolution rates for α- and β-polymorphs of nitrofurantoin. 
Adopted from reference 69.  
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3.17 PLASMA TREATMENT OF GLASS SUBSTRATES 
 
We used 1 dram glass vials for crystallization and glass microscope slides as controls to 
test the surface properties. We cleaned these substrates (slides and vials) with water and 
dried them prior to plasma oxidation. Glass is made of amorphous silica and contains 
surface siloxy and silanol groups. Treating the glass substrates with oxygen plasma 
removed surface contaminants and increased the content of hydroxyl groups. We 
oxidized the substrates with oxygen plasma for 30-40 seconds using the SPI Plasma Prep 
II etcher that operated at 13.56 MHz under a 200 micron vacuum. The substrates are 
highly reactive when they are taken out of the plasma etcher and atmospheric humidity 
helped the formation of surface silanol groups (Figure 3.1a). To avoid any other surface 
reactions, we used these vials for crystallization experiments immediately after plasma 
treatment.  
 
3.18 FABRICATION OF FLUOROUS MONOLAYERS 
 
We fabricated silane monolayers with fluorous head groups by treating the plasma-
oxidized glass substrates with silanizing reagents Cl3Si-(CH2)2-(CF2)5-CF3 or Cl3Si-
(CH2)2-(CF2)7-CF3. Initial experiments in this work used the surfaces with –C6F13 and  
–C8F17 groups. The results obtained from both monolayers are qualitatively similar. From 
here on, we only report the results obtained with fluorous monolayers that exposed  
–C6F13 groups at the interface. 
 
We prepared ~1 mM solutions of the silanizing reagents in dichloromethane and quickly 
transferred these solutions into plasma treated vials until they are filled. To keep the 
solutions away from atmospheric moisture, we capped the vials and allowed the 
silanization to take place for about ninety minutes. We monitored the vials throughout 
this time and discarded any vials that showed excessive cloudiness, which is an indication 
of disproportionate bulk polymerization. Shorter times may lead to incomplete surface 
polymerization and longer reaction times typically lead to multilayers on the surface. In 
our work, the length of silanization (that is, formation of surface monolayers or possible 
multilayers) did not affect the outcome of our crystal growth experiments. Once the 
solution treatment is complete, we rinsed the vials thoroughly with dichloromethane 
followed by ethyl acetate to remove any unreacted silane monomers. We baked the vials 
in an oven at 100-110 °C for three hours to complete the reaction between any dangling 
silanol groups at the interface of glass and silanizing reagent.  
 
We assumed that the fabrication of silane monolayers on the glass substrates is complete 
(Figure 3.1b) after the heat treatment. These monolayers showed distinct wetting 
behavior characteristic of perfluorinated surfaces. Contact angle measurements (Figure 
3.4) showed that the water droplets bead on the fluorous monolayers (θ = 105°) and fully 
spread on the plasma treated glass (θ = 0°). We use these highly hydrophilic vials as the 
sticky substrates and the fluorous vials as nonstick substrates. We expect the vials with 
surface silanol groups to promote the nucleation of kinetic polymorph and the vials with 
fluorous surfaces to inhibit any nucleation at the interface. We refer to the former 
substrates as hydroxylated vials and the latter as fluorous vials. 
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(a) (b)
 
Figure 3.4 Spreading and beading of one microliter droplet of water on (a) hydroxylated 
and (b) fluorous surfaces. The image in (a) is taken a fraction of a second after the drop is 
placed; within a second the droplet spreads completely on the surface and becomes 
invisible to the camera.  
 
3.19 CRYSTAL GROWTH IN HYDROXYLATED AND FLUOROUS VIALS 
 
At the beginning of each series of crystal growth experiments, we prepared a large 
quantity of 21 mM nitrofurantoin solution in acetonitrile. We started with 17-19 mM 
solution and heated it at 60 °C for 15-20 minutes until its volume is reduced to give the 
required 21 mM concentration. We transferred this freshly prepared solution to ten 
hydroxylated and ten fluorous 1 dram vials until each one of the vessels is filled to a third 
of its height (~ 1.8 mL). To control the rate of evaporation, we covered the vials with 
perforated aluminum foils or closed them with screw-caps containing a set number of 
holes.  
 
α
0.5 mm 0.2 mm
β
 
Figure 3.5 Experimental crystal morphologies of α- and β-polymorphs of nitrofurantoin 
grown from 21 mM acetonitrile solutions.  
 
In fluorous vials, one or two initial crystals of the α-polymorph appeared at the bottom of 
the vessels after 70-75 hours when 35-50% of the solution had evaporated. The solution 
is fully evaporated in both vials in 120-140 hours. Crystals in the fluorous vials had thick 
tabular morphology, orange color, and sizes in the range 0.5-1.2 mm (Figure 3.5). In 
hydroxylated vials, multiple crystals of the β-polymorph appeared on the walls, at the 
solvent front, within 4-6 hours. As the evaporation continued, more crystals of the β-
polymorph grew along the moving solvent front (Figure 3.6). In stark contrast, no crystals 
are seen on the walls of fluorous vials (Figure 3.6) in hundreds of crystallization 
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experiments carried out in this work. Crystals on the walls of hydroxylated vials had thin 
plate-like morphology, pale-yellow color, and smaller sizes in the range 0.01-0.5 mm 
(Figure 3.5). These experiments are repeated at least eight times using 21 mM solutions 
of nitrofurantoin and the results obtained are similar. We characterized the materials 
formed at various locations in the vials using optical microscopy, infrared (IR) and 
Raman spectroscopy, single crystal and powder X-ray diffraction (PXRD) analysis, 
differential scanning calorimetry (DSC) and thermal gravimetric analysis (TGA). 
 
(a) (b)
(c) (d)
 
Figure 3.6 Crystallization of nitrofurantoin in fluorous (left) and hydroxylated (right) vials. 
(a-b) Side views of the vials showing clean walls of fluorous vials and crystal-laden walls 
of hydroxylated vials. (c) View perpendicular to the bottom of the fluorous vial showing 
crystals of α-polymorph. (d) Magnified view of the wall of hydroxylated vial showing 
crystals of β-polymorph. 
 
3.20 VISUAL OBSERVATIONS 
 
The color of nitrofurantoin solution and optical transparency of glass vials allowed us to 
visually monitor the progress of crystallization. Figure 3.7 shows three distinct stages 
during the evaporation of solutions in hydroxylated and fluorous vials. At the onset of 
crystallization (Figure 3.7a), freshly transferred solutions in both types of vials are pale-
yellow in color and show opposing wetting behavior in vials with different surfaces. The 
concave menisci in hydroxylated vials indicate that the solution wets the walls of these 
vials. In contrast, the menisci are flat in fluorous vials; the solution does not wet the walls 
of fluorous vials confirming the xenophobic nature of these surfaces.  
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Figure 3.7 Monitoring of crystal growth in hydroxylated (left two) and fluorous (right two) 
vials. Notice the differences in the menisci in two types of vials in top two images and 
darkening of solution color in fluorous vials in the middle image. Notice the crystal growth 
on the walls of hydroxylated vials. 
 
An image taken after 48 hours of evaporation (Figure 3.7b) shows two important 
characteristics of crystallization. First, crystal growth occurs on the walls of hydroxylated 
vials as solvent evaporates and nothing crystallizes on the walls of fluorous vials. Second, 
the solutions in different vials show markedly different colors indicating different 
concentrations of the remaining solutions. In hydroxylated vials the solution turns slightly 
orange (or dark-yellow) compared to the beginning. In fluorous vials, however, the 
solution displays an intense orange-red color with a much higher concentration of 
nitrofurantoin. These observations can be explained by the suppressed nucleation and 
crystal growth on the walls of the fluorous vials, which lead to a higher remnant 
concentration.  
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Following the evaporation further, we observed that some crystals are formed in the bulk 
solution in fluorous vials (as well as in hydroxylated vials) that sank to the bottom and 
continued to grow. At the completion of the evaporation (Figure 3.7c), crystals are found 
only at the bottom of fluorous vials; on the hydroxylated vials crystals are found on the 
walls and at the bottom. Characterization of the crystals using various techniques 
described below confirmed that while the stable α-polymorph crystallized selectively in 
fluorous vials the metastable β-polymorph crystallized in hydroxylated vials. 
 
3.21 IR AND RAMAN CHARACTERIZATION OF POLYMORPHS 
 
We collected the IR spectra of polymorphs on a Spectrum One FT-IR Spectrometer 
(Perkin Elmer) equipped with an ATR (attenuated total reflectance) accessory. 
Acquisition of ATR-IR spectra is fast and uses a small amount (1-2 mg) of sample. The 
two polymorphs of the nitrofurantoin showed distinguishable IR absorptions (Figure 3.8); 
thus we used IR spectroscopy as the first technique to characterize the products of 
crystallization. 
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Figure 3.8 IR Spectra of α- (top) and β-polymorphs (bottom) of nitrofurantoin grown in 
fluorous and hydroxylated vials.  
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We used the overall pattern as well as several characteristic bands to distinguish between 
the polymorphs and assess the hydrogen bond strengths in the solid state. The N-H 
stretching vibrations of the imide group result in a relatively broad band with a peak at 
3140 cm-1 in α-polymorph and a narrower band at 3279 cm-1 in β-polymorph. The N-H 
out-of-plane bending absorptions are observed at 740 cm-1 in α-polymorph and at 713 
cm-1 in β-polymorph. The differences in the stretching and bending frequencies infer 
different hydrogen bond interactions of the N-H groups in the two polymorphs. The N-H 
group in α-polymorph participates in stronger N-H···O interactions (dN···O: 2.85 Å, θN-H···O: 
171°) than in β-polymorph (dN···O: 2.82 Å, θN-H···O: 155°; see Section 3.22 for more 
details).70 Stronger hydrogen bonding interactions shift the stretching frequencies to the 
lower value (due to the lengthening of N-H covalent bond) and bending frequencies to 
the higher value (due to strengthening of H···O noncovalent bond).  
 
The differences in hydrogen bonding can also be observed in the C=O stretching 
frequencies. Both α- and β-polymorphs show strong bands for C=O groups at 1719 cm-1 
and 1728 cm-1 respectively. Lower stretching frequency indicates longer C=O bond in the 
α-polymorph, again attributed to stronger hydrogen bonding. The broadness of the C=O 
band in the β-polymorph is due to the significantly different C=O distances, 1.22 and 
1.19 Å. The corresponding C=O distances in the α-polymorph are 1.21 and 1.20 Å. The 
longer C=O bond in each corresponds the carbonyl group that participates in hydrogen 
bonding. The differences in IR absorption intensities and positions allowed the quick 
identification of the two polymorphs of nitrofurantoin. 
 
We collected the Raman spectra of two polymorphs on a DXR Raman Microscope 
(Thermo Scientific). Raman spectroscopy does not require sample preparation; it is 
complementary to IR spectroscopy and provides information on molecular vibrations. 
The high sensitivity of this technique allows the detection of small changes in vibrational 
frequencies that may occur due to changes in conformations or crystalline environment. 
Figure 3.9 shows the Raman spectra of α- and β-polymorphs of nitrofurantoin.  
 
The main differences between the two polymorphs are seen in the positions and relative 
intensities of -NO2 group and C=N bonds. The -NO2 stretch occurs at 1342 cm-1 in α-
polymorph and 1347 cm-1 in β-polymorph. This small shift may be attributed to the 
different N-O distances arising from C-H⋅⋅⋅O-N interactions in the crystals. There are also 
noticeable differences in the relative peak intensities in the fingerprint region. For 
example, an intense band associated with C=N appears at 1609 cm-1 for α-polymorph; 
the same band is relatively weak in the β-polymorph and appears at 1608 cm-1.  
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Figure 3.9 Raman Spectra of α- (top) and β-polymorphs (bottom) of nitrofurantoin grown 
in fluorous and hydroxylated vials.  
 
3.22 SINGLE CRYSTAL X-RAY DIFFRACTION ANALYSIS 
 
The two polymorphs of nitrofurantoin had similar morphologies, PXRD patterns (Section 
3.23), and thermograms (Section 3.24). In order to unequivocally assess the identity of 
the polymorphs, we characterized their structures by single crystal X-ray analysis. We 
selected the crystals suitable for diffraction under a microscope and mounted them on a 
kapton loop or mesh using a small amount of paratone or mineral oil. We collected the X-
ray data using Mo-Kα radiation (λ = 0.71073 Å) on a Bruker APEX II diffractometer 
equipped with CCD detector and Oxford Cryostream Plus low-temperature device. Table 
3.1 lists the parameters for data collection and structure refinement.71  
 
Nitrofurantoin molecules adopt planar conformations in both α- and β-polymorphs. 
Molecules pack into layers in both cases (Figure 3.10); hydrogen bonds are seen within 
the layers and van der Waals and pi-stacking interactions are seen between the layers. 
Though layers are separated by shorter distances in the β-form, stronger stacking 
interactions between furan and hydantoin rings are seen in the α-polymorph. Despite the 
differences in the intralayer and interlayer arrangements, the overall packing efficiencies 
of both polymorphs are almost identical (Table 3.1). 
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Table 3.1 Crystallographic data for α- and β-polymorphs of nitrofurantoin. The 
temperature of data collection is given as T. Packing coefficient, Ck*, is calculated using 
the program PLATON.72 
 α β 
Emp. formula C8H6N4O5 C8H6N4O5 
Formula wt. 238.17 238.17 
Crystal system triclinic monoclinic 
Space group P-1 P21/n 
a (Å) 6.7903(3) 7.6783(6) 
b (Å) 7.6026(4) 6.4505(5) 
c (Å) 9.7657(5) 18.7849(16) 
α (°) 106.993(2) 90 
β (°) 103.841(2) 91.910(5) 
γ (°) 92.355(2) 90 
V (Å3) 464.78(4) 929.88(13) 
Z 2 4 
Dcalc (Mg/m3) 1.702  1.701 
F (000) 244 488 
µ 0.145 0.145 
R1 0.0350 0.0367 
wR2 0.1006 0.1031 
GoF 1.050 1.036 
N-total 5926 15027 
N-independent 2902 2956 
N-observed 2590 2422 
N-parameters 158 178 
T (K) 100 100 
θ range 2.26-30.93 2.83-31.03 
Index ranges 
-9 ≤ h ≤ 9 -11 ≤ h ≤ 11 
 
-5 ≤ k ≤ 10 -8 ≤ k ≤ 9 
 
-14 ≤ l ≤ 14 -27 ≤ l ≤ 27 
Crystal size (mm3) 0.40×0.37×0.20 0.25×0.16×0.16 
Crystal shape prism plate 
Crystal color orange yellow-orange 
Solvent CH3CN CH3CN 
Ck* 0.751 0.749 
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Figure 3.10 Interlayer packing in α- (top) and β-polymorphs (bottom) of nitrofurantoin.  
 
Within the layers, molecules form head-to-head hydrogen bonded dimers in the α-form 
and head-to-tail catemers in the β-form (Figure 3.11). The dimers and catemers are 
further linked by C−H⋅⋅⋅O interactions to form two-dimensional networks. We mentioned 
in the previous section that IR spectra suggest that α-polymorph exhibits stronger 
N−H⋅⋅⋅O hydrogen bonds than the β-polymorph. In this context, it is interesting to look at 
the geometrical parameters of the N−H⋅⋅⋅O hydrogen bonds. One of the quick indicators 
of the hydrogen bond strengths is the distance between the donor and acceptor atoms (in 
this case, N and O atoms). Consideration of the N⋅⋅⋅O distances alone (α: 2.84 Å; β: 2.80 
Å)73 would lead us to the erroneous conclusion that hydrogen bonds are stronger in the β-
form.  
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Figure 3.11 Dimeric and catemeric arrangement of N−H⋅⋅⋅O hydrogen bonds within the 
layers in the crystal structures of α- (top) and β-polymorphs (bottom) of nitrofurantoin.  
 
In our X-ray studies, we have located the H-atoms of the imide groups from the 
difference Fourier maps and refined them without constraints. In the β-form, the imide N-
H bond is bent towards the O-atom to try to form a linear hydrogen bond (θN−H⋅⋅⋅O: 162°). 
This bending of N-H bond leads to a strained geometry at the imide N-atom. Formation 
of fully linear hydrogen bond (θN−H⋅⋅⋅O: 180°) will require a much greater strain at the N-
atom. For this reason, the N−H⋅⋅⋅O hydrogen bond is weaker in the β-form. In the α-
polymorph no such strain is required to form a linear hydrogen bond. One other factor, 
the angle at the acceptor,74 also contributes to the weakening of hydrogen bond in the β-
polymorph. Only in the α-polymorh are the hydrogen bonds formed along the direction 
of acceptor lone pairs (the C=O⋅⋅⋅H angles in the α- and β-polymorphs are 118° and 
176°). In summary, the stable α-polymorph of nitrofurantoin forms stronger hydrogen 
bonds with geometries closer to the ideal values. The β-polymorph, in attempting to 
attain these ideal supramolecular geometries, imparts molecular strain in itself and 
becomes less stable.75  
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3.23 POWDER X-RAY DIFFRACTION ANALYSIS 
 
We collected the X-ray diffraction data on powder (polycrystalline) samples on a Bruker 
D8 FOCUS diffractometer using Cu-Kα-radiation (λ = 1.54056 Å) equipped with a 
vertical goniometer and a one-dimensional scintillation counter as the detector. The X-
rays are generated at power settings of 40 kV and 40 mA. For X-ray data collection 
Bragg-Brentano geometry is applied. Before PXRD analysis, the crystals obtained from 
the experiments are gently pulverized with mortal and pestle, transferred into the glass 
sample holders (1.6 cm × 2.0 cm) and exposed to X-rays over the 2θ range 5-45° in the 
increments of 0.04° and at a scan rate of 3° per minute. Figure 3.12 shows experimental 
powder patterns of both nitrofurantoin polymorphs along with the patterns calculated 
from their single crystal X-ray structures. The experimental PXRD patterns confirm that 
crystals grown in the fluorous vials belong to the α-polymorph while crystals grown in 
the hydroxylated vials represent the β-polymorph. Generally, PXRD method is the most 
common and unequivocal tool to identify the solid state phases.  In the case of anhydrous 
polymorphs of nitrofurantoin, the powder diffraction patters are very similar. The most 
intense peaks for both polymorphs occur at almost the same 2θ value, 28.6° and 28.8° for 
α- and β-polymorphs respectively. As expected, these most intense peaks correspond to 
the planes (021) and (20-4) containing closely packed layers of nitrofurantoin molecules. 
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Figure 3.12 Calculated (top) and experimental (bottom) PXRD patterns of α- (left) and β-
polymorphs (right) of nitrofurantoin.  
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3.24 THERMAL ANALYSIS 
 
We collected the DSC data with a DSC-2920 (TA Instruments) calorimeter in 
hermetically sealed and crimped aluminum pans. Samples are heated in the range of 25-
350°C at different heating rates of 5, 10, 15, 20, 25 and 30 °C per minute. The DSC 
traces of α- and β-polymorphs are shown in Figure 3.13. Both polymorphs show similar 
behavior, a small endotherm corresponding to their melting followed by a large exotherm 
associated with their decomposition. The decomposition of the drug upon heating is also 
confirmed by independent TGA experiments. It is known that, upon heating 
nitrofurantoin decomposes into gases such carbon monoxide, carbon dioxide and nitrogen 
oxides. In addition, this drug decomposes if contacted with metals such as aluminum. In 
our experiments, we noted that the α-polymorph undergoes decomposition faster than the 
β-polymorph when heated in aluminum pans. Under slow heating conditions, the 
decomposition exotherm overshadows the melting endotherms (Figure 3.13). The melting 
and decomposition traces get separated and shift to higher temperatures at higher rate of 
heating. With the lowest rate of heating, 5 °C per minute, the melting endotherms are not 
easily detected, especially in case of α-polymorph. 
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Figure 3.13 DSC Thermograms of α- (top) and β-polymorphs (bottom) of nitrofurantoin 
showing melting endotherms followed by exotherms corresponding to decomposition. The 
thermograms are collected at different rates of heating (5-30 °C per minute). 
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3.25 EFFECT OF RATE OF EVAPORATION  
 
In order to see the influence of the rate of evaporation on the nucleation of different 
polymorphs we performed crystallization under various evaporation conditions (Figure 
3.14). We controlled the rates of evaporation by a combination of the number of 
perforations in the caps and location of the experiments. Closed chambers and vials with 
caps that had one small hole afforded the slowest rate of evaporation (0.15 mL/day) and 
open vials in chambers under mild suction gave the fastest rate of evaporation (0.92 
mL/day). Fluorous vials gave only the stable α-polymorph at slower evaporation rates, 
and hydroxylated vials gave only the less stable β-polymorph at faster evaporation rates. 
As the rate of evaporation increased to the levels of 0.7 to 0.9 mL/day, a small fraction of 
the crystals of β-polymorph appeared in the fluorous vials. No matter how slow the rate 
of evaporation, the hydroxylated vials always yielded a significant portion of β-
polymorph. These observations indicate that fluorous substrates can influence the 
nucleation only when other conditions are optimized. Faster evaporations lead to rapid 
supersaturations where multiple nucleation events (of both polymorphs) take place inside 
the vials. Under these conditions, the sheer number of the kinetic nuclei enables their 
growth into crystals aided by other factors such as smaller volumes of remaining solution.  
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Figure 3.14 Relative amount of α-polymorph in fluorous (red) and hydroxylated (blue) 
vials as a function of the rate of evaporation. Note the exclusive growth of α-polymorph in 
fluorous vials when the rate of evaporation is less than 0.6 mL/day. Note also the exclusive 
growth of β-polymorph in hydroxylated vials when the rate of evaporation is greater than 
0.4 mL/day. 
 
The evaporation rates we reported here are only relevant to crystallizations carried out in 
1 dram (~5 mL) vials containing approximately 1.8 mL of 21 mM acetonitrile solutions. 
For other vials of different sizes, different initial volumes and different initial 
concentrations, the absolute numbers of the rates of evaporation changed but the overall 
trend remained same. We repeated the experiments five times and within each 
experiment we tested five fluorous and five hydroxylated vials. The data presented in 
Figure 3.14 is based on all these experiments.   
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3.26 EFFECT OF INITIAL CONCENTRATION  
 
All the work presented until Section 3.24 is based on 21 mM acetonitrile solutions that 
are evaporated at a rate of 0.45 mL per day. The choices of solvent, initial concentration 
and rate of evaporation came from several initial experiments that led us to find ideal 
conditions for exploiting the xenophobic nature of fluorous surfaces. In this section, we 
present the effect of initial concentration on the outcome of crystallization. We kept the 
size of the vial (1 dram), initial volume (1.8 mL), solvent (acetonitrile), and rate of 
evaporation (0.45 mL/day) constant in these experiments. We began with 2 mM solutions 
and gradually increased the concentrations up to 40 mM and documented the results 
(Figure 3.15). As above, we repeated the experiments five times and within each 
experiment we tested five fluorous and five hydroxylated vials. The data presented in 
Figure 3.15 is based on all these experiments.  
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Figure 3.15 Relative amount of α-polymorph in fluorous (red) and hydroxylated (blue) 
vials as a function of initial concentration. Note the exclusive growth of α-polymorph in 
fluorous vials when the initial concentration is less than 30 mM. Note also the exclusive 
growth of β-polymorph in hydroxylated vials when the initial concentration is greater than 
20 mM.  
 
At concentrations below 30 mM, α-polymorph consistently and selectively crystallized in 
fluorous vials. At higher concentrations, partial crystallization of β-polymorph is seen in 
these vials; higher the concentration, greater is the mole fraction of the β-polymorph. In 
hydroxylated vials, solutions with initial concentrations greater than 20 mM gave the 
crystals of β-polymorph exclusively. Solutions with lower concentrations (2 to 16 mM) 
gave a mixture of α- and β-polymorphs; typically crystals of α-polymorph are always 
seen at the bottom of the vials. Higher the dilution, greater is the mole fraction of the α-
polymorph. It is important to distinguish the results in the two types of vials. Fluorous 
vials can yield the crystals of stable polymorph under conditions that normally favor the 
growth of metastable polymorph, but the reverse is not true for hydroxylated vials. The 
exclusive growth of metastable polymorph in hydroxylated vials occurs only when other 
conditions (higher initial concentrations or faster rates of evaporation) allow it. For the 
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results reported in this and the previous section, we separated the crystals of two 
polymorphs into lots by visual inspection, quantified the lots by gravimetry, and 
characterized them by IR spectroscopy. 
 
3.27 REMNANT CONCENTRATION  
 
One of the best clues about the processes that happen inside the fluorous vials is given by 
the darkening of solution color as a function of evaporation. From the inspection of 
several experiments, we noted that solutions in fluorous vials turned increasingly more 
intense in color than the ones in hydroxylated vials (Figure 3.7). To assess these changes 
in a more quantitative manner, we set up a triplicate of experiments with 21 mM 
acetonitrile solutions that evaporated at a rate of 0.45 mL per day. In each experiment, we 
used 20 fluorous and 20 hydroxylated vials, each with 1.8 mL of the solution. As the 
evaporation continued we tested the remnant concentration of the solution, every four 
hours, in both types of vials. We measured the remnant concentration in every 
experiment by gravimetry (by taking 0.1 mL of solution, evaporating it on a cover slip, 
and weighing) and one experiment by UV-Vis spectroscopy (by taking 0.1 mL of 
solution and subjecting it to serial dilutions and plotting the λmax against a calibration 
trace).  
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Figure 3.16 Remnant concentrations of the solutions in fluorous (red) and hydroxylated 
(blue) vials as a function of evaporation time. Notice the steep increase in the remnant 
concentration in fluorous vials for one and half days. Each point in the plot represents a 
mean value from three experiments. The data had a minimum error of 4% and a maximum 
error of 21%. 
 
The results from these triplicate experiments (Figure 3.16) show that concentration of the 
remaining solutions increase steeply in fluorous vials until about 36 hours and stay 
constant for 36 more hours. We found it difficult to measure the remnant concentration 
after this point because the solution is highly supersaturated and leads to immediate 
precipitation when touched with a micropipette or a needle. In contrast, the 
concentrations of the solutions in hydroxylated vials remained constant and increased 
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only slightly after about 40 hours of evaporation. These results suggest, as can be visually 
observed, that crystallization of metastable polymorph on the walls of hydroxylated vials 
keeps the remnant concentration of the solution constant. In the fluorous vials, decreased 
volumes and lack of crystallization increase the remnant concentration. The flattening of 
concentration in fluorous vials after certain time indicates the homogeneous nucleation in 
solution and crystallization of the stable polymorphs.  
 
3.28 POLYMORPH SELECTION BY OSTWALD RIPENING  
 
We tested two contrasting surfaces, one highly hydrophilic and the other xenophobic, for 
the crystal growth of nitrofurantoin. Some salient facts of our experiments are: (a) 
crystals of β-polymorph appear on the walls of hydroxylated vials within few hours, (b) 
these crystals are formed at the evaporating solvent front and continue to grow on the vial 
walls until the completion of evaporation, (c) no crystals are formed on the walls of 
fluorous vials even at faster rates of evaporation and higher initial concentrations, (d) 
fluorous vials yield only the α-polymorph (under most conditions) and hydroxylated vials 
give the β-polymorph, (e) only in fluorous vials the remnant concentration continues to 
increase for a significant time after the beginning of crystallization, (f) the number of 
crystals formed in hydroxylated vials far exceeds the number of crystals in fluorous vials, 
and (g) crystals of the stable polymorph formed in fluorous vials are significantly larger 
than the crystals of metastable polymorph grown in hydroxylated vials. 
 
These results can be best understood by two interrelated processes well-known in 
physical organic chemistry, Ostwald rule of stages and Ostwald ripening. Ostwald rule of 
stages states that “in all processes, it is not the most stable state with the lowest amount of 
free energy that is initially formed but the least stable state lying nearest in the free 
energy to the original state”. According to this rule, the nuclei of the kinetic form, the β-
polymorph, nucleate first because their free energy is lying closer to the free energy of 
solute molecules in the saturated solution. Another way expressing this idea is that the β-
polymorph has a smaller nucleation barrier than the α-polymorph (Figure 3.17) and 
hence it can nucleate first. 
 
Nucleation, described in Chapter 2, is a critical step in the crystallization of different 
polymorphs. Each polymorph has its own characteristic nucleation barrier, ∆G* and 
critical size of the cluster, r* that is stable enough to grow into a crystal. Molecules in 
supersaturated solutions aggregate to form nuclei of different polymorphs. Various nuclei 
compete for molecules dissolved in solution and kinetic nuclei tend to adsorb most 
molecules at the beginning. Kinetic nuclei are usually higher in number at the onset of 
crystallization because of their lower nucleation barrier. Kinetic nuclei are formed faster 
in the solution but they also have greater solubility (than nuclei of thermodynamic 
polymorphs) and tend to dissolve more readily. If these kinetic nuclei can stick to some 
surface to lower their surface energy, they can survive in the solution and grow further 
into crystals. This is the process that is observed when crystallization is performed in the 
hydroxylated vials. In other words, crystal growth of kinetic polymorph is promoted by 
heterogeneous nucleation on the hydroxylated surfaces.  
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In case of fluorous vials, the xenophobic nature of the vial surfaces does not allow the 
adsorption of kinetic nuclei on to the vial walls and forces these nuclei to dissolve back 
into solution. We call this process the suppression of nucleation at fluorous interfaces. 
With time, increased supersaturation lowers the nucleation barrier of the thermodynamic 
form, the α-polymorph, and promotes the formation of nuclei of this stable polymorph. 
Given that thermodynamic nuclei have lower solubility than the kinetic nuclei, crystals of 
α-polymorph tend to grow while those of β-polymorph dissolve back into solution. This 
process, the growth of a thermodynamic polymorph at the expense of a kinetic 
polymorph, is called Ostwald ripening. 
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Figure 3.17 Free energy diagram for a dimorphic system showing the nucleation barriers 
for kinetic (blue) and thermodynamic (red) polymorphs. Note that ∆G* and r* of kinetic 
polymorph are smaller than ∆G* and r* of thermodynamic polymorph. 
 
3.29 SUMMARY AND CONCLUSION  
 
W developed a new and generic method to promote the growth of the stable polymorphs 
by suppressing the nucleation of metastable polymorph at xenophobic interfaces. While 
previous methods use promotion of heterogeneous nucleation as a means to drive crystal 
growth on the surfaces, our method uses inhibition of heterogeneous nucleation to 
selectively grow crystals away from the surfaces. Unlike the previous approaches, our 
method does not require prior knowledge of the crystal structures of polymorphs and as 
such it should be applicable to many pharmaceutical and other types of compounds that 
exhibit polymorphism. We have shown that crystallization in fluorous vessels can be an 
effective tool to distinguish between polymorphs that have similar densities, packing 
fractions and lattice energies. Further work, not presented here, has shown that same 
results can be obtained with the trigonal and P-monoclinic polymorphs of carbamazepine. 
Fluorous surfaces are not omniphobic; they are xenophobic. In this context, it will be 
interesting to test the crystallization of compounds that contain fluorous moieties. Indeed, 
up to 20% of pharmaceuticals now contain fluorine atoms and a good portion of them 
contain fluorous fragments. In the next chapter we will discuss the reverse inhibition in 
the growth of a polymorphic drug that exhibits fluorous crystal faces. 
 
SUPPRESSION OF NUCLEATION AT FLUOROUS INTERFACES  61 
 
3.30 REFERENCES 
 
1. Bernstein, J., Polymorphism in Molecular Crystals. Clarendon Press: Oxford, 2002. 
2. Brittain, H. G., Polymorphism in Pharmaceutical Solids. Marcel Dekker: New York, 
1999. 
3. Byrn, S. R.; Pfeiffer, R. R.; Stowell, J. G., Solid-State Chemistry of Drugs. 2nd ed.; 
SSCI: West Lafayette, 1999. 
4. Hilfiker, R., Polymorphism in the Pharmaceutical Industry. Wiley-VCH: Weinheim, 
2006. 
5. Chemburkar, S. R.; Bauer, J.; Deming, K.; Spiwek, H.; Patel, K.; Morris, J.; Henry, 
R.; Spanton, S.; Dziki, W.; Porter, W.; Quick, J.; Bauer, P.; Donaubauer, J.; 
Narayanan, B. A.; Soldani, M.; Riley, D.; McFarland, K., Dealing with the Impact of 
Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development. Org. 
Proc. Res. Dev. 2000, 4, 413-417. 
6. Rodriguez-Spong, B.; Price, C. P.; Jayasankar, A.; Matzger, A. J.; Rodriguez-
Hornedo, N., General principles of pharmaceutical solid polymorphism. A 
supramolecular perspective. Adv. Drug Delivery Rev. 2004, 56, 241-274. 
7. Desiraju, G. R., Crystal Engineering: The Design of Organic Solids. Elsevier: 
Amsterdam, 1989. 
8. Allesoe, M.; Van Den Berg, F.; Cornett, C.; Joergensen, F. S.; Halling-Soerensen, B.; 
De Diego, H. L.; Hovgaard, L.; Aaltonen, J.; Rantanen, J., Solvent diversity in 
polymorph screening. J. Pharm. Sci. 2008, 97, 2145-2159. 
9. Morissette, S. L.; Almarsson, O.; Peterson, M. L.; Remenar, J. F.; Read, M. J.; 
Lemmo, A. V.; Ellis, S.; Cima, M. J.; Gardner, C. R., High-throughput crystallization: 
polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug 
Delivery Rev. 2004, 56, 275-300. 
10. Peterson, M. L.; Morissette, S. L.; McNulty, C.; Goldsweig, A.; Shaw, P.; LeQuesne, 
M.; Monagle, J.; Encina, N.; Marchionna, J.; Johnson, A.; Gonzalez-Zugasti, J.; 
Lemmo, A. V.; Ellis, S. J.; Cima, M. J.; Almarsson, O., Iterative High-Throughput 
Polymorphism Studies on Acetaminophen and an Experimentally Derived Structure 
for Form III. J. Am. Chem. Soc. 2002, 124, 10958-10959. 
11. Lowenstam, H. A.; Weiner, S., On Biomineralization. Oxford University Press: New 
York, 1989. 
12. Mann, S., Biomineralization. Oxford University Press: New York, 2002. 
13. Lahav, M.; Leiserowitz, L., Tailor-made auxiliaries for the control of nucleation, 
growth and dissolution of two- and three-dimensional crystals. J. Phys. D 1993, 26, 
B22-B31. 
14. Davey, R. J.; Blagden, N.; Potts, G. D.; Docherty, R., Polymorphism in Molecular 
Crystals: Stabilization of a Metastable Form by Conformational Mimicry. J. Am. 
Chem. Soc. 1997, 119, 1767-1772. 
15. He, X.; Stowell, J. G.; Morris, K. R.; Pfeiffer, R. R.; Li, H.; Stahly, G. P.; Byrn, S. R., 
Stabilization of a Metastable Polymorph of 4-Methyl-2-nitroacetanilide by 
Isomorphic Additives. Cryst. Growth Des. 2001, 1, 305-312. 
16. Kwon, O. P.; Kwon, S.-J.; Jazbinsek, M.; Choubey, A.; Losio, P. A.; Gramlich, V.; 
Guenter, P., Morphology and Polymorphism Control of Organic Polyene Crystals by 
Tailor-made Auxiliaries. Cryst. Growth Des. 2006, 6, 2327-2332. 
62 CHAPTER 3  
 
17. Lancaster, R. W.; Karamertzanis, P. G.; Hulme, A. T.; Tocher, D. A.; Lewis, T. C.; 
Price, S. L., The polymorphism of progesterone: stabilization of a 'disappearing' 
polymorph by co-crystallization. J. Pharm. Sci. 2007, 96, 3419-3431. 
18. Mullin, J. W., Crystallization. 4th ed.; Butterworth-Heinemann: New York, 2001. 
19. Kuzmenko, I.; Rapaport, H.; Kjaer, K.; Als-Nielsen, J.; Weissbuch, I.; Lahav, M.; 
Leiserowitz, L., Design and Characterization of Crystalline Thin Film Architectures 
at the Air-Liquid Interface: Simplicity to Complexity. Chem. Rev. 2001, 101, 1659-
1696. 
20. Frostman, L. M.; Ward, M. D., Nucleation of Molecular Crystals beneath 
Guanidinium Alkanesulfonate Monolayers. Langmuir 1997, 13, 330-337. 
21. Briseno, A. L.; Mannsfeld, S. C. B.; Ling, M. M.; Liu, S.; Tseng, R. J.; Reese, C.; 
Roberts, M. E.; Yang, Y.; Wudl, F.; Bao, Z., Patterning organic single-crystal 
transistor arrays. Nature 2006, 444, 913-917. 
22. Carter, P. W.; Ward, M. D., Directing Polymorph Selectivity During Nucleation of 
Anthranilic Acid on Molecular Substrates. J. Am. Chem. Soc. 1994, 116, 769-770. 
23. Toworfe, G. K.; Composto, R. J.; Shapiro, I. M.; Ducheyne, P., Nucleation and 
growth of calcium phosphate on amine-, carboxyl- and hydroxyl-silane self-
assembled monolayers. Biomater. 2005, 27, 631-642. 
24. Ulman, A., Formation and Structure of Self-Assembled Monolayers. Chem. Rev. 
1996, 96, 1533-1554. 
25. Love, J. C.; Estroff, L. A.; Kriebel, J. K.; Nuzzo, R. G.; Whitesides, G. M., Self-
Assembled Monolayers of Thiolates on Metals as a Form of Nanotechnology. Chem. 
Rev. 2005, 105, 1103-1169. 
26. Aizenberg, J.; Black, A. J.; Whitesides, G. M., Control of crystal nucleation by 
patterned self-assembled monolayers. Nature 1999, 398, 495-498. 
27. Banno, N.; Nakanishi, T.; Matsunaga, M.; Asahi, T.; Osaka, T., Enantioselective 
crystal growth of leucine on a self-assembled monolayer with covalently attached 
leucine molecules. Journal of the American Chemical Society 2004, 126, 428-429. 
28. Meldrum, F. C.; Flath, J.; Knoll, W., Chemical Deposition of PbS on Self-Assembled 
Monolayers of 16-Mercaptohexadecanoic Acid. Langmuir 1997, 13, 2033-2049. 
29. Cox, J. R.; Dabros, M.; Shaffer, J. A.; Thalladi, V. R., Selective crystal growth of the 
anhydrous and monohydrate forms of theophylline on self-assembled monolayers. 
Angewandte Chemie, International Edition 2007, 46, 1988-1991. 
30. Frostman, L. M.; Bader, M. M.; Ward, M. D., Nucleation and Growth of Molecular 
Crystals on Self-Assembled Monolayers. Langmuir 1994, 10, 576-582. 
31. Hiremath, R.; Basile, J. A.; Varney, S. W.; Swift, J. A., Controlling Molecular Crystal 
Polymorphism with Self-Assembled Monolayer Templates. Journal of the American 
Chemical Society 2005, 127, 18321-18327. 
32. Hiremath, R.; Varney, S. W.; Swift, J. A., Selective growth of a less stable polymorph 
of 2-iodo-4-nitroaniline on a self-assembled monolayer template. Chem. Commun. 
2004, 2676-2677. 
33. Lee, A. Y.; Ulman, A.; Myerson, A. S., Crystallization of Amino Acids on Self-
Assembled Monolayers of Rigid Thiols on Gold. Langmuir 2002, 18, 5886-5898. 
34. Mitchell, C. A.; Yu, L.; Ward, M. D., Selective Nucleation and Discovery of Organic 
Polymorphs through Epitaxy with Single Crystal Substrates. J. Am. Chem. Soc. 2001, 
123, 10830-10839. 
SUPPRESSION OF NUCLEATION AT FLUOROUS INTERFACES  63 
 
35. Hillier, A. C.; Ward, M. D., Epitaxial interactions between molecular overlayers and 
ordered substrates. Phys. Rev. B 1996, 54, 14037-14051. 
36. Bonafede, S. J.; Ward, M. D., Selective Nucleation and Growth of an Organic 
Polymorph by Ledge-Directed Epitaxy on a Molecular Crystal Substrate. J. Am. 
Chem. Soc. 1995, 117, 7853-7861. 
37. Cashell, C.; Corcoran, D.; Hodnett, B. K., Secondary nucleation of the β-polymorph 
of L-glutamic acid on the surface of α-form crystals. Chem. Commun. 2003, 374-375. 
38. Yu, L., Nucleation of One Polymorph by Another. J. Am. Chem. Soc. 2003, 125, 
6380-6381. 
39. Yu, L., Survival of the fittest polymorph: how fast nucleater can lose to fast grower. 
CrystEngComm 2007, 9, 847-851. 
40. Carter, P. W.; Ward, M. D., Topographically directed nucleation of organic crystals 
on molecular single-crystal substrates. J. Am. Chem. Soc. 1993, 115, 11521-11535. 
41. Lang, M.; Grzesiak, A. L.; Matzger, A. J., The Use of Polymer Heteronuclei for 
Crystalline Polymorph Selection. J. Am. Chem. Soc. 2002, 124, 14834-14835. 
42. Liberski, A. R.; Tizzard, G. J.; Diaz-Mochon, J. J.; Hursthouse, M. B.; Milnes, P.; 
Bradley, M., Screening for Polymorphs on Polymer Microarrays. J. Comb. Chem. 
2008, 10, 24-27. 
43. Price, C. P.; Grzesiak, A. L.; Matzger, A. J., Crystalline polymorph selection and 
discovery with polymer heteronuclei. J. Am. Chem. Soc. 2005, 127, 5512-5517. 
44. Chyall, L. J.; Tower, J. M.; Coates, D. A.; Houston, T. L.; Childs, S. L., Polymorph 
Generation in Capillary Spaces: The Preparation and Structural Analysis of a 
Metastable Polymorph of Nabumetone. Cryst. Growth Des. 2002, 2, 505-510. 
45. Childs, S. L.; Chyall, L. J.; Dunlap, J. T.; Coates, D. A.; Stahly, B. C.; Stahly, G. P., 
A Metastable Polymorph of Metformin Hydrochloride: Isolation and Characterization 
Using Capillary Crystallization and Thermal Microscopy Techniques. Cryst. Growth 
Des. 2004, 4, 441-449. 
46. Ha, J.-M.; Wolf, J. H.; Hillmyer, M. A.; Ward, M. D., Polymorph Selectivity under 
Nanoscopic Confinement. J. Am. Chem. Soc. 2004, 126, 3382-3383. 
47. Hamilton, B. D.; Hillmyer, M. A.; Ward, M. D., Glycine Polymorphism in Nanoscale 
Crystallization Chambers. Cryst. Growth Des. 2008, 8, 3368-3375. 
48. Zaccaro, J.; Matic, J.; Myerson, A. S.; Garetz, B. A., Nonphotochemical, laser-
induced nucleation of supersaturated aqueous glycine produces unexpected g-
polymorph. Cryst. Growth Des. 2001, 1, 5-8. 
49. Erdemir, D.; Chattopadhyay, S.; Guo, L.; Ilavsky, J.; Amenitsch, H.; Segre, C. U.; 
Myerson, A. S., Relationship between Self-Association of Glycine Molecules in 
Supersaturated Solutions and Solid State Outcome. Phys. Rev. Lett. 2007, 99, 115702. 
50. Lyczko, N.; Espitalier, F.; Louisnard, O.; Schwartzentruber, J., Effect of ultrasound 
on the induction time and the metastable zone widths of potassium sulphate. Chem. 
Engg. J. 2002, 86, 233-241. 
51. Childs, S. L.; Mougin, P.; Stahly, B. C. Screening for solid pharmaceutical forms by 
ultrasound crystallization and cocrystallization using ultrasound. 2005089375, 2005. 
52. Kurotani, M.; Hirasawa, I., Polymorph control of sulfamerazine by ultrasonic 
irradiation. J. Cryst. Growth 2008, 310, 4576-4580. 
53. Louhi-Kultanen, M.; Karjalainen, M.; Rantanen, J.; Huhtanen, M.; Kallas, J., 
Crystallization of glycine with ultrasound. Int. J. Pharm. 2006, 320, 23-29. 
64 CHAPTER 3  
 
54. Capes, J. S.; Cameron, R. E., Contact line crystallization to obtain metastable 
polymorphs. Cryst. Growth Des. 2007, 7, 108-112. 
55. Capes, J. S.; Cameron, R. E., Effect of polymer addition on the contact line 
crystallization of paracetamol. CrystEngComm 2007, 9, 84-90. 
56. Dawson, A.; Allan, D. R.; Belmonte, S. A.; Clark, S. J.; David, W. I. F.; McGregor, 
P. A.; Parsons, S.; Pulham, C. R.; Sawyer, L., Effect of High Pressure on the Crystal 
Structures of Polymorphs of Glycine. Cryst. Growth Des. 2005, 5, 1415-1427. 
57. Fabbiani, F. P. A.; Allan, D. R.; David, W. I. F.; Davidson, A. J.; Lennie, A. R.; 
Parsons, S.; Pulham, C. R.; Warren, J. E., High-Pressure Studies of Pharmaceuticals: 
An Exploration of the Behavior of Piracetam. Cryst. Growth Des. 2007, 7, 1115-
1124. 
58. Fabbiani, F. P. A.; Allan, D. R.; David, W. I. F.; Moggach, S. A.; Parsons, S.; 
Pulham, C. R., High-pressure recrystallisation - a route to new polymorphs and 
solvates. CrystEngComm 2004, 6, 504-511. 
59. Fabbiani, F. P. A.; Allan, D. R.; Parsons, S.; Pulham, C. R., An exploration of the 
polymorphism of piracetam using high pressure. CrystEngComm 2005, 7, 179-186. 
60. Fabbiani, F. P. A.; Pulham, C. R., High-pressure studies of pharmaceutical 
compounds and energetic materials. Chem. Soc. Rev. 2006, 35, 932-942. 
61. Dunitz, J. D.; Bernstein, J., Disappearing Polymorphs. Acc. Chem. Res. 1995, 28, 
193-200. 
62. Horvath, I. T.; Rabai, J., Facile catalyst separation without water: fluorous biphase 
hydroformylation of olefins. Science 1994, 266, 72-75. 
63. Gladysz, J. A.; Curran, D. P.; Horvath, I. T., Handbook of Fluorous Chemistry. 
Wiley-VCH: Weinheim, 2004. 
64. Wasserman, S. R.; Tao, Y. T.; Whitesides, G. M., Structure and reactivity of 
alkylsiloxane monolayers formed by reaction of alkyltrichlorosilanes on silicon 
substrates. Langmuir 1989, 5, 1074-1087. 
65. Kulinich, S. A.; Farzaneh, M., Hydrophobic properties of surfaces coated with 
fluoroalkylsiloxane and alkylsiloxane monolayers. Surf. Science 2004, 573, 379-390. 
66. Cox, J. R.; Ferris, L. A.; Thalladi, V. R., Selective growth of a stable drug polymorph 
by suppressing the nucleation of corresponding metastable polymorphs. Angew. 
Chem. Int. Ed. 2007, 46, 4333-4336. 
67. Pienaar, E. W.; Caira, M. R.; Lotter, A. P., Polymorphs of nitrofurantoin. 2. 
Preparation and x-ray crystal structures of two anhydrous forms of nitrofurantoin. J. 
Crystallogr. Spectrosc. Res. 1993, 23, 785-790. 
68. Nitrofurantoin can also be crystallized as two different monohydrates and at least two 
solvates of this drug are known. See: Pienaar, E. W.; Caira, M. R.; Lotter, A. P., 
Polymorphs of nitrofurantoin. I. Preparation and x-ray crystal structures of two 
monohydrated forms of nitrofurantoin. J. Crystallogr. Spectrosc. Res. 1993, 23, 739-
744.  
69. Caira, M. R.; Pienaar, E. W.; Loetter, A. P., Polymorphism and pseudopolymorphism 
of the antibacterial nitrofurantoin. Mol. Cryst. Liq. Cryst. Sci. Technol., Sect. A 1996, 
279, 241-264. 
70. We collected the IR spectra at room temperature. To be consistent, we give the 
distances and angles from the room temperature crystal structures reported by others, 
and not from the low temperature data collected by us (Section 3.22). Though the 
SUPPRESSION OF NUCLEATION AT FLUOROUS INTERFACES  65 
 
absolute values of distances and angles change slightly between room and low 
temperature datasets, the trends remain the same.  
71. The data were measured using φ and ω scans of 0.5° per frame; each frame was 
exposed to X-rays for 10-20 seconds depending on the scattering power of the crystal. 
Unit cell parameters were determined using three mutually perpendicular φ scans with 
12 frames per scan. Using the orientation matrix obtained from the unit cell, a 
hemisphere was searched with the program COSMO to determine the number of runs 
and frames needed for 0.75 Å resolution, 100 % completeness, and at least two fold 
redundancy when the crystal system is set to triclinic. Cell parameters were refined 
over all the equivalent reflections in the hemisphere during the data integration. Data 
integration was performed using the program SAINT and absorption corrections were 
applied using SADABS multiscan technique. The structures were solved by the direct 
methods and refined by the least squares methods on F2 using the program SHELXL-
97 incorporated in SHELXTL-PC. Typically, all the non-H-atoms were refined 
anisotropically and all H-atoms other than those attached to N or O atoms were 
calculated by geometrical methods and refined using a riding model. Structural 
analysis was performed by a combination of programs that include XP, XSHELL, 
Platon, and Mercury. Structural diagrams shown in this thesis were prepared using the 
program Mercury.  
72. Spek, A. L., Single-crystal structure validation with the program PLATON. J. Appl. 
Crystallogr. 2003, 36, 7-13. 
73. Values in this section are taken from our low temperature structures. For room 
temperature data see Section 3.21. 
74. Murray-Rust, P.; Glusker, J. P., Directional hydrogen bonding to sp2- and sp3-
hybridized oxygen atoms and its relevance to ligand-macromolecule interactions. J. 
Am. Chem. Soc. 1984, 106, 1018-1025. 
75. Thalladi, V. R.; Nuesse, M.; Boese, R., The Melting Point Alternation in α,ω-
Alkanedicarboxylic Acids. J. Am. Chem. Soc. 2000, 122, 9227-9236. 
 
 
  
 
 
 
 
 
 
 
TH
IS
 P
AG
E 
LE
FT
 IN
TE
NT
IO
NA
LL
Y 
BL
AN
K
  
 
 
4  FLUOROUS PHARMACEUTICALS – INHIBITION OF NUCLEATION AT HYDROPHILIC SURFACES 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
TH
IS
 P
AG
E 
LE
FT
 IN
TE
NT
IO
NA
LL
Y 
BL
AN
K
FLUOROUS PHARMACEUTICALS – INHIBITION OF NUCLEATION … 69 
 
4.1 PHARMACEUTICALS WITH FLUOROUS FRAGMENTS  
 
Fluorinated pharmaceuticals, though unknown until a few decades ago, constitute 20% of 
the marketed drugs today.1-3 Much of the interest in fluorinated pharmaceuticals emerges 
from the small size and high electronegativity of fluorine atom and also the xenophobic 
nature of fluorous fragments.4 The van der Waals radius of fluorine (1.47 Å) lies between 
those of hydrogen (1.2 Å) and oxygen atoms (1.52 Å).5 For this reason, research in drug 
discovery often involves replacement of H-atoms or –OH groups by F-atoms. Fluorinated 
pharmaceuticals, drugs that contain either aromatic F-atoms or fluorous fragments, can 
enhance the binding between drug and the receptor species through electronic properties, 
assist the diffusion of the drug across the lipid membranes through lipophilic interactions, 
and induce conformational or other changes by causing or relieving steric strain.6 
O N
+
C
F
F
F
H
Cl
H(a)
(b)
 
Figure 4.1 (a) Molecular structure of fluoxetine hydrochloride, a fluorous pharmaceutical 
marketed as Prozac.7 (b) Crystal structure of Prozac showing the hydrogen bonded layers 
that expose fluorous groups at the potential growth faces.8  
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We are interested in those drugs that contain fluorous fragments such as –CF3 groups.9 
We expect that in the solid state, these fluorous fragments, due to their xenophobic 
nature, aggregate into pockets, columns or sheaths that are isolated from hydrogen 
bonding functional groups. Fluoxetine hydrochloride, the top selling fluorinated drug, 
serves as a good example (Figure 4.1).7 Crystal structure of this drug shows distinct 
lamellar domains of hydrogen bonds, aromatic-aromatic interactions and fluorous-
fluorous interactions.8 We anticipate that many pharmaceuticals with –CF3 or other –
CmFn fragments adopt similar isolated fluorous domains and lend themselves well for the 
crystal growth studies in hydroxylated and fluorous vials. In such circumstances, drug 
crystals with xenophobic surfaces are expected to show the inverse trend. Stable 
polymorphs are expected to grow on glass or hydroxylated surfaces and metastable 
polymorphs on fluorous surfaces. To test this hypothesis, we have selected flufenamic 
acid, an anti-inflammatory drug,10 as a model pharmaceutical.11-13 Flufenamic acid 
exhibits temperature induced transitions between polymorphs;14-15 below we discuss the 
two types of solid state phase transitions that can occur in a given system and their 
thermodynamic relations. 
 
4.2 ENANTIOTROPIC AND MONOTROPIC PHASE TRANSITIONS 
 
Polymorphs of a compound have different crystal structures and hence different lattice 
free energies.16 A higher energy, less stable, polymorph can transform to a lower energy, 
more stable, polymorph either spontaneously or by external induction such as pressure, 
temperature or some other factor.17-19 Transformation of polymorphs at constant pressure 
is determined by the difference in their free energies (∆G = ∆H - T∆S). The difference in 
enthalpy ∆H refers to the difference in lattice structure and energy, and the difference in 
entropy ∆S refers to lattice vibrations and disorder. Under specific conditions, a 
spontaneous transformation involves decrease in free energy (∆G is negative), and a 
transformation is not spontaneous if there is an increase in free energy (∆G is positive). 
The thermodynamic conditions and possible directions of the transformations between 
two polymorphs and liquid for a single component system are shown in Figure 4.2.20-21 
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Figure 4.2 Thermodynamic relationships between polymorphs that are (a) enantiotropic 
and (b) monotropic. Free energy and enthalpy curves for two polymorphs and liquid are 
drawn. Note the crossing of free energy curves in the enantiotropic system. 
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In an enantiotropic system (Figure 4.2a), the two polymorphs can interconvert, as a 
function of temperature, prior to melting. The temperature at which one form transforms 
to the other is called the phase transition temperature. Examination of free energy curves 
indicates that prior to transition temperature, form A is more stable; form B is more stable 
after the transition point. At the transition temperature, both polymorphs are in 
equilibrium with each other. 
 
In a monotropic system (Figure 4.2b), one of the two polymorphs is always stable prior to 
melting. Polymorph B can transform to polymorph A but reverse transition does not take 
place. This is the difference between enantiotropic and monotropic systems: in the former 
the phase transition is reversible and in the latter it is irreversible. A closer look at the 
enthalpy curves in Figure 4.2 is instructive. In a monotropic system, the B→A conversion 
involves a net reduction in enthalpy; that is the process is exothermic. In an enantiotropic 
system, an exothermic event refers to B→A transition and an endothermic event indicates 
A→B transition. Based on the type of transition, exo- or endothermic, we can tell 
whether a particular polymorph is stable or metastable at a given temperature. The 
knowledge of polymorphic behavior (monotropic or enantiotropic) of a compound is 
important in the pharmaceutical industry. Unexpected transformation of one polymorph 
to another can pose problems in the drug development. Relative thermodynamic 
stabilities of polymorphs strongly depend on pressure and temperature and phase 
transitions can be induced by changes in temperature or pressure that often occur in the 
formulation processes such as tableting, grinding, and drying. 
 
4.3 FLUFENAMIC ACID 
 
Flufenamic acid, an analgesic with a fluorous fragment, is multimorphic and up to eight 
polymorphs (I – VIII) have been reported.14-15 Five of these polymorphs (IV – VIII) are 
observed on a hot stage during heating; they are fleeting and their characterization is 
difficult. The literature contains limited or no physical data on these five forms.22 Of the 
remaining three polymorphs, forms I and III can be grown from solutions and form II 
can be obtained by sublimation or fusion. The thermodynamic relationships between 
different polymorphs are shown in Figure 4.3. In this work we are primarily interested in 
polymorphs I and III; they can readily obtained at room temperature and they are 
previously characterized by thermal, diffraction and spectroscopic methods. Figure 4.3 
shows that forms I and III are enatiotropically related. Below 42 ºC, form III is the 
thermodynamically stable polymorph, and form I is the metastable polymorph. Above 42 
ºC polymorph I becomes stable and form III metastable. Form II is monotropic with 
respect to form I, and enantiotropic with respect to form III. Above 104 ºC, form II 
becomes more stable than form III. The relationships between other polymorphs are not 
fully established; they are plotted in Figure 4.3 to give a complete picture of reported 
data. 
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Figure 4.3 Relative free energies of various polymorphs of flufenamic acid plotted as a 
function of temperature. Adopted from references 14 and 15. 
 
It is reported that crystallization of flufenamic acid from different solutions yield 
polymorph III from solvents with lower boiling points (< 80 °C), polymorph I from 
solvents with higher boiling points (> 130 °C), and a mixture of both polymorphs from 
solvents with intermediate boiling points.23 In these experiments, saturated solutions are 
made near the boiling points of solvents and crystal growth is induced near those 
temperatures. This study indicates that the type of polymorph crystallized from a given 
solvent depends on the temperature of crystal growth; these results are in accordance with 
the transition temperature between forms I and III. These results are also relevant to our 
temperature dependent crystallization studies discussed in Section 4.10. The IR, DSC and 
X-ray data available for polymorphs I and III will be useful in this work for comparison 
and confirmation of results. Additionally, forms I and III exhibit distinct colors, white 
and pale-yellow, and morphologies, plates and needles. Most importantly, forms I and III 
possess layered crystal structures with sheaths of –CF3 groups and potentially they can 
exhibit crystal faces that are fluorous and xenophobic. We explored the crystal growth of 
these two polymorphs in hydroxylated and fluorous vials to influence crystal nucleation 
and to control polymorphism. 
 
4.4 CRYSTAL GROWTH IN HYDROXYLATED AND FLUOROUS VIALS 
 
We prepared the hydrophilic and fluorous substrates using the methods described in 
Chapter 3.24-26 For each series of crystallization experiments, we prepared 78 mM 
solution of flufenamic acid in ethanol by stirring the solution at 60°C for 20 minutes. We 
transferred this freshly prepared solution into ten hydroxylated and ten fluorous 1 dram 
vials until each vial is filled to a third of its height (~1.8 mL). We covered the vials with 
screw-caps containing holes and allowed ethanol to evaporate slowly. After almost 
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complete evaporation of solvent (~6 days), crystals of form I grew selectively in fluorous 
vials while crystals of form III grew in hydroxylated vials. In sharp contrast to 
crystallizations of nitrofurantoin (Chapter 3) or other drugs that did not contain fluorous 
groups, crystals of flufenamic acid did not nucleate or grow on the vial walls of either 
hydroxylated or fluorous vials (Figure 4.4a). Crystals grown in the fluorous vials are 
white with plate-like morphology while needle shaped pale-yellow crystals are grown in 
hydroxylated vials (Figures 4.4b-c). We repeated these crystallization experiments at 
least five times and obtained reproducible results. 
0.5 mm 0.5 mm
(a) (b) (c)
 
Figure 4.4 (a) Crystal growth of flufenamic acid from the same bulk solution in 
hydroxlayed (left) and fluorous (right) vials.  Notice the yellow color of the form III 
crystals in the left vial and white color of form I crystals in the right vial. Microscopic 
images of (b) form I crystals grown in a fluorous vial and (c) form III crystals grown in a 
hydroxylated vial. 
 
We characterized the crystalline products by optical microscopy, IR spectroscopy, single 
crystal and powder X-ray diffraction methods. These methods showed that the white 
plates formed in fluorous vials belong to polymorph I and the yellow needles crystallized 
in hydroxylated vials belong to polymorph III. In both types of surfaces nuclei did not 
stick to the walls of the vials and crystals are formed at the end of the evaporation process 
(Figure 4.4a). These results suggest that there is no specific interaction between 
xenophobic nuclei of flufenamic acid and the hydroxylated and fluorous surfaces of vials. 
 
4.5 VISUAL OBSERVATIONS 
 
Figure 4.5 shows stepwise crystallization process in hydroxylated and fluorous vials. The 
image on the top shows the beginning of the crystallization. The two types of surfaces 
exhibit different wetting properties with hydroxylated vials having higher affinity for 
ethanol than fluorous vials. The concave menisci in the former vials are more deeper than 
those in the latter. The bottom image shows the crystallization process after four days. 
Flufenamic acid does not crystallize on the walls of hydroxylated and fluorous vials 
during solvent evaporation. This observation suggests that crystal nuclei do not attach to 
the hydroxylated surfaces even though ethanol wets these surfaces. In addition, no visible 
crystallization occurs on the walls of fluorous vials implying that the attraction between 
two fluorous surfaces is not strong enough to promote the adhesion of crystal nuclei. It is 
possible that a fluorous solvent with better wetting properties will promote the crystal 
nucleation on the walls of the fluorous vials. We did not perform these experiments in 
this work. As mentioned above, crystals appeared at the end of the evaporation with 
yellow needles in the hydroxylated vials and white plates in the fluorous vials. 
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0 days
4 days
 
Figure 4.5 Monitoring of crystal growth of flufenamic acid in hydroxylated (left two) and 
fluorous (right two) vials. Notice the differences in the menisci. Notice the lack of 
crystallization on the walls of fluorous and hydroxylated vials. 
 
4.6 IR SPECTROSCOPIC CHARACTERIZATION OF SOLID FORMS 
 
Forms I and III show several gross similarities and some important differences in their 
IR spectra (Figure 4.6). Both forms show broad adsorptions of O−H stretching vibrations 
in the region 3500-2250 cm-1 characteristic for carboxylic acid. Intramolecular N−H⋅⋅⋅O 
bonds between imine and carbonyl groups and intermolecular O−H⋅⋅⋅O bonds between 
carboxylic acid groups are responsible for these broad absorptions. The C=O stretching 
absorption occurs at 1651 cm-1 in form I and at 1655 cm-1 in form III. These values are 
significantly lower than expected for an aromatic carboxylic acid; the reduction in 
stretching frequency of C=O is caused by intramolecular hydrogen bonding with imine 
group, in addition to the conjugation with the phenyl ring. Between the two polymorphs, 
the slightly lower C=O absorption frequency for form I is a result of slightly elongated 
C=O bond that is involved in stronger N−H⋅⋅⋅O=C hydrogen bonds with imine group. The 
C=O distances for polymorphs I and III are 1.234 Å and 1.230 Å respectively.27-28 The 
imine N−H stretching vibrations absorb at 3320 cm-1 for form I and at 3314 cm-1 for form 
III. These values appear to contradict the previous statement (stronger N−H⋅⋅⋅O=C 
hydrogen bonds in form I). The apparent contradiction arises from the different 
conformations of flufenamic acid molecules in forms I and III (Figure 4.7). Significant 
differences between the two polymorphs can be also be observed in the fingerprint region 
(Figure 4.6c) The bond distances given above are taken from previously reported crystal 
structures determined at room temperature. Molecular structures in Figure 4.7 are plotted 
from low temperature X-ray crystal structures determined by us. 
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Figure 4.6 IR Spectra of (a) polymorph I and (b) polymorph III grown in fluorous and 
hydroxylated vials. These two images show the IR spectra of flufenamic acid in the range 
3650-650 cm-1. (c) Overlaid IR spectra of forms I (green) and III (orange) given in the 
range 1850-650 cm-1. 
 
(a) (b)
 
Figure 4.7 Molecular conformations of flufenamic acid in (a) polymorph I and (b) 
polymorph III. Notice the opposing orientations of –COOH and –CF3 groups in form III. 
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Table 4.1 Crystallographic data for polymorphs I and III of flufenamic acid. The 
temperature of data collection is given as T. Packing coefficient, Ck*, is calculated using 
the program PLATON.29 
 I III 
Emp. formula C14H10F3NO2 C14H10F3NO2 
Formula wt. 281.23 281.23 
Crystal system triclinic monoclinic 
Space group P21/c   C2/c 
a (Å) 12.413(7) 39.6466(11) 
b (Å) 7.753(5) 5.04810(10) 
c (Å) 12.677(7) 11.9577(4) 
α (°) 90 90 
β (°) 94.739(12) 91.907(2) 
γ (°) 90 90 
V (Å3) 1215.8(12) 2391.89(11) 
Z 4 8 
Dcalc (Mg/m3) 1.536 1.562 
F (000) 576 1152 
µ 0.134 0.136 
R1 0.0369 0.0332 
wR2 0.0984 0.0926 
GoF 1.038 1.040 
N-total 15125 13315 
N-independent 3028 3028 
N-observed 2626 2592 
N-parameters 189 189 
T (K) 100 100 
θ range 1.65 -28.28 2.06 - 28.50° 
Index ranges 
-16 ≤ h ≤ 16 -52 ≤ h ≤ 52 
 
-9 ≤ k ≤ 10 -6 ≤ k ≤ 6 
 
-16 ≤ l ≤ 16 -15 ≤ l ≤ 15 
Crystal size (mm3) 0.24×0.22×0.20 0.32×0.30×0.07 
Crystal shape plate needle 
Crystal color white pale-yellow 
Solvent ethanol ethanol 
Ck* 0.710 0.720 
 
4.7 CRYSTAL STRUCTURES OF FORMS I AND III 
 
In order to assess the identity of two polymorphs, we determined their three-dimensional 
structures by single crystal X-ray diffraction methods. Full details of the data collection 
methodology and crystal structure solution, refinement and analysis are given in Chapter 
3. Table 4.1 lists the key crystallographic data for polymorphs I and III of flufenamic 
acid. In both forms, carboxylic acid groups form O−H⋅⋅⋅O hydrogen bonded dimers, with 
the O···O distances of 2.642 Å in I and 2.629 Å in III. The carbonyl and imine groups in 
both polymorphs form intramolecular N−H⋅⋅⋅O hydrogen bonds, with the N··O distances  
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Figure 4.8 Crystal structure of polymorph I showing hydrogen bonded layers. Notice the 
interdigitation of adjacent layers and sheaths of –CF3 groups. 
 
 
Figure 4.9 Crystal structure of polymorph III.  Notice the hydrogen bonded layers and 
fluorous sheaths between the layers. Contrast Figures 4.8 and 4.9 to notice the absence of 
corrugation and interdigitation in form III. 
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of 2.649 Å in form I and 2.677 Å in form III. The phenyl rings are twisted with respect to 
each other (interplanar angles are 51.2° in form I and 41.8° in form III) to alleviate the 
repulsions between the H-atoms on different rings. In both polymorphs, the carboxylic 
acid groups are nearly coplanar with the attached rings (angle between the planes of acid 
dimers and phenyl rings are 4.3° in form I and 6.3° in form III). 
 
The major difference between the two forms at a molecular level occurs in the relative 
orientation of the –COOH and –CF3 groups (Figure 4.7). In form I, both groups point 
roughly in the same direction; in form III they point in the opposite direction (caused by 
the rotation of phenyl ring bearing –CF3 group around the C–N bond). Thus forms I and 
III can be considered as conformational and orientational (or packing) polymorphs. The 
most important feature of the structures is that both polymorphs contain hydrogen bonded 
layers that are separated by fluorous sheaths of –CF3 groups (Figures 4.8 and 4.9). One of 
the important reasons in our selection of flufenamic acid as a model pharmaceutical is 
that the two solution grown polymorphs have two-dimensional fluorous sheaths. Based 
on the understanding that hydrogen bonds are stronger and –CF3⋅⋅⋅F3C– interactions are 
weaker, we hypothesized that larger or largest crystal faces of the two polymorphs will 
expose the fluorous surfaces. The rate of crystal growth in a direction is proportional to 
the rate of attachment of molecules in that direction.30 It is safe to assume that rate of 
growth along the hydrogen bonding is much faster than along the direction of fluorous 
interaction. Thus, we surmised that the larger or largest crystal faces of form I and III 
will be fluorous. 
 
 
Figure 4.10 Beading of water droplets on the largest of faces of flufenamic acid 
polymorphs I (left) and III (right). 
 
To examine the nature of these faces, we conducted contact angle measurements with 
water droplets on these crystals. Spreading of water should occur if the largest surfaces 
are hydrophilic (–COOH groups at the interface); beading of water should occur if the 
surfaces are hydrophobic (–CF3 groups at interface). Figure 4.10 shows the images of 
water droplets on the largest faces of polymorphs I and III. The measured contact angles 
are in the range 100-102° and the crystal faces are highly hydrophobic, proving our 
hypothesis that these faces expose fluorous groups. We assume further in our 
rationalization of the results that crystal nuclei of these polymorphs also expose similar 
fluorous surfaces. 
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4.8 POWDER X-RAY DIFFRACTION ANALYSIS 
 
We pulverized the crystalline products obtained from the experiments with mortar and 
pestle and exposed the ground materials to X-rays on a Bruker D8 Focus powder 
diffractometer. We collected the data in the 2θ range 3-45° at an increment of 0.04° and a 
scan rate of 4° per minute. Figure 4.11 shows experimental powder patterns of both 
polymorphs of flufenamic acid along with the patterns calculated from their single crystal 
structures. The experimental PXRD patterns confirm that while crystals grown in the 
fluorous vials correspond to polymorph I, those grown in hydroxylated vials belong to 
polymorph III. Unlike the polymorphs of nitrofurantoin, flufenamic acid polymorphs 
show distinct PXRD patterns. We use PXRD analysis as a tool to confirm that crystals in 
the bulk sample had the same structures as the ones described in previous section. 
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Figure 4.11 Calculated (top) and experimental (bottom) PXRD patterns of polymorphs I 
(left) and III (right) of flufenamic acid. Notice the correspondence between the calculated 
and experimental patterns for a given polymorph and the contrast between the different 
polymorphs. 
 
4.9 THERMAL ANALYSIS OF PHASE TRANSITIONS 
 
We collected the differential scanning calorimetry (DSC) data in hermetically sealed and 
crimped aluminum pans. We heated the samples in the range of 25-350°C at 10 and 2 °C 
per minute. The DSC traces of polymorphs I and III are shown in Figure 4.12. Both 
polymorphs show a single endotherm corresponding to the melting when heated at the 
rate of 10 °C per minute (133 °C for I and 126 °C for III). These melting points agree 
with the reported values. 
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Figure 4.12 DSC Thermograms of polymorphs I (top) and III (bottom) showing melting 
endotherms. The thermograms are recorded at a rate of 10 °C per minute. 
 
We tested the enantiotropic relationship between forms I and III in the calorimeter using 
different rates of heating. It is known that form III is more stable than form I below 42 
°C.14 If the polymorphs are heated at the rate of 10 °C per minute they do not show any 
other phase transitions other than melting endotherms. If the polymorphs are heated at the 
slower rate of 2 °C per minute, polymorph III shows a small endotherm at 120 °C just 
below the melting point (Figure 4.13).15 Forms I and III are enantiotropic; that form III 
absorbs heat when transformed to form I, indicates that form III is the more stable 
polymorph at room temperature (below the transition point). 
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Figure 4.13 DSC Thermogram of polymorph III showing a small endotherm at 120 °C 
corresponding to III→I transition and a large melting endotherm at 133 °C. The 
thermogram is recorded at a rate of 2 °C per minute. 
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4.10 CRYSTAL GROWTH ABOVE THE PHASE TRANSITION TEMPERATURE 
 
Flufenamic acid provided us with a unique system to test whether the surface effects 
would be reversed if the crystallization were carried out at a higher temperature. We 
hypothesized that if the crystal growth is allowed to occur above the phase transition 
temperature, form I (now stable) should appear in hydroxylated vials and form III (now 
metastable) should appear in fluorous vials. We tested a series of experiments with 
ethanol at temperatures in the range of 50-70 °C, but the rapid evaporation of ethanol in 
these conditions yielded mostly form III regardless of the surface used. We carried out 
further experiments in toluene solutions due to its ability to dissolve flufenamic acid and 
its relatively slower rate of evaporation in the region 70-90 °C compared to other solvents 
tested. 
5
2θ (°)
10 15 25 30 3520
Form I
Form II
Form III
 
Figure 4.14 PXRD Patterns of forms I, II and III. Form II is grown from toluene solutions 
in fluorous vials at 80 °C. 
 
We prepared 42 mM solutions of flufenamic acid in toluene by heating at 60 °C for about 
20 minutes and used them for crystallizations immediately. A set of hydroxylated and 
fluorous vials containing these solutions are kept at 80 °C in an oven. In the hydroxylated 
vials, white crystals are formed at the bottom and in the fluorous vials off-white colored 
crystals appeared. We characterized the crystals in hydroxylated vials using PXRD and 
confirmed that they belong to polymorph I. Our hypothesis seemed to have worked in 
that at higher temperatures the stable polymorph I crystallized in vials with repelling 
surfaces. What formed in the fluorous vials is yet to be determined with confidence, but 
the PXRD analysis gave us a pattern that did not match polymorph I or III, but had 
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several peaks that matched polymorph II (Figure 4.14). Interestingly, the off-white 
crystals formed in fluorous vials turned white in color within 24 hours, and PXRD 
analysis revealed that these crystals belong to polymorph I. It is known that form II is 
metastable and exhibits a monotropic relationship with form I at all temperatures. The 
transition of form II to form I is therefore not surprising; once the II→I transition occurs, 
it is an irreversible process and the crystals remain as form I at room temperature. 
 
4.11 SUMMARY AND CONCLUSION 
 
We explored two contrasting surfaces for the crystal growth of polymorphs of flufenamic 
acid at temperatures below and above the phase transition temperature. We showed that 
both hydroxylated and fluorous surfaces influence the growth of polymorphs in these two 
temperature ranges. The hydroxylated surfaces are highly hydrophilic and the fluorous 
surfaces are highly hydrophobic. When the drug is crystallized from ethanol solution at ~ 
25 °C, crystals of metastable polymorph I grow exclusively in fluorous vials. Under the 
same conditions, from the same stock solution, only crystals of stable polymorph III 
grow in the hydroxylated vials.  On both types of vials crystals appeared at the end of the 
solvent evaporation and nothing crystallized on the walls of hydroxylated and fluorous 
surfaces. These results are in contrast with our previous studies using indomethacin, 
nitrofurantoin, carbamazeine and other drugs, for which crystals always nucleated on the 
walls of the hydroxylated vials along the solvent front.  
 
The change in the nature of hydroxylated surfaces from being sticky to nonstick can be 
understood by noting that flufenamic acid is the only drug we screened that contains 
fluorous fragments (–CF3) in the molecular structure. As stated in Section 4.7 we surmise 
(based on the water contact angles of largest crystal faces) that fluorous nuclei of this 
drug are highly hydrophobic and do not attach to the hydroxylated surfaces. Thus, 
nucleation of metastable form is suppressed on the walls allowing for the stable form to 
nucleate and grow into crystals. In our previous studies we used xenophobic vial surfaces 
to promote the growth of thermodynamic form by suppressing the nucleation of kinetic 
form. In this study, we showed the reverse inhibition, clusters of kinetic polymorph 
exhibit fluorous surfaces and do not nucleate on hydrophilic surfaces. In fluorous vials, 
the growth of kinetic form may be promoted by favorable interactions between fluorous 
nuclei and fluorous surfaces of the vial. The observation that crystals did not nucleate on 
the walls of the fluorous vials can be attributed to poor wetting properties of the ethanol 
and the weaker fluorous⋅⋅⋅fluorous interactions between the nuclei and vial walls. It is 
possible that microscopic nuclei are attached to the surface and allow the growth of 
metastable form in the fluorous vials. Further studies using fluorinated solvents for 
crystallization can resolve some of these issues.  
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5.1 BACKGROUND  
 
Multicomponent solids, be they cocrystals or solid solutions, may be viewed as materials 
that can exhibit functions superior or unavailable to the individual components.1 Though 
molecular complexes have been studied for a long time,2-7 the design of cocrystals 
containing more than two different components remains a challenging task.8 Except for a 
few notable contributions,9-15 most studies on organic cocrystals led only to the formation 
of binary organic solids.1 In contrast, metals and inorganic compounds readily form 
multicomponent solids in the form of solid solutions.16, 5 Creating multicomponent solid 
solutions of organic molecules, however, is challenging because these molecules possess 
intricate shapes and participate in directional intermolecular interactions.5 Consequently, 
most of the molecule based solid solutions contain only two components.17 Here we 
describe a supramolecular approach for the preparation of solid solutions that contain 
three or more organic molecules. The principal advantage of solid solutions is that their 
properties can be modulated by gradual modification of the relative ratio of the 
components.18  
 
5.2 MOLECULAR CRYSTALS 
 
This work involves crystalline solids that contain single and multiple components and in 
this context it is useful to define the terms molecular crystal, cocrystal and solid solution. 
A molecular crystal is a periodic single component solid in which the component 
molecules are arranged on a three-dimensional lattice (Figure 5.1a). The rationalization 
and design of crystal structures are the central goals of crystal engineering both to prepare 
functional solids and to advance our understanding of crystal growth, polymorphism, and 
structure-property relationships.2 Polymorphs, crystals of the same compound with 
different structures, have attracted much recent interest because of their importance in 
pharmaceutical processing.19-22 Early work in crystal engineering laid the foundations for  
 
(a) (b) (c)
 
Figure 5.1 Schematic representations of (a) a crystal, (b) a cocrystal and (c) a solid 
solution. (a) A single-component crystal is a solid with periodic arrangement of one type of 
molecule. (b) The cocrystal shown here is made from two different molecules; its repeat 
unit, however, contains three molecules. This is an example of a binary cocrystal with a 
trimolecular repeat unit. (c) The molecular solid solution shown here is made from two 
different molecules that have similar sizes and shapes. The components are arranged on a 
periodic lattice but distributed randomly throughout the crystal. In a cocrystal the 
components are in a stoichiometric ratio; in a solid solution, they are not. All three solids 
have periodic structures; all are crystalline materials.  
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the design of two-component solids and the concepts and tools of crystal engineering are 
now being applied in the preparation of multicomponent pharmaceutical solids.23 In the 
past, multicomponent solids are prepared as either cocrystals or solid solutions (Figures 
5.1b and 5.1c). 
 
5.3 COCRYSTALS 
 
Cocrystals are periodic crystalline solids that contain two or more components in a 
stoichiometric ratio (Figure 5.1b).3 Cocrystals have different properties than the crystals 
of individual components; they are now being considered as new forms of medicines to 
alter the solubility, dissolution rate, bioavailability, or other properties of pharmaceutical 
drugs.24-26 Cocrystals can be made from two molecules of any shape or size that have 
complementary hydrogen bond functionalities. The crystal structures of cocrystals are 
different from the pure components and cocrystals often exhibit different sets of 
hydrogen bonding patterns and supramolecular synthons.27 We are exploring the design 
of cocrystals due to their applications in pharmaceutical formulations and also because 
we use them as starting points to create supramolecular solid solutions.28 
 
5.4 MOLECULAR SOLID SOLUTIONS 
 
Solid solutions and cocrystals are similar in that they are crystalline and have the overall 
three-dimensional periodicity, but they differ from each other in several ways. The 
components within the solid solutions are in nonstoichiometric ratios, they are distributed 
randomly throughout the crystal, and they must be of similar size and shape in order to 
form an organic alloy (Figure 5.1c).5 Thermodynamically, solid solutions can be easier to 
form due to entropic gain achieved from the freedom of nonstoichiometric ratios and 
random distribution of components. They are akin to metallic alloys in that the different 
components can be added in diverse ratios to achieve different properties. The major 
limitation of molecular solid solutions is that different components must be of similar 
size and shape, and given the complicated three-dimensional structures of most organic 
and pharmaceutical molecules it is difficult to identify and synthesize the analogues of 
target molecules. 
 
5.5 SUPRAMOLECULAR SOLID SOLUTIONS 
 
Molecular solid solutions are made of two or more molecules that are of the same shape 
and size. Supramolecular solid solutions are made of two or more supermolecules or 
molecular assemblies that have the same shape and size. Figure 5.2 shows our strategy 
for forming supramolecular solid solutions. We begin with a trimolecular motif wherein a 
central target molecule (A) is connected to two peripheral molecules (B or C) through 
similar intermolecular interactions. If the two peripheral molecules are identical, binary 
cocrystals AB2 or AC2 are formed. If they are different, a ternary cocrystal BAC or 
ternary solid solutions A(BnC1-n)2 (0 < n < 1) can be formed depending on the size and 
shape similarities of these peripheral molecules. Adding another isosteric component (D)  
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Figure 5.2 (a and b) Binary cocrystals AB2 and AC2. Note that B and C have similar 
shapes and sizes. In these diagrams, AB2 and AC2 adopt different crystal structures. (c) 
Ternary solid solution made of A, B and C. In this diagram, the solid solution adopts the 
structure of AB2; it can as well adopt AC2 or some other structure. The trimolecular 
assemblies in (c) may have BAB, CAC or BAC configurations. The overall composition of 
the ternary solid solution is An(B+C)2n. (d) Quaternary solid solution made of A, B, C and 
D, with an overall composition An(B+C+D)2n. 
 
 
leads to a quaternary solid solution. We have used a trimolecular motif to illustrate the 
concept; a bimolecular motif or any higher order motif can be used with the same 
effectiveness to prepare alloys. 
 
Because this strategy does not require the analogues of target molecule, it allows the 
preparation of solid solutions of any potential target molecule by adding complementary 
molecules of same size and shape. These complementary molecules can be selected 
depending on the function one is after. This supramolecular strategy makes it easy to 
prepare truly multi-component solid solutions that contain multiple (>3) different 
components. In this chapter, we will show the generality of our approach using four 
different target molecules and two different supramolecular synthons.  
 
5.6 SUPRAMOLECULAR SYNTHONS 
 
When designing cocrystals or solid solutions it is important to consider all possible 
intermolecular interactions such as hydrogen bonds, pi···pi stacking, C−H···X (X = N, O, F 
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or pi) interactions and halogen bonds. Hydrogen bonds between N and O atoms are easier 
to incorporate into a multicomponent solid owing to the preponderance of functional 
groups containing these heteroatom and differences in acidities and basicities of donor 
and acceptor molecules. Hydrogen bonds can exist as single point, two-point or multi-
point recognition motifs. In this context supramolecular synthons are defined as 
“structural units within supermolecules which can be formed and/or assembled by known 
or conceivable synthetic operations involving intermolecular interactions”.27 Figure 5.3 
shows some selected hydrogen bonded supramolecular synthons that we have used in our 
group in the preparation of multicomponent solids. 
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Figure 5.3 Some supramolecular synthons studied in this work. All the synthons are based 
on interactions between unlike functional groups; these are also termed heterosynthons. (a) 
Hydroxy-aza synthon. (b) Acid-pyridyl synthon; usually associated with a corollary 
C−H⋅⋅⋅O interaction. (c) Acid-amide synthon. (d) Acid-aminopyridyl synthon. (e) A three 
point synthon based on N-H···N and N-H···O hydrogen bonds. 
 
5.7 DABCO AND 4-X-PHENOLS 
 
We use the trimolecular template in Figure 5.2 and begin with the preparation of binary 
cocrystals and ternary, quaternary and quinary solid solutions formed by [2,2,2]-
diazabicyclooctane (DABCO) and 4-X-phenols (X = Cl, CH3, Br, I). We use DABCO as 
the central molecule and 4-X-phenols as the peripheral molecules (Figure 5.4). Each 
phenol molecule donates one hydrogen bond and a DABCO molecule accepts two 
hydrogen bonds. Together they form a stoichiometric binary cocrystal (two different 
components) with a repeat unit that contains three components and sustained by two 
O−H···N hydrogen bonds. 
 
The chloro, methyl, bromo and iodo substituents of 4-X-phenols have similar shapes, 
comparable sizes (20, 24, 28, 32 Å3)29 and do not interfere with the O−H···N hydrogen 
bonding required for the trimolecular assembly. We surmised that the size, shape, and 
chemical similarity of these 4-X-phenols will enable the formation of solid solutions 
when DABCO is crystallized with two, three or four different phenols. We call these 
crystalline materials supramolecular solid solutions because their repeat unit is a 
trimolecular assembly.  
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Figure 5.4 Molecular structures and nomenclature of cocrystals and solid solutions based 
on DABCO and 4-X-phenols.  
 
5.8 CRYSTAL STRUCTURES OF BINARY COCRYSTALS 
 
Single crystals of binary cocrystals and ternary, quaternary and quinary solid solutions 
(having appropriate quantities of phenols and DABCO) suitable for X-ray diffraction 
were grown from benzene solutions (Table 5.1, Figure 5.5). Our initial work focused only 
on the 4-chloro-, 4-methyl- and 4-bromophenols because of their size similarity and the 
knowledge that chloro-methyl and chloro-bromo exchanges have been attempted before.2 
After successfully preparing the multicomponent solids based on these phenols, we 
extended our work to the 4-iodophenol. Table 5.1 gives the unit cell data for a total of 
fifteen multicomponent solids, four cocrystals and eleven solid solutions, made from all 
possible binary, ternary, quaternary and quinary combinations of DABCO and 4-X-
phenols. 
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ClCl
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BrBr
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Figure 5.5 Hydrogen bonded trimolecular assemblies in binary cocrystals (left) and ternary 
solid solutions (right). 
 
 
Table 5.1 Unit cell data for binary cocrystals and ternary, quaternary and quinary solid 
solutions. Space groups are given in the column spgr. Full crystal structures are 
determined for all the binary and ternary cocrystals; for higher order solid solutions 
only unit cells are determined.  
Name spgr a (Å) b (Å) c (Å) β (°) V (Å3) 
ClCl C2/c 17.987 9.256 11.241 101.85 1831.7 
MeMe C2/c 18.351 9.179 11.254 102.73 1849.0 
BrBr P21/n 6.456 18.577 15.914 91.05 1908.2 
II P21/n 6.518 19.139 16.229 91.04 2024.3 
ClMe C2/c 18.178 9.202 11.260 102.36 1839.9 
ClBr P21/c 18.231 9.165 11.354 94.88 1890.2 
MeBr P21/n 6.443 18.559 15.884 91.36 1898.7 
ClI P21/n 6.484    18.694 15.953 91.15 1933.2 
MeI P21/n 6.459 18.882 16.017 90.86 1953.1 
BrI P21/n 6.485 18.868 16.031 90.06 1961.5 
ClMeBr P21/n 6.443 18.442 15.778 91.59 1874.0 
ClMeI P21/n 6.463 18.605 15.819 91.56 1901.4 
ClBrI P21/n 6.479 18.640 15.941 90.94 1924.2 
MeBrI P21/n 6.466 18.749 15.976 90.91 1936.6 
ClMeBrI P21/n 6.467 18.567 15.869 91.34 1904.7 
 
The binary cocrystals ClCl and MeMe are isostructural; Figures 5.6a and 5.6b show the 
structures of ClCl and MeMe. The unit cell of MeMe is larger than ClCl in accordance 
with the larger size of the methyl groups (Table 5.1). As expected, DABCO binds to two 
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phenol molecules through O−H···N hydrogen bonds (Figure 5.5). This trimolecular 
assembly is situated on a two-fold axis; that is, the two phenols are symmetry related. 
The packing of these assemblies in three-dimensions is governed by C−H···O, C−H···pi  
and van der Waals (vdW) interactions. 
 
In the crystal structure of BrBr (Figure 5.6c) the hydrogen bonded trimolecular assembly 
is located on a general position; that is, the two phenols are not related by symmetry. 
Within the crystal, these assemblies are extended into interconnected chains through 
type-I and type-II Br···Br interactions.30 It is likely that BrBr crystallizes in a structure 
different than ClCl and MeMe in order to accommodate these interactions. Despite the 
marked differences in their structures, the trimolecular assemblies in all the cocrystals 
adopt similar conformations (Figure 5.7). Noting this similarity and the similarities in the 
molecular structures of phenols, we attempted the preparation of ternary solid solutions 
of ClMe, ClBr and MeBr (Figure 5.4). 
 
(b)
(a)
(c)
O
c a
b
O
c a
b
O c
b
a
 
Figure 5.6 Crystal structures of (a) ClCl and (b) MeMe (c) BrBr. In (c) dashed lines show 
the O−H···N hydrogen bonds and Br···Br contacts. Note that the overall structures of the 
ClCl/MeMe and BrBr cocrystals are different. 
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Figure 5.7 Overlay of trimolecular assemblies in binary cocrystals. 
 
5.9 CONTINUOUS SERIES OF TERNARY SOLID SOLUTIONS 
 
We crystallized ClMe, ClBr and MeBr series of solid solutions with varying proportions 
of corresponding phenols and characterized them using powder X-ray diffraction analysis 
(Figure 5.8)31 and IR and 1H-NMR spectroscopy. We also determined the crystal 
structures of the ternary solid solutions containing DABCO and the respective phenols in 
1:1:1 proportion (Table 5.1, 50X-50Y in Figure 5.8). In these structures, the 
exchangeable groups (Cl, CH3, Br) show ~50% occupancy on both phenols (Figure 5.5). 
 
The 50Cl-50Me ternary solid solution is isostructural to ClCl and MeMe (Figure 5.9); 
the volume of its unit cell lies between the volumes of unit cells of ClCl and MeMe 
(Table 5.1). Powder X-ray analysis of the ClMe series (from 90Cl-10Me to 10Cl-90Me) 
shows a gradual change of the structure from ClCl to MeMe. The 50Cl-50Br solid 
solution adopts the crystal structure of ClCl, albeit with decreased symmetry (C2/c → 
P21/c; Table 5.1; Figure 5.9). Yet the volume of its unit cell is close to that of BrBr 
indicating the presence of bromine in the crystal. The ClBr series of solid solutions adopt 
the ClCl structure up to 40Cl-60Br; from 30Cl-70Br to 10Cl-90Br they adopt the BrBr 
structure (Figure 5.8). In contrast to ClBr, the 50Me-50Br solid solution adopts the 
structure of BrBr. MeBr solid solutions adopt MeMe structure only upto 90Me-10Br. 
From 80Me-20Br to 10Me-90Br they adopt the structure of BrBr. 
 
The Br-atom is larger than Cl-atom and CH3 group; it also participates in polarization 
induced attractive Br···Br interactions. Given these two facts, one would expect that ClBr 
and MeBr would adopt the structure of BrBr to accommodate the larger Br atoms and 
attractive Br···Br interactions. It is therefore surprising that ClBr adopts the structure of 
ClCl and not BrBr. The Cl-atom in ClCl forms 5 contacts to non H-atoms at vdW+0.2 Å 
separation, and 7 contacts at vdW+0.3 Å separation. If ClBr were to adopt the BrBr 
structure, the Cl-atom would form no contacts even at the separation of vdW+0.3 Å. In 
contrast, the vdW contacts made by the CH3 group do not change significantly between 
MeMe or MeBr structure. It is possible that ClBr adopts the ClCl structure because in 
this structure the Cl-atoms are involved in intermolecular contacts that are of stabilizing 
nature. 
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Figure 5.8 PXRD Patterns of series of ClMe, ClBr and MeBr solid solutions. We labeled 
these solid solutions such that the total phenol content in them is 100%. Thus, 60Cl-40Br 
indicates that the ternary solid solution consists of 60% chlorophenol and 40% bromo-
phenol. The corresponding binary cocrystals, e.g. 0Me-100Br and 100Me-0Br, border each 
series at the top and bottom. 
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Figure 5.9 Crystal structures of ternary solid solutions. Note that ClMe (a) and ClBr (b) 
adopt the structure of ClCl/MeMe whereas MeBr (c) adopts the structure of BrBr. 
 
The X-ray diffraction methods provide useful, yet limited, structural information of solid 
solutions. Single crystal X-ray analysis affords the structure of the repeat unit as an 
average of millions of such units. Consequently, we cannot distinguish which of the 
following compositions the ternary solid solutions adopt: (i) binary motifs AB2 and AC2 
randomly mixed throughout the crystal; (ii) random mixture of AB2, AC2, and BAC, or 
(iii) ternary motifs BAC statistically disordered over two positions such that B and C are 
superposed in the average structure. We can, however, ascertain from these X-ray studies 
that the repeat unit is indeed a trimolecular assembly and that the solid solution as a 
whole contains three different components. 
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5.10 SPECTROSCOPIC CHARACTERIZATION OF TERNARY SOLID SOLUTIONS  
 
The IR spectra were recorded in ATR mode on a Perkin Elmer Spectrum One 
spectrometer. For each measurement only one crystal was taken, which was washed with 
benzene and dried in air with filter papers immediately prior to the experiment. The broad 
double hump seen in the region of 1600-2800 cm-1 is characteristic of O−H stretching 
absorption and overtone from O-H bending respectively (Figure 5.10). An important 
feature of these spectra is that the broad peak at 3000-3600 cm-1 (corresponding to 
O−H···O hydrogen bonding in pure phenols) is absent in all of them. These spectra 
conclusively show that binary cocrystals as well as ternary solid solutions contain only 
heteromolecular assemblies. We have also collected the 1H-NMR spectra of binary 
cocrystals and all the ternary solid solutions. These spectra showed that the relative 
contents of DABCO and phenols within a crystal selected for NMR analysis are in 
agreement with the expected result. 
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Figure 5.10 IR spectra of binary cocrystals and ternary solid solutions. Note that ClMe and 
ClBr adopt the structure of ClCl/MeMe whereas MeBr adopts the structure of BrBr.  
 
5.11 TRENDS IN THE MELTING POINTS OF SOLID SOLUTIONS 
 
Figure 5.11 shows the differential scanning calorimetry (DSC) results from ClBr, ClMe 
and MeBr series of ternary solid solutions. The melting points of ClBr solid solutions 
gradually decrease from ClCl to 40Cl-60Br, and then increase to BrBr. Figure 5.11 
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illustrates that solid solutions offer the unique ability to modulate the physical properties 
of materials in an almost continuous fashion. 
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Figure 5.11 DSC traces of ClBr, MeBr and ClMe solid solutions. In some instances, 
melting is immediately followed by the decomposition of DABCO. In most cases, the 
decomposition of DABCO takes place around 170 °C. 
 
5.12 QUATERNARY AND QUINARY SOLID SOLUTIONS 
 
The utility of the supramolecular approach to the solid solutions is exemplified by our 
synthesis of the four quaternary (four-component) solid solutions and a quinary (five-
component) solid solution from DABCO and four different phenols. (Table 5.1). For 
example, the ClMeBr solid solution is made from equimolar quantities of the 
corresponding phenols and the volume of its unit cell (1874 Å3) is close to the average of 
unit cell volumes of ClCl, MeMe and BrBr (1863 Å3). From the unit cell dimensions 
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(Table 5.1) and powder X-ray diffraction patterns (Figure 5.17 below), it can be seen that 
ClMeBr adopts the structure of BrBr. 
 
The following figures show the characterization of ClMeBr by various methods (DSC, 
IR, NMR and PXRD). The unit cell parameters of ClMeBr reported in Table 5.1 are 
determined by single crystal X-ray diffraction. The IR spectrum (Figure 5.12) shows that 
a single crystal of ClMeBr has only heteromolecular assemblies and the 1H NMR 
spectrum (Figure 5.13) shows that DABCO and three phenols are in 1.5:1:1:1 ratio. The 
DSC thermogram shows that ClMeBr has a distinct melting point that is different from 
the corresponding binary cocrystals or ternary solid solutions (Figure 5.14).  
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Figure 5.12 IR spectrum of ClMeBr showing the double hump (in the region 1600-2800 
cm-1) characteristic of hydrogen bonding between DABCO and phenols. 
 
As with IR, for 1H NMR spectroscopy only one crystal (washed and dried) was used in 
each experiment to avoid contamination from any physisorbed materials. The peaks 
corresponding to different phenols and DABCO are assigned using colored circles and 
polygons in Figure 5.13. In binary cocrystals there are eight phenolic protons (two 
distinct sets; each consisting of four protons) and twelve DABCO protons. In order to aid 
in the analysis of ternary solid solutions, the total proton content (eight) of the phenols is 
integrated to be ~200 units. The twelve protons on DABCO then integrate to ~300 units. 
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Figure 5.13. 1H NMR spectrum of ClMeBr solid solution collected on a 400Mz NMR 
spectrometer in acetone-d6 solvent. The peak at 5.63 ppm belongs to CH2Cl2 that 
contaminated acetone-d6. 
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Figure 5.14. DSC Trace of ClMeBr solid solution (open circles) showing the melting 
endotherm. DSC Traces of binary cocrystals and 50X-50Y-ternary solid solutions are 
shown for comparison. 
 
We have characterized the other three quaternary solid solutions and the quinary solid 
solution ClMeBrI in a similar manner. Figure 5.15 shows the 1H-NMR spectrum of 
ClMeBrI, taken from a single crystal. The quinary solid solution and the four quaternary 
solid solutions have melting points that are distinct from the corresponding binary 
cocrystals and ternary solid solutions (Figures 5.14 and 5.16). It is important to recognize 
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that ClMeBr, ClMeI, ClBrI, and MeBrI are four-component solid solutions and 
ClMeBrI is a five-component solid solution prepared on the basis of a three-component 
supramolecular assembly. These results show that our approach to the solid solutions is 
an effective method to create truly multicomponent organic alloys. Unit cell data (Table 
5.1) and powder diffraction patterns (Figure 5.17) indicate that ClMeBr (and other four 
component) and ClMeBrI solid solutions adopt the structure of BrBr. 
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Figure 5.15 1H NMR spectrum of ClMeBrI solid solution collected on a 600Mz NMR 
spectrometer in chloroform-d solvent. 
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Figure 5.16 DSC Traces showing the comparison of the melting endotherms of the binary 
cocrystal and ternary, quaternary and quinary solid solutions containing 4-iodophenol. 
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Figure 5.17 PXRD Patterns of ClMeBrI (bottom trace) four quaternary solid solutions. 
PXRD Patterns of BrBr and ClCl are shown for comparison. Note that all the four- and 
five-component solid solutions adopt the structure of BrBr.  
 
5.13 PREPARATION OF COCRYSTALS AND SOLID SOLUTIONS BY GRINDING 
 
All the cocrystals and solid solutions described above were grown by solution 
crystallization through the slow evaporation of solvent. The advantage of this method is 
that it can yield pure crystalline materials suitable for single crystal X-ray analysis; it 
allows determination of crystal structures and gives access to the three-dimensional 
coordinaties of atoms in the molecule. There are, however, certain limitations associated 
with the preparation of multicomponent materials through solution crystallization. The 
solvent or mixture of solvents should be adjusted based on solubility of the individual 
components. In addition, an undesired solvate of the target cocrystal can be crystallized 
instead of the unsolvated product. An alternative approach to make multicomponetnt 
materials is to use the solid-state grinding method.32-34 The main advantage of this 
method is that it minimizes the solubility problems of disparate components. At its best, 
this method does not use solvents; in the case of liquid assisted grinding it uses only 
small volumes of solvent. For this reason, the grinding method offers a green and 
environment-friendly approach to the preparation of cocrystals. A notable disadvantage 
of this technique is the inability to prepare diffraction quality crystalline products; that is, 
crystal structures of the products obtained are usually not determined. The mechanism of 
how solid state grinding affects cocrystallization is not yet clearly understood.35 It is 
suggested that molecular complexes may be formed through vapor diffusion 
mechanism.36 We wished to test the neat grinding method in the preparation of our 
cocrystals and solid solutions from DABCO and appropriate phenols. Molecular 
complexes of all possible combinations of the components are formed after 20 minutes of 
solvent free grinding. The products were characterized by IR, DSC and PXRD methods. 
Figure 5.18 shows the PXRD patterns of quaternary and quinary solid solutions which 
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match well with the PXRD patterns of the corresponding products crystallized from 
solution. 
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Figure 5.18 PXRD Patterns of solid solutions prepared by solvent-free grinding. Note the 
continuous shift of the peaks along 2θ due to the differences in unit cell volumes. 
 
Materials that have multiple components can exhibit properties that are different from the 
individual components and often they provide access to phenomena and properties 
unavailable to single component materials. The advantage of the supramolecular 
approach shown in Figure 5.2 is that any target molecule capable of forming hydrogen 
bonds can in principle be complexed with a set of molecules (with exchangeable groups) 
to form solid solutions. The physical properties of these solid solutions can be finely 
tuned by changing the nature and relative ratio of the different components. This 
approach should be useful to all the situations in which binary systems are currently used, 
but it may find distinctive use in pharmaceutical form selection.37, 38  
 
5.14 MULTICOMPONENT SOLIDS WITH DABCO AND 3-X-PHENOLS 
 
We wished to test the generality of our supramolecular approach (Figure 5.2) described 
above and applied it to other systems. At the beginning, we proceeded with a small 
change at the molecular level; we replaced the 4-X-phenols with 3-X-phenols and kept 
DABCO as the central molecule. It should be noted that very rarely do meta- and para-
substituted compounds show similarity in their structures; though the change we have 
made appears small, at a supramolecular level this change can be significant.  
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Figure 5.19 Molecular structures and nomenclature of cocrystals and solid solutions based 
on DABCO and 3-X-phenols.  
 
We have made all the fifteen possible multicomponent solids, four binary cocrystals and 
eleven three- to five-component solid solutions, using DABCO and 3-X-phenols (Figure 
5.19). We label these materials in the format Cl'Cl' (with a prime next to the 
exchangeable group) to distinguish them from multicomponent solids made from 
DABCO and 4-X-phenols. We determined the crystal structures of all the cocrystals and 
most of the solid solutions (Table 5.2). Unlike in the DABCO:4-X-phenols, the four 
cocrystals made from DABCO and 3-X-phenols adopt four different crystal structures as 
suggested by their unit cell parameters given in Table 5.2. Nevertheless, all the cocrystals 
contain the expected trimolecular assembly in which DABCO and phenol molecules are 
joined by O−H⋅⋅⋅N hydrogen bonds. While the trimolecular assembly sits on a two-fold 
axis in Cl'Cl', in Me'Me', Br'Br', and I'I' the trimolecular repeat units are situated in 
general positions. In addition, one of the two independent phenol molecules in Me'Me' is 
disordered over two positions. Crystal structures of these four cocrystals are given in 
Figures 5.20 to 5.23.  
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Table 5.2 Unit cell data for binary cocrystals and ternary, and quaternary solid 
solutions made from DABCO and 3-X-phenols. Space groups are given in the column 
spgr.  
Name spgr a (Å) b (Å) c (Å) α (°) β (°) γ (°) V (Å3) 
Cl'Cl' C2/c 17.470 9.357 11.133 90 104.50 90 1761.84 
Me'Me' P-1 6.543 12.518 12.652 115.39 103.20 91.30 902.86 
Br'Br' P21/c 13.679 9.410 15.722 90 112.62 90 1867.97 
I'I' Pbcn 21.637 9.658 18.655 90 90.00 90 3898.16 
Cl'Me' P21/c 13.180 9.397 15.914 90 111.85 90 1829.45 
Cl'Br' P21/c 15.662 9.332 13.414 90 112.21 90 1815.04 
Me'Br' P21/c 15.857 9.364 13.560 90 112.19 90 1864.17 
Cl'I' P21/c 15.798 9.364 13.594 90 111.87 90 1866.28 
Br'I' P21/c 14.030 9.522 15.943 90 112.56 90 1966.97 
Cl'Me'Br' P21/c 13.496 9.407 15.775 90 112.09 90 1855.60 
Cl'Me'I' P21/c 13.691 9.420 15.872 90 111.94 90 1898.84 
Cl'Br'I' P21/c 13.690 9.443 15.787 90 112.15 90 1890.21 
Me'Br'I' P21/c 13.806 9.410 15.825 90 111.97 90 1906.72 
 
 
Figure 5.20 Crystal structure of Cl'Cl'. Notice the similarity between this structure and the 
structures of ClCl and MeMe belonging to 4-X-phenols (Figure 5.6).  
 
 
Figure 5.21 Crystal structure of Me'Me'. One of the two m-cresol molecules are disordered 
over two positions; only one position is shown here. Contrast this structure with that of 
Cl'Cl' (Figure 5.20).  
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Figure 5.22 Crystal structure of Br'Br'. Contrast this structure with those of Cl'Cl' (Figure 
5.20) and Me'Me' (Figure 5.21).  
 
 
Figure 5.23 Crystal structure of I'I'. Contrast this structure with the structures of other 
three congeners (Figures 5.20-5.22).  
 
 
The crystal structure of Cl'Cl', the smallest of the four X'X' cocrystals, is isostructural to 
those of ClCl and MeMe. The other three cocrystals adopt different structures to 
accommodate intermolecular interactions specific to the corresponding exchangeable 
group. In Me'Me' the disordered phenol rings are situated atop the DABCO molecule 
such that short C−H⋅⋅⋅pi contacts can be formed with the phenol acting as the C−H⋅⋅⋅pi  
acceptor and DABCO acting as the donor. Short Br⋅⋅⋅pi interactions are found in Br'Br'; 
one of the two symmetry independent 3-bromophenol molecules is connected to another 
symmetry related molecule through short contact between the Br-atom and center-point 
of a C=C in the ring (dBr⋅⋅⋅pi: 3.35Å and θC−Br⋅⋅⋅pi: 174.2°). Charge transfer interactions 
between halogen atom and aromatic ring are well-known; the larger the halogen atom, the 
greater the polarizability, and greater is the stability of the interaction. The second 
symmetry independent phenol molecule in Br'Br' forms a C−H⋅⋅⋅O hydrogen bonded 
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dimer with an inversion related molecule (dC⋅⋅⋅O: 3.34Å, dH⋅⋅⋅O: 2.47Å, and θC−H⋅⋅⋅O: 
149.2°). In I'I' the I-atom of one phenol molecule is connected to the I-atom on another 
phenol molecule (that is not related by symmetry) at a separation of 3.69Å.  
 
While the overall crystal structures are a result of delicate interplay between various 
intermolecular interactions in the solid state and conditions under which the crystals are 
grown, the differences between these four cocrystals seem to originate from the different 
steric (size) and chemical (noncovalent bonding) requirements of the groups Cl, Me, Br 
and I. These findings are of concern because our goal in this work is to prepare to 
supramolecular solid solutions that contain various combinations of these phenols. One of 
the three requirements for forming molecular solid solutions, postulated by 
Kitaigorodskii, is that two components should have similar crystal structures. The other 
two requirements are the similarity in size and similarity in shape of the components. Our 
concern is alleviated to some extent by the observation that the trimolecular assemblies in 
four cocrystals exhibit similar conformations (Figure 5.24).  
 
 
Figure 5.24 Overlay of trimolecular assemblies in X'X' binary cocrystals. 
 
It is instructive to ask the question, why do X'X' crystals show so much structural 
diversity compared to XX crystals? The answer has two important interrelated 
components. The conformational freedom of the trimolecular assembly coupled with the 
placement of X group at the meta position can lead to different starting geometries in 
solution. These different geometries can be seen in the overlay diagram shown in Figure 
5.24. When the X groups are at the para position, the rotation of phenols around the 
O−H⋅⋅⋅N hydrogen bonds does not lead to cis-trans type of geometries. In other words, 
the hydrogen bonded assemblies in XX complexes have fewer starting geometries than in 
in X'X' systems. These observations suggest that crystal design with conformationally 
flexible molecules or supermolecules has lower predictability than their rigid counter 
parts. In the case of supermolecules, one way to minimize this problem is to use multi-
point hydrogen bonding synthons between the components. In the present design, we use 
a single point synthon, O−H⋅⋅⋅N hydrogen bond, as a design element. We show in 
Chapter 6 that use of a two-point synthon gives greater predictability over local geometry 
and minimizes complications in the outcomes of crystal design. 
 
The high overlay coefficient between hydrogen bonded assemblies of different X'X' 
cocrystals encouraged us to attempt the preparation of solid solutions using these 
108 CHAPTER 5  
 
materials. Indeed, mixing of DABCO and different 3-X-phenols in appropriate ratios in 
solution followed by evaporation yielded single crystals of the respective 
multicomponent solid solutions. We determined the crystal structures of most of the 
ternary solid solutions and unit cell parameters for quaternary and quinary solid solutions 
(Table 5.2). Figure 5.25 shows the trimolecular repeat units in Cl'Cl' and Br'Br' 
cocrystals and the 50:50 ternary solid solution Cl'Br'. This representative example shows 
that it is indeed possible to make solid solutions of X'X' cocrystals even though 
individually they adopt very different structures. One of the implicit advantages of the 
supramolecular solid solutions is that the repeat unit is a supermolecule that is larger than 
the molecules. Thus, within these supermolecules the change we make (e.g., replacing Cl 
with Br) is relatively smaller and the overall similarity coefficient between the repeat 
units is higher, which allows them to form solid solutions. 
 
Br'Br'
Cl'Br'
Cl'Cl'
 
Figure 5.25 Trimolecular assemblies in Cl'Cl' and Br'Br' cocrystals and Cl'Br' solid 
solution. Note that two chlorophenol molecules in Cl'Cl' are related by a two-fold axis; in 
Br'Br' the phenol molecules are symmetry independent. The Cl'Br' solid solution adopts 
the structure of Br'Br' cocrystal. 
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Figure 5.26 PXRD Patterns of Cl'Me' series of solid solutions. We labeled these solid 
solutions such that the total phenol content in them is 100%. Thus, 60Cl'-40Me' indicates 
that the ternary solid solution consists of 60% 3-chlorophenol and 40% m-cresol.  
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Figure 5.27 DSC traces of Cl'Me' series of solid solutions. Notice the gradual change in 
the melting points.  
 
Following our success in the preparation of ternary solid solutions and the other higher 
order solutions containing equimolar quantities of 3-X-phenols, we prepared the 
continuous series Cl'Me', Cl'Br' and Me'Br' solid solutions. In each series, we prepared 
a total of nine solid solutions and characterized them with IR and NMR spectroscopy and 
PXRD analysis. Figure 5.26 shows the diffraction patterns of Cl'Me' series as a 
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representative example. Again, the structures smoothly transition from one cocrystal 
(Cl'Cl') to another (Me'Me'). As with the XY series, the X'Y' series of solid solutions 
also showed a continuous change in their physical properties. The melting endotherms 
determined by DSC showed gradual transition in the melting points of different solid 
solutions. Figure 5.27 shows the DSC thermograms of Me'Br' series as a representative 
example.  
 
5.15 MULTICOMPONENT SOLIDS WITH 4,4'-BIPYRIDYL AND 4- AND 3-X-PHENOLS 
 
To further examine the efficacy of our approach, we began the preparation of solid 
solutions that contained a new target central molecule while preserving the peripheral 
phenol molecules. The central molecule we chose for this purpose is 4,4'-bipyridyl (BP), 
an aromatic diaza compound that is, like DABCO, capable of forming two hydrogen 
bonds with phenolic donors. The N-atoms are less basic in BP than they are in DABCO 
and the backbone is aromatic. While the lower basicity can decrease the potency of 
cocrystallization, the aromatic rings in BP can lead to well-developed and more ordered 
crystals. Our work in these systems is in early stages and in this chapter we limit our 
discussion to some binary cocrystals and ternary solid solutions. We expect that this 
system will also yield higher order solid solutions just the way DABCO complexes did. 
Table 5.3 shows the unit cell data on some of the multicomponent solids we have 
crystallized so far. This data shows that BP-X series BP-X' series of cocrystals adopt 
different structures; within each series however different cocrystals adopt similar 
structures. We have shown the repeat units of some of the crystal structures in Figure 
5.28. 
 
Table 5.3 Unit cell data for binary cocrystals and ternary solid solutions made from BP 
and 3-X- and 4-X-phenols. Space groups are given in the column spgr.  
Name spgr a (Å) b (Å) c (Å) β (°) V (Å3) 
BP-BrBr P21/c 11.710 9.959 18.703 107.25 2083.0 
BP-II P21/c 19.369 9.612 19.327 110.78 3364.4 
BP-BrI P21/c 19.091 9.567 19.411 112.00 3287.0 
 
      
BP-Cl'Cl' P21/c 7.379 17.749 7.709 99.52 995.8 
BP-Br'Br' P21/c 7.550 17.502 7.811 100.51 1014.8 
BP-I'I' P21/c 8.061 16.140 8.585 104.42 1081.8 
BP-Cl'Br' P21/c 7.466 17.639 7.755 99.99 1005.7 
BP-Me'Br' P21/c 7.577 17.436 7.868 100.62 1021.7 
BP-Cl'I' P21/c 7.748 17.050 8.094 101.89 1046.3 
BP-Br'I' P21/c 7.834 16.826 8.204 102.50 1055.8 
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BP-Br'Br'
BP-Cl'I'
BP-Br'I'
BP-Me'Br'
 
Figure 5.28 Trimolecular assemblies in some of the cocrystals and solid solutions formed 
by BP and 3-X- and 4-X-phenols.  
 
 
5.16 MULTICOMPONENT SOLIDS WITH HYDROXY⋅⋅⋅AMINO RECOGNITION 
 
The organic alloys we described so far have used a single point hydrogen bond between 
hydroxy and aza groups. Once the hydrogen bonds are formed between a central diaza 
molecule and two peripheral phenol molecules, the assembly becomes ‘saturated’ and 
does not form further hydrogen bonds. In other words, the supramolecular repeat unit in 
these complexes is a discrete trimolecular assembly. We wished to further test the 
generality of our approach by applying it to compounds that can form extended hydrogen 
bonded arrays upon cocrystallization.  
 
Hydroxy and amine groups are common functional groups in organic chemistry and for 
the most part they have been used in crystal engineering as hydrogen bond donors with 
other acceptors such as pyridyl N-atom or carbonyl O-atom. In the early 1990s it has 
been explicitly recognized that (a) the hydroxy group has two lone pairs and one H-atom 
and amine group has two H-atoms and one lone pair (Figure 5.29a) and (b) these two 
groups are complementary in terms of their hydrogen bonding capabilities.39-42 If the two 
groups are present in 1:1 stoichiometry in a crystal, each group would form a total of four 
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bonds, one covalent and three noncovalent. The hydroxy group donates one hydrogen 
bond and accepts two, and the amine group donates two and accepts one hydrogen bond. 
Each heteroatom then adopts a tetrahedral geometry which allows us to deduce possible 
supramolecular structures.39 Hydroxy⋅⋅⋅amino recognition refers to the noncovalent 
bonding of these two groups such that each group is saturated with respect to hydrogen 
bonding and adopts a tetrahedral geometry.43 It is possible that other factors can influence 
the bonding between hydroxy and amine groups and prevent them from forming 
hydroxy⋅⋅⋅amino recognition.44  
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Figure 5.29 (a) Hydrogen bond complementarity of hydroxy and amine groups showing 
the lone pairs and H-atoms. (b-d) Some superstructures resulting from hydroxy⋅⋅⋅amino 
recognition. See text for details.  
 
Figure 5.29 shows some of the possible superstructures that can be built from 
hydroxy⋅⋅⋅amino recognition. These structures range from discrete clusters such as the 
cubic arrangement (Figure 5.29b), one-dimensional tapes such as adjoined squares across 
opposite edges (Figure 5.29c) or two-dimensional sheets such as adjoined hexagons 
(Figure 5.29d) across all edges (honeycomb structure if the hexagon is planar and 
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wurtzite structure if the hexagon adopts a chair conformation).39 There are other possible 
superstructures that can result from hydroxy⋅⋅⋅amino recognition.  
 
In order to apply the hydroxy⋅⋅⋅amino recognition to our approach of supramolecular 
solid solutions, we have selected hydroquinone (HQ) as central molecule and para-
substituted anilines (4-X-anilines) as the peripheral molecules. A distinct advantage with 
this system is that we can choose 1,4-diaminobenzene (pheneylenediamine, PD) as the 
central molecule and para-substituted phenols (4-X-phenols) as the peripheral molecules. 
When taken together, the HQ:4-X-aniline complexes and PD:4-X-phenol complexes can 
be isostructural and provide us with yet another way of incorporating multiple molecules 
into a single crystalline solid solution. To date, we have been able to crystallize all the 
four possible cocrystals and ternary solid solutions of HQ:4-X-aniline complexes and two 
cocrystals of the PD: 4-X-phenol complexes (Table 5.4) 
 
Table 5.4 Unit cell data for binary cocrystals and ternary solid solutions made from HQ 
and 4-X-anilines and binary cocrystals made from PD and 4-X-phenols. Space groups 
are given in the column spgr.  
Name spgr a (Å) b (Å) c (Å) α (°) β (°) γ (°) V (Å3) 
HQ-ClCl P21/c 10.674 6.152 13.405 90 97.57 90 872.60 
HQ-MeMe P-1 6.013 8.527 17.815 86.40 84.87 89.88 908.00 
HQ-BrBr P21/n 4.522 9.063 22.172 90 93.49 90 907.03 
HQ-II P21/c 10.873 4.930 18.108 90 93.24 90 969.21 
HQ-ClBr P21/n 4.569 9.003 21.791 90 92.94 90 895.27 
HQ-ClI P21/c 10.661 4.868 17.958 90 94.21 90 929.47 
 
        
PD-BrBr P21/c 10.637 4.829 18.159 90 95.60 90 928.19 
PD-II P21/c 10.616 5.376 16.479 90 92.19 90 939.67 
 
We crystallized the multicomponent solids in Table 5.4 using combinations of solutions 
that included ethanol, methanol, ether and benzene. The anilines tended to decompose in 
solutions due to exposure to light and air and frequently posed problems in preparing 
good quality crystals. Crystallizations in dark and under relatively dry environments gave 
purer crystalline products. We characterized the cocrystals and solid solutions by IR and 
NMR spectroscopy, PXRD and DSC as well as single crystal diffraction analysis.  
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(b)(a)
(c)
 
Figure 5.30 Crystal structure of HQ-BrBr showing (a-b) hydroxy⋅⋅⋅amino recognition in 
Figure 5.29c and (c) interlayer packing.  
 
(b)(a)
(c)
 
Figure 5.31 Crystal structure of HQ-II showing (a-b) hydroxy⋅⋅⋅amino recognition in 
Figure 5.29c and (c) interlayer packing. Notice the difference in molecular orientations 
compared to HQ-BrBr. 
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Figure 5.32 Crystal structure of HQ-ClCl showing (a-b) hydroxy⋅⋅⋅amino recognition in 
Figure 5.29c that is disrupted at one N-H group and (c) interlayer packing.  
 
 
Figure 5.33 Crystal structure of HQ-MeMe showing a disrupted hydroxy⋅⋅⋅amino 
recognition pattern. Note that one of the two N-H groups and a C-H from methyl group 
form N−H⋅⋅⋅pi and C−H⋅⋅⋅pi interactions (not drawn on image) with adjacent toluidine rings.  
 
Figures 5.30a and 5.30b show the hydrogen bonding around hydroxy and amine groups 
in HQ-BrBr. Each of the heteroatom is involved in three hydrogen bonds and adopts 
tetrahedral geometry. The overall superstructure is that of adjoined squares, a one-
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dimensional pattern, shown in Figure 5.29c. Each HQ molecule is involved in such 
superstructure at both hydroxy groups leading a two-dimensional layer structure (Figure 
5.30c). Bromoaniline molecules project outward from this layer at each corner of the 
square and lead to an interdigitated packing of successive layers. Crystals of HQ-II adopt 
a very similar structure (Figure 5.31) with hydroxy⋅⋅⋅amino recognition in Figure 5.29c 
and an interdigitated layered packing.  
 
Though HQ-ClCl adopts a similar overall structure (Figure 5.32c), it does not exhibit full 
hydroxy⋅⋅⋅amino recognition (Figures 5.32a and 5.32b). In this structure, one of the N-H 
groups does not form N−H⋅⋅⋅O hydrogen bond; instead it forms an N−H⋅⋅⋅pi bond with the 
neighboring HQ molecule. The HQ-MeMe cocrystal adopts a completely different 
structure (Figure 5.33) with broken hydroxy⋅⋅⋅amino recognition. In this structure also, 
one of the two N-H groups is involved in N−H⋅⋅⋅pi bond; this time, however, the bond is 
donated to the aromatic ring of a neighboring aniline molecule.  
HQ-ClBr
HQ-ClI
 
Figure 5.34 Crystal structures of HQ-ClBr and HQ-ClI showing portions of a single layer. 
Note that HQ-ClBr is isostructural to HQ-BrBr (Figure 5.30) and HQ-ClI is isostructural 
to HQ-II (Figure 5.31).  
 
Despite the differences in these structures, different binary cocrystals can be combined 
together to form ternary solid solutions. Todate, we have been able to obtain diffraction 
quality crystals of two ternary solid solutions. Crystals of HQ-ClBr are isostructural to 
HQ-BrBr and crystals of HQ-ClI are isostructural to HQ-II (Figure 5.34). Further 
characterization with DSC showed that the solid solutions have distinct melting 
endotherms compared to the individual cocrystals or physical mixtures of corresponding 
cocrystals.  
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Figure 5.35 Crystal structure of PD-BrBr showing (a-b) hydroxy⋅⋅⋅amino recognition in 
Figure 5.29c and (c) interlayer packing. Note that this structure is similar to HQ-II. 
 
Figure 5.36 Crystal structure of PD-II showing the interlayer packing.  
 
After successfully preparing the HQ based cocrystals, we wished to test if PD based 
cocrystals can be formed with 4-X-phenols, and if such cocrystals exhibited any 
relationship with the corresponding HQ cocrystals. Table 5.4 shows that the two 
cocrystals PD-BrBr and PD-II indeed show similarities to HQ-II at the unit cell level. 
Full structural determination showed that PD-BrBr is isostructural with HQ-II (Figure 
5.35) and PD-II has the same overall structure (Figure 5.36) as HQ-II but with some 
variations in the parameters of hydroxy⋅⋅⋅amino recognition. These structures show some 
of the diversity seen in compounds containing stoichiometric amounts of hydroxy and 
amine groups. They also illustrate the power of supramolecular solid solutions to create 
multicomponent solids using different types of supramolecular synthons and target 
materials.  
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5.17 SUMMARY AND CONCLUSION 
 
We have developed a supramolecular approach for the preparation of multicomponent 
organic alloys.28 This approach involves the (a) preparation of molecular assemblies in 
solution from a target molecule and a set of other molecules that have the same size and 
shape and (b) crystallization of all the components into a single crystalline solid. We call 
the obtained products supramolecular solid solutions because the repeat unit in these 
alloys is a molecular assembly (Figure 5.2).  
 
We have successfully prepared six different series of multicomponent solids; they 
included four different target molecules and two different supramolecular synthons. We 
showed that solid solutions can be made from cocrystals that adopt different structures 
independently. Often in a continuous series of solid solutions the structure changes from 
one cocrystal type to the other.  
 
The approach we developed for multicomponent solids is generic; it is applicable to any 
target molecule capable of forming hydrogen bonding or other specific intermolecular 
interactions. Cocrystals are extensively used in the preparation of photographic, 
magnetic, optical, liquid crystalline and pharmaceutical materials.1 We believe extension 
of our concept to these research areas will lead to new and unforeseen discoveries and 
materials with improved properties. In the pharmaceutical realm, for example, the ability 
to continuously tune physical properties is rarely explored. In addition, we believe that 
supramolecular solid solutions offer a way to prepare cocrystals that are otherwise 
unyielding by methods such as seeding or additives. We envisage several applications of 
our approach that include pharmaceutical alloys with fine-tunable properties, crystals 
with reduced symmetry (for nonlinear optics), organic semiconductors and templates for 
solid state photochemistry. 
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6.1 INTRODUCTION 
 
6.1.1 Background. The scope of this thesis chapter is distinct from previous chapters. 
The work described here has multilevel goals. The initial goal of this work is to make 
octupolar nonlinear optical (NLO) materials based on trigonal metal-carboxylate (TMC) 
clusters. Because we use manganese as the metal species in these TMCs and because 
extended frameworks based on the TMCs can potentially have defined cavities within the 
crystals, this project has other attendant goals in the creation of magnetic and porous 
materials. Materials with NLO characteristics are the basis for the modulation and routing 
functions of current optoelectronic and future all-optical devices.1 These devices are used 
in a range of industries, but most notably in telecommunications and optical data 
processing. Currently, widely used NLO materials are inorganic solids, such as LiNbO3 
(lithium niobate), LiB3O5 (lithium borate) and KH2PO4 (potassium dihydrogen-
phosphate). Purely inorganic solids such as these, though robust and efficient, are 
difficult to modify and not amenable to create improved optical materials.  
 
6.1.2 Dipolar Organic Materials. Studies in the past three decades have shown that 
organic molecules with “donor−conjugated-bridge−acceptor” (D−pi−A) geometry possess 
attractive NLO properties.2 Nonlinear optical materials based on these dipolar molecules 
display ultrafast response time and better processability compared to traditional inorganic 
solids. Organic dipolar molecules can be modified to improve NLO properties by 
increasing the length of the pi-electron bridge and the strength of the donor and acceptor 
groups. Despite this control, D−pi−A structures have some defects. One of these defects is 
that dipole-dipole interactions result in anti-parallel (centrosymmetric) molecular 
arrangement, which causes cancellation of NLO activity in the solid state. To overcome 
the dipolar intermolecular interactions various approaches have been explored. In one 
approach, the poled polymer technique, a polymer with covalently attached dipoles is 
heated close to its glass-transition temperature and then cooled to room temperature while 
a strong electric field is applied.1 Under the influence of the field, the dipolar molecules 
are forced to arrange in acentric fashion. The drawback of this method is that molecules 
relax, with time, back into anti-parallel orientations.  
 
acceptor group
donor group
dipole octupole
 
 
Figure 6.1 Schematic representation of dipole and octupole. 
 
6.1.3 Octupolar Symmetries. To overcome the intrinsic limitations of dipolar species, a 
new non-dipolar model has been proposed for the creation of NLO materials (Figure 
6.1).3 This model introduced species that have come to be known as octupolar molecules. 
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Octupolar symmetry has several advantages. It removes the ground state dipole moment 
in the molecules, which can promote assemblies other than anti-parallel centrosymmetric 
packing. Another major advantage of octupoles is that they are three-dimensional, that is, 
their hyperpolarizabilities (β’s), can be much larger than the one-dimensional dipolar 
species. In addition, the β of octupoles can be continuously increased with increasing 
conjugation while that of dipolar structures increases to a maximum value and then 
decreases with extended conjugation. Yet another advantage of octupoles is that they can 
be expressed in different symmetries (Figure 6.2), that is, a number of routes can be 
explored for making new and improved NLO materials.4 
 
ab c d
 
Figure 6.2 Various symmetries of octupolar systems. (a) Cube octupole with eight 
alternated charges at the corners. (b) Tetrahedral octupoles generated by projection of the 
charges into center of the cube. (c) and (d) Trigonal octupoles generated by  projection onto 
the plane of the cube. 
 
6.1.4 Octupolar Molecular Materials. First discovered octupolar molecule that showed 
NLO activity was 1,3,5-triamino-2,4,6-trinitrobenzene.5 Most of the known trigonal 
octupolar systems are based on organic molecules. The trigonal (Figures 6.2c and 6.2d) 
and tetrahedral (Figure 6.2b) octupolar symmetries are relatively easy to design based on 
the well established trigonal and tetrahedral geometries in organic molecules. For 
example, the functionalization at 1,3, and 5 positions of aromatic systems (phenyl,6-8 
triazine,9-12 or boroxane13) produces the 2D molecules with trigonal (C3, C3v, D3 or D3h) 
symmetry (Figures 6.2c and 6.3a). Trigonal symmetry shown in Figure 6.2d can be 
achieved, for example, based on C+ template (crystal violet, Figure 6.3c). Other 
molecular octupoles in which 3D symmetries are used include tetrahedral (Td) tin 
derivative14 or bis(bipyridyl) zinc(II) complex (Figures 6.2b and 6.3d)15 and the cubic 
paracyclophane derivative (Figures 6.2a and 6.3b).16 Recently, chemists have been using 
coordination chemistry as a powerful tool to synthesize octupolar molecules. The first 
transition-metal complex ([Ru(2,2’-bpy)3]2+[PF6]2-) with large β values was reported by 
Zyss.17 After this work many octupolar NLO materials based on metal complexes have 
been investigated.18-20  
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Figure 6.3 Examples of 2D and 3D octupolar molecules with trigonal, tetrahedral and 
cubic symmetries. 
 
6.1.5 Octupolar 2D Supramolecular Materials. To date, the design of octupolar NLO 
materials has focused mostly on molecular systems. Assembly of octupolar molecules 
into acentric networks, however, has not been fully explored. Figure 6.4 shows three 
network arrangements that we will encounter in this study. Two of them 63 and 36 nets 
possess nodes with trigonal symmetry and they are good candidates for supramolecular 
octupolar assemblies. Two reports from the literature explored the 2D trigonal 36 
networks based on organic and metal complex chromophores (Figure 6.5).21, 22, 12 We 
note here that both these designs offer synthons (herringbone interactions and coordinate 
bonds) that direct the molecular arrangement in two dimensions. The assembly in the 
third dimension, however, is not controlled by predetermined functional groups. In other 
words, these materials adopt 3D noncentrosymmetry by chance; the design was limited 
only to two dimensions. The absence of such supramolecular octupolar materials 
indicates the difficulty in the design of systems that have octupolar symmetry and that 
can assemble into acentric solid state structures. 
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44  network 63 network 36 network
 
Figure 6.4 Representation of 2D network arrangements. The XY terminology used here has 
its origin in defining nets as a collection of nodes connected by linkers. In 63 net, for 
example, each node is connected to 3 other nodes, and the smallest cycle contains 6 nodes. 
 
 
a b
 
Figure 6.5 Schematic representation of 2D octupolar materials. (a) 2,4,6-Triaryloxy-1,3,5-
triazines. (b) Trigonal network made from [Cd3(µ3-OH)(L)3(py)3]2+, L = 4-[2-(4-
pyridyl)ethenyl]benzoate. 
 
6.1.6 Critical Need for 3D Octupolar Supramolecular Materials. The purpose of this 
work is to develop a strategy for the synthesis of 3D octupolar materials that can show 
high NLO activity at molecular and crystalline state. As NLO molecules we propose 
trigonal metal-organic clusters (Figure 6.6); these clusters offer synthetic design 
analogous to organic compounds and possess robustness of inorganic systems. Special 
advantages of metal-organic framework structures include: strong bonding that provides 
network robustness, bridging ligands that can be modified by organic synthesis, and the 
ability to create desired geometrical assembly. The clusters can first be created and 
studied at molecular level (that is, 0D systems); these clusters can then be assembled into 
2D or 3D frameworks through metal-ligand bonding. By selecting proper organic ligands 
we can tailor physical properties and through a combination of metal species, carboxy 
and aza ligands, it may be possible to design materials for applications in catalysis, 
magnetism, sorption, and non-linear optics.  
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Figure 6.6 Molecular structure of TMC. This cluster consists of trigonal planar M3O group 
in which central oxygen functions as bridging ion. All the metals display octahedral 
coordination. 
 
6.1.7 Functionalized Materials based on Metal Carboxylate Clusters. Some examples 
from recent literature illustrate the utility of metal-organic frameworks in the above 
mentioned applications. Kim and coworkers reported chiral metal-organic framework for 
the catalysis of enantioselective trans-esterification reactions (Figure 6.7a).23 Of special 
interest is also the design of stable nano- or micro porous networks. Porous materials are 
mainly used for size selective sorption, molecular recognition, or gas storage. Yaghi and 
coworkers demonstrated crystalline extra-large porous frameworks made of octahedral 
Zn4O nodes with pore sizes up to 28.8Å (Figure 6.7b).24, 25 These materials can sorb 240 
mL/g of methane at 36 atm. Metal-organic frameworks can also show interesting 
magnetic properties. Antiferromagnetism, ferrimagnetism and ferromagnetism are 
common phenomena of the magnetic spins in solid state. The nanoscale metal-organic 
Kagome lattice built by Zawarotko and colleagues has interesting (spin frustrated) 
magnetic properties at room temperature.26 This Kagome lattice is formed from dicopper 
paddle-wheel cluster with isophthalate bridges (Figure 6.7c). 
 
a b c
 
Figure 6.7 Examples of frameworks built from metal-carboxylate clusters (a) Chiral 
hexagonal framework made from [Zn3O)(OOCR)6(H2O)3]2-. (b) Porous solids constructed 
by octahedral Zn4O(OOCR)6 units, and (c) Kagome network based on Cu2(OOCR)4 units. 
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6.2 DESIGN, SYNTHESIS, AND IR ANALYSIS OF TMCS 
 
Our work so far has been primarily synthetic in nature. We have just begun to 
characterize the crystal structures obtained from various TMC derivatives synthesized in 
this work. We will describe two categories of TMC related structures and two other 
clusters with higher nuclearity (Mn6 and Mn13), and their potential use as nodes in 
generating new types of porous frameworks. We are currently in the process of obtaining 
NLO characterizations of these compounds through collaboration. We begin with our 
original design strategy that we hoped will generate 3D acentric structures. 
 
6.2.1 Design strategy for 3D Octupolar Materials. Our strategy for making 2D trigonal 
octupolar assemblies and their possible arrangement in three dimensions is shown in 
Figure 6.8. This design starts with the molecular trigonal units shown in Figure 6.8a. 
When these two octupolar units are connected at their corners, they can form an acentric 
hexagonal 2D network (Figure 6.8b). Stacking of the 2D networks can lead to either 3D 
noncentrosymmetric (Figure 6.8c) or 3D centrosymmetric structure (Figure 6.8d). We 
should note here that the 63 net in Figure 6.8b is based on two different nodes (centers of 
red and blue triangles). If one were to consider the topology of this net based on any one 
node (red or blue) this net will then become a 36 net, that is, it is acentric in two 
dimensions. 
 
+ or
a b c d
2D acentric 3D acentric 3D centric
 
Figure 6.8 Strategy for the synthesis of 3D noncentrosymmetric crystals. 
 
We have designed trigonal metal clusters to achieve 3D acentric structures exclusively. 
The geometry of the TMC enables the binding of three in-plane monodentate ligands 
projected trigonally, and six out-of-plane bridging bidentate ligands projected 
perpendicular to the Mn3O core. We use pyridine derivatives for the first set of ligands, 
and benzoic acid derivatives for the second set of ligands; we refer to them, in the 
following sections, as pyridyl and acid ligands. Use of TMCs allows 3D design (Figure 
6.9). These TMCs are also modular in their design, that is, one can make multiple 
derivatives through changes in metal ions and two sets of ligands. 
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Figure 6.9 Expected 3D arrangement of trigonal metal organic frameworks. (a) TMC 
viewed down z-axis. (b) Side view of TMC (down y-axis). (c) Acentric assembly of TMC 
along the z-axis by an appropriately shaped diacid. (d) 2D noncentrosymmetric 
arrangement of TMCs and triazines in xy-plane.  
 
6.2.2 Synthetic Approach. The strategy shown in Figure 6.9 involves combining three 
different entities (metal ions, pyridyl ligands, and acid ligands) in one pot to create 
network solids. To synthesize 3D acentric materials directly is ambitious and turned out 
to be challenging. Our initial attempts to create such 3D material through one pot 
synthesis led to insoluble powders (that may well be the desired materials) that are 
difficult to characterize. We quickly realized the need to learn synthetic as well as 
structural chemistry of TMCs and decided to explore the synthesis and structures of 
discrete TMCs. We argued that due to their trigonal symmetry these TMCs should act as 
useful candidates to explore 36 nets. Also, we hoped to explore metal-to-ligand and 
ligand-to-metal charge transfer within these TMCs to modulate β. The question that we 
faced at this point was – where to start? We needed to decide on the types of metal, the 
in-plane ligands and the bridging ligands. Thus, we approached the Cambridge Structural 
Database (CSD) to determine the known structural chemistry of TMCs. 
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Figure 6.10 Quest fragment used in the CSD query. All the bonds attached to Mn are 
defined as ‘any’ bonds. Only aza and carboxylate ligands are searched. 
 
6.2.3 Known Structural Chemistry of TMCs – CSD Analysis. Figure 6.10 shows the 
CSD search fragment we used to retrieve the known TMC structures. We chose to restrict 
the search to in-plane ligands with aza donors and carboxylates as bridging ligands. This 
search showed 104 hits with TMC units, of which 71 are unique. That is, the other 33 hits 
belong to duplicate structure determinations. The following features appeared from an 
analysis of these structures. Of the 71 structures, 54 TMCs are based on homo-metallic 
cores (that is all the three metal ions are same), and 17 TMCs are based on hetero-
metallic cores. A gratifying finding is that these TMCs are not restricted to any specific 
metal species. Currently TMCs with Fe, Cr, V, Mn, Zn, Ru, and Ga metal ions are 
known. Another way of classifying the 71 hits is based on the space group symmetry: 41 
of these TMCs crystallize in centrosymmetric space groups, and 30 belong to acentric 
space groups. A large number (50) of these TMCs include non-aromatic acid ligands. Of 
the 21 TMCs that contain aromatic pyridyl and acid ligands, most of them are based on 
benzoic acid and pyridine.  
 
We are interested in exploring all-aromatic TMCs because they are expected to show 
high β values (systems with closely spaced multiple aromatic units can show large β 
values even in the absence of conjugation; see for example NLO activities of 
calixarenes27). Most of the reported studies are centered on synthesis, characterization, 
magnetism, and intermetallic charge transfer of TMCs. Little or no attention is placed on 
the NLO effects and supramolecular structural control of TMCs. We anticipated that 
creating a number of TMCs with different acid and pyridyl ligands will lead to the 
discovery of new network topologies and new chemistry with a rich variety of 
compounds. 
 
A key feature of TMC systems, like other metal containing systems, is that they display 
structural portability. That is, TMCs containing different metal species, but similar 
ligands have similar structure. This feature is especially useful in the current study 
because electronic character of the core can be modulated to control the nonlinear 
properties of the clusters19. A relevant example that illustrates the structural portability 
involves: [M3O(AcO)6Py3]+[X-]. A variety of homo- and hetero-metallic TMCs based on 
this core are isostructural. We expect that our studies based on one metal species (that is, 
Mn) can be extended to other metals without the loss of designed structural features. 
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6.2.4 Synthesis of Discrete TMCs. As shown above a number of metal ions can be used 
to prepare TMCs. We chose Mn as the metal species in this work because Mn based 
TMCs are stable and they can be created under aerobic conditions (Figure 6.11). An 
advantage with Mn TMCs is that they can be synthesized using a predictable 
conproportionation reaction.28 In addition, Mn TMCs can be prepared in two flavors; we 
call them charged TMCs and neutral TMCs (Equations 1 and 2; see below). Charged 
TMCs contain three Mn3+ ions as part of the Mn3O core; that is when a full cluster is 
formed the cluster will have one unit of positive charge ([Mn3O(RCOO)6L3]+). On the 
other hand, the neutral TMCs have the general formula Mn3O(RCOO)6L3; that is the 
overall charge of the cluster is zero. Our initial interest and focus is on the charged 
TMCs, because we hoped that these TMCs can have full trigonal symmetry at the 
molecular level, at least in solution. In neutral TMCs, the molecules may or may not 
maintain trigonal symmetry because the charge can be localized or delocalized on the 
metal ions (that is the arrangement can be: Mn2+Mn3+Mn3+ or [Mn2.66+]3). One final note 
on the choice of the anion: we used perchlorate (ClO4-) anion in this study largely 
because of synthetic ease. We expect that these anions can be replaced by safer anions 
such as BF4- if these TMCs were ever to be synthesized in large scale. 
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Figure 6.11 Scheme for the synthesis of TMC. 
 
The following two equations show the conproportionation reactions for the synthesis of 
neutral and charged TMCs.  
 
13Mn2+ + 2[MnO4]- + 6H+ → 5[Mn3O]6+ + 3H2O [formation of neutral TMC]  
(Eq. 1) 
12Mn2+ + 3[MnO4]- + 14H+ → 5[Mn3O]7+ + 7H2O [formation of charged TMC]  
(Eq. 2) 
 
We found that these reactions are highly reliable and can be achieved selectively by 
manipulating the experimental conditions. Oxidation can be carried out with KMnO4 or 
nBu4NMnO4; again we found that the latter reagent is more reliable and broadly 
applicable for the synthesis of a range of TMCs. One particularly attractive experimental 
feature of these neutral and charged TMCs is their markedly different color: charged 
TMCs are brown in color and the neutral clusters are dark green. For the following 
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syntheses, all chemicals and solvents were purchased from commercial sources and used 
without further purification. All manipulations were performed under aerobic conditions. 
 
6.2.4.1 Synthesis of nBu4NMnO4. This compound was synthesized by a slight 
modification of a literature report.29 Aqueous solutions of KMnO4 (2.50g, 15.8 mmol, 
dissolved in 60 mL of water) and nBu4NBr (6.00g, 18.6 mmol, dissolved in 40 mL of 
water) were mixed together with vigorous stirring. After 20 minutes a purple precipitate 
was filtered, washed with deionized water (500mL) and a small amount (25-50 mL) of 
diethyl ether, and dried in vacuo. The typical yield of this reaction was >80%. After 
drying, the product was placed in an Erlenmeyer flask and the flask was quickly sealed 
under N2 gas using parafilm. This sealed flask was then kept in a refrigerator and the 
permanganate was used in the synthesis of TMC within one week.  
 
6.2.4.2 Synthesis of Charged TMCs ([Mn3O(OOCR)6L3]ClO4). The complexes were 
prepared following the modified method described by Vincent.30 Mn(O2CMe)2·4H2O 
(2.00g, 8.15 mmol) and acid (61.4 mmol) and pyridine (30.7 mmol) derivatives were 
dissolved in 25-50 mL of absolute EtOH in an Erlenmeyer flask. To this mixture was 
added nBu4NMnO4 (1.14g, 3.15 mmol) in small portions under continuous stirring. 
Immediately after adding the permanganate, NaClO4 (0.69g, 5.65mmol) was added in 
portions, and 15 minutes after this latter addition a brown solid product appeared in the 
flask. This brown precipitate was collected by filtration and dried in vacuo. 
Recrystallization was carried out in dichloromethane, acetonitrile, or benzene; after 
several days small gold colored microcrystals of the desired products were obtained. The 
morphology of these crystals depended on the TMC and hinted at the possibility of 
different types of underlying structures. Typical yields in these reactions were in the 
range of 70 – 85%.  
 
6.2.4.3 Synthesis of Neutral TMCs (Mn3O(OOCR)6L3). To obtain neutral complexes the 
procedure described above was modified, that is the amount of nBu4NMnO4 was reduced 
according to the stoichiometric ratio given in Equation 1 above. Only 1.25 mmol of 
nBu4NMnO4 was required to react with 8.15 mmol of Mn(O2CMe)2·4H2O. After the 
addition of nBu4NMnO4 the homogenous solution was turned to a dark green color. The 
mixture was stirred for 1h and the product was left undisturbed overnight in the 
refrigerator. The resultant precipitate was collected by filtration (yield: >80%). 
Recrystallization from dichloromethane, acetonitrile, or EtOH yielded brown crystals 
with TMC dependent morphologies. 
 
 
6.2.5 Selection of Ligands (Acids and Pyridines). The major criterion we applied in 
selecting these ligands is that they must be aromatic and conjugated. We chose functional 
groups that do not interfere with the formation of TMC. Also, we chose relatively simple 
groups so that we can understand structural chemistry of a molecule with complicated 
shape. The deliberate choice of electron donating and withdrawing groups on acids as 
well as pyridyl ligands is to test the effects on β with these variations. Tables 6.1 and 6.2 
show the acid and pyridyl ligands used in the TMC synthesis. Frequently we refer to 
TMCs with the acid and pyridyl acronyms shown in these Tables. For example, ‘BA-4P’ 
refers to a TMC made from six benzoic acid and three 4-picoline ligands. One more note 
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on the acronyms used: we refer to charged clusters as TMCs; neutral clusters are always 
referred as neutral TMCs. Table 6.3 lists current status of various TMCs we are working 
with. 
 
Table 6.1 Molecular structures and acronyms of acid ligands used in the 
synthesis of TMCs.  
AE35NO2BA35MeBA35ClBA
mTA3ClBA3BrBA4NO2BAAA
pTA4CNBA4ClBA4BrBABA
BrHOOC ClHOOC HOOC CN HOOC CH3
HOOC NO2 HOOC
Br
HOOC
Cl
HOOC
CH
3
HOOC
Cl
Cl
HOOC
CH
3
CH
3
HOOC
NO
2
NO
2
HOOC OMe
HOOC
HOOC
O
OMe
 
 
 
Table 6.2 Molecular structures and acronyms of pyridyl ligands used in the synthesis 
of TMCs.  
Imd35ClPy
35Lu34Lu3CNPy3BrPy3P
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Table 6.3 Current status of TMCs synthesized in this work. 
 
S - Synthesized charged TMCs. 
S - Synthesized neutral TMCs. 
C – TMCs for which crystallographic data were collected. 
 
6.2.6 Spectroscopic Characterization of TMCs. Though Mn TMCs made in this work 
are thoroughly soluble in organic solvents, especially CHCl3, it is not easy to collect 1H 
NMR (or 13C NMR) spectra of these compounds due to the influence of the paramagnetic 
Mn ions.31 This influence results in broadened and highly separated peaks (chemical 
shifts range from -150 to +100 ppm in 1H NMR). The analysis of these spectra is not 
trivial; in fact, this analysis itself is part of major research in organic-inorganic 
spectroscopy. We have thus resorted to IR spectroscopy as a quick tool to verify the 
formation of TMCs in our reactions. Our IR analysis showed two interesting features: (i) 
it is easy to distinguish between neutral and charged TMCs; and (ii) acid ligands have 
distinguishable, characteristic bands but pyridyl ligands do not have such bands, at least 
in the typical 600 – 4000 cm-1 region. 
 
6.2.6.1 Distinguishing Charged and Neutral TMCs through IR Spectroscopy. Figure 6.12 
shows the IR spectra of some representative charged and neutral TMCs. The region 
between 1700 and 600 cm-1 is dominated by absorptions due to the symmetric and 
asymmetric stretching of the bridging carboxylate groups (ν-COO). These are strong 
bands appearing at about 1380 cm-1 and 1600 cm-1
 
respectively. The medium strong 
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bands due to the absorption by the perchlorate anion (ν-Cl−O) are found near 1100 cm-1 
for all charged TMCs. Several IR bands below 800 cm-1 may be assigned to other acid 
and pyridine absorptions. One of these bands at about 620 cm-1, however, arises from an 
asymmetric stretch of the central Mn3O unit. The main difference between charged and 
neutral TMCs is the absence of perchlorate stretching near 1100 cm-1 (contrast Figures 
6.12a and b). We use this region to diagnose the TMC products obtained in our synthesis. 
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                                    a                                                          b 
Figure 6.12 Comparison of IR spectra of the charged (a) and neutral (b) TMCs. 
 
6.2.6.2 Finger Prints of Acid and Pyridyl Ligands in IR Spectra. As noted above, acid 
groups can be differentiated and identified from IR spectra. The main differences in a 
series of TMCs that differ only in acid groups lie in the asymmetric stretching zone (νas-
COO) of the carboxylate groups. In Figure 6.13a we analyze IR spectra of three TMCs 
with same pyridyl ligand but different acid ligands. The fine structure in the νas-COO 
region shows that for pTA-34Lu and mTA-34Lu there is only one strong band (~1600 
and ~1574 cm-1); however for the BA-34Lu this band is split into two bands (at ~1604 
and ~1568 cm-1). The symmetric stretching (νs-COO) always appears at ~1380 cm-1 as a 
single band (Figures 6.13a and 6.13b). A similar analysis for pyridyl ligands (Figure 
6.13b; same acid ligand but different pyridyl ligands) shows that there are no 
characteristic peaks that can tell one pyridyl ligand from another. The three spectra 
shown in Figure 6.13b do not differ noticeably. 
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                                     a                                                        b 
Figure 6.13 IR spectra of TMCs with (a) different acid ligands and (b) different pyridyl 
ligands. 
 
6.3 CRYSTAL STRUCTURAL ANALYSIS OF TMCS 
 
6.3.1 General Considerations in Structural Analysis. As noted earlier much of my 
effort in this work was focused on the synthesis of TMCs (both charged and neutral). Our 
structural analysis is still at an early stage; therefore we will limit our discussion only to 
the structures of charged TMCs. Of the 65 charged TMCs synthesized, about 30 
compounds showed good crystallinity, but only 17 were good enough for single crystal 
X-ray data analysis. These compounds typically adopt layered structures in the solid 
state, and displayed some of the known crystal growth and structure analysis problems 
with layered structures. We frequently encountered layer misalignment or twinning; 
typically we had to mount 3-4 crystals on the diffractometer before a single crystal was 
found that can give reasonable unit cell data. Also, even after the data collection these 
systems routinely gave problems during structure solution and refinement. For these 
reasons, most of the structures in this study are only partially solved and/or refined. In 
future work I will spend more time towards the complete refinement of these structures 
and their detailed analysis. We classified the 10 TMC structures (to be discussed in the 
following sections) into two categories; structures of these two categories along with 
those of hexa- and tridecanuclear Mn-carboxylate clusters are presented below. Table 6.4 
shows the salient crystallographic parameters for the structures reported here. Figure 6.14 
shows the numbering scheme used in this study; consistency in this numbering simplifies 
comparison across a series of derivatives (see, for example, Table 6.6). 
 
 
 
 
 
 
 
 
TRIGONAL MANGANESE CARBOXYLATES – OCTUPOLAR NLO MATERIALS 139 
 
 
Table 6.4 Space group and unit-cell data for the structures reported in this work.  
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Figure 6.14 Atom numbering scheme used in this study. Acid rings are labeled C12-C17, 
C22-C27, C32-C37, C42-C47, C52-C57, and C62-C67, and pyridine rings are labeled N71C71-C75, 
N81C81-C85, N91C91-C95. Rings numbered from C12-C17 to C42-C47 correspond to Type-I acid 
ligands; rings C52-C57 and C62-C67 correspond to Type-II acid ligands (see Section 6.3.6). 
Similarly, Type-A pyridyl ligand is numbered N71C71-C75 and, Type-B pyridyl ligands are 
numbered N81C81-C85 and N91C91-C95.  
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6.3.2 Structures Adopting Idealized Acentric 63 Networks. We began our analysis 
with BA-Py, a TMC with no substituents on either acid or aza-aromatic ligands. We 
expected that this will be a good starting point for exploring and designing new types of 
structures within the family of all-aromatic TMCs. Our CSD analysis showed that there 
are several analogues of BA-Py reported in the literature; Table 6.5 provides some details 
of metal ions, counter anions, and solvated guest species included in the crystals. Each 
structure in this Table is identified with a REFCODE, a unique name assigned to each 
entry in the CSD.  
All these structures (except VOVBAJ) have similar crystal structures; they follow the 
general trend that metal ions can be exchanged without the loss of structural similarity. 
These entries also display the crystallographic problems we referred to above, and these 
problems are responsible for: (i) incorrect space group assignment; (ii) lack of coordinate 
data on solvated molecules; and (iii) incompletely refined anions. This incomplete data 
on anions and solvates again refer to the major focus of the previous studies: that is, they 
are concerned with the molecular structure of TMC but not with the supramolecular 
structure. Two key points (in addition to those listed in footnotes § and ** on next page) 
can be concluded from an analysis of the structures in Table 6.5: (i) They contain both 
homo and hetero-metallic TMCs; (ii) They contain significantly different anions. But, all 
the anions adopt pseudo-octahedral geometry in the crystal.  
 
Table 6.5 Molecular and crystal structural analogues of [Mn3O(BA)6Py3]+[ClO4]-C6H6 
 
 
We have synthesized charged Mn-TMC with BA and Py ligands, and grown single 
crystals of its benzene solvate, that is ([Mn3O(BA)6Py3]+[ClO4]-C6H6). So far the single 
crystals obtained from this compound are small and not suitable for single crystal X-ray 
studies. The hexagonal prism morphology of the crystals, however, points to a structure 
similar to the analogues listed in Table 6.5. IR analysis showed stretchings for 
carboxylate and perchlorate species; that is, we have a charged TMC. Powder X-ray 
diffraction analysis of the sample matches with those of BA-Py analogues shown in 
Table 6.5. Based on these results, we attribute the structure of BA-Py to structures in 
Table 6.5, and in the following discuss its structure based on the Cr (GOMWUA). 
 
6.3.3 Crystal Structure of [Mn3O(BA)6Py3]+[ClO4]-C6H6 (based on GOMWUA). 
This compound crystallizes in the trigonal space group P63/m. The discussion of its 
structure is divided into a description of molecular structure and the assembly of TMC 
units into 36 networks through C–H⋅⋅⋅O hydrogen bonds. Guest inclusion and an analysis 
toward structural mimicry and structural variation are discussed at the end of this section. 
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                      a                                                                        b 
Figure 6.15 (a) Molecular structure of BA-Py complex, (b) Assembly of trigonal 
units into 36 network. TMCs and perchlorate anions (green color) are shown in 
ball-and-stick model and benzene molecules are shown in space-filling model. 
Hydrogen atoms are omitted for clarity. 
 
6.3.3.1 Molecular Structural Features. The TMC unit is located on a 6 (3/m) axis in the 
crystal, that is, it maintains molecular symmetry in the crystal (Figure 6.15a). This means 
that the TMC is noncentrosymmetric at molecular level, and all acid ligands are 
symmetry related as are the pyridyl ligands. In terms of atom labeling (see Figure 6.14) 
all acid rings are now numbered C12-C17 and all pyridyl rings are labeled N71C71-C57. The 
guest molecule (benzene in this structure; disordered pyridine in GOMWUA) is also 
located on 6  (3/m) axis. The counter ion (that is, ClO4-), is also located on a 63/m axis. 
Perchlorate ion should be tetrahedral; but, by the imposition of 63/m symmetry, it is 
disordered and adopts pseudo-octahedral geometry in which four O atoms occupy six 
positions at the apices of a pseudo-octahedron. We note that all O atoms of the 
perchlorate ion are symmetry equivalent. All the Mn ions adopt octahedral coordination 
as expected. All the pyridyl ligands lie perpendicular to the plane of central Mn3O unit. 
 
6.3.3.2 C–H⋅⋅⋅O Hydrogen Bonding between and ClO4- and TMC. Major intermolecular 
interactions in this structure exist between the positively charged TMC and negatively 
charged perchlorate ion. The interactions, however, are not of ionic character (the + 
charge on the TMC is largely confined the central Mn3O core, whereas perchlorate 
interacts with peripheral phenyl rings). Each of the six O atoms in perchlorate anion is 
connected to six distinct TMC units through short C–H⋅⋅⋅O hydrogen bonds (Table 6.6). 
One of the meta C–H groups from each benzoate contributes to this hydrogen bonding; 
each TMC is therefore connected to six ClO4- ions and vice versa. Three of these six 
TMCs are in one layer; three others are in an adjacent layer; these layers are parallel to 
(001), that is, ab-plane. Benzoate C–H groups are more acidic and easily accessible (less 
hindered) compared to the pyridyl C–H groups; therefore, it seems logical that they are 
involved in these short C–H⋅⋅⋅O hydrogen bonds. 
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6.3.3.3 Guest Inclusion in TMC Layers – Acentric 36 Networks. As mentioned above, 
this is a layered structure in which TMC units along with solvated benzene molecules are 
packed into one layer and perchlorate anions are sandwiched between adjacent TMC 
layers. In each layer, TMCs are arranged into a 36 network, that is, if lines were to be 
drawn between central O atoms of nearest TMCs (within the layer) they would result in a 
trigonal 36 network with O atoms acting as nodes. TMCs are held into this trigonal 
network through short C–H⋅⋅⋅O hydrogen bonds they form with perchlorate anions. The 
trigonal arrangement of TMCs (enforced by C–H⋅⋅⋅O bonds between TMCs and 
perchlorate anions), however, results in the juxtaposition of benzoate rings as shown in 
Figure 6.15b. Due to the 3D shape of the TMC molecule, this juxtaposition creates a 
cavity within the layers, and solvated benzene molecule occupies this cavity. It is 
important to note that reasonably short C–H⋅⋅⋅C contacts (C⋅⋅⋅C 3.7-3.8 Å) are seen 
between the benzoate rings forming this cavity, but this type of phenyl⋅⋅⋅phenyl 
arrangement is distinctly different from the traditional herringbone and stacking 
interactions usually adopted by aromatic rings.  
 
Table 6.6 Geometrical parameters for C–H⋅⋅⋅O Interactions*. 
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* C–H bond lengths are normalized to 1.08 Å. N/A = Not applicable. 
 
Table 6.7 Geometrical parameters for the interactions between aromatic rings. 
 
 * Angle between the planes of interacting aromatic rings. 
 
6.3.3.4 Structural Analysis for Further Design. The trigonal layer structure shown in 
Figure 6.15b is acentric, but the adjacent layers are inversion related. This inversion is 
favored by stacking interactions between acid rings between layers (Table 6.7). We 
analyzed this structure in terms of short intermolecular contacts to identify portions of 
TMC that are critical for the formation of the trigonal network, and portions that are not. 
We expected that changing the non-critical portions will allow us to reproduce this 
trigonal structure, and that changing the critical portion will result in different types of 
networks. It is obvious that we can introduce new groups on either the benzoate or the 
pyridyl (or both) groups. All the CH groups on the benzoate phenyl rings are involved in 
short contacts with the nearest O or C atoms. That is, replacing these CH groups will 
most likely influence the trigonal structure. The CH groups on the pyridyl molecules, 
however, are not involved in any short contacts. The nearest contact atoms (along the CH 
bond vectors) are about 4.2-4.5 Å away from the carbon atoms of the pyridyl ring. 
Therefore, we argued that substituting H-atoms on pyridyl rings (with simple groups such 
as CH3) should retain the current trigonal structure. 
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In the following, we discuss structures that resulted from substituting the pyridyl CH 
groups. An analysis of the intermolecular contacts around trapped benzene molecule is 
also interesting. Benzene makes van der Waals contacts with benzoate rings above and 
below its molecular plane. Along the CH bond vector, however, the nearest contacts are 
4-7 Å away (from the C atoms). We also argued that replacing the benzene with guest 
molecules such as mesitylene and trichlorobenzene should retain the current structure, 
but, so far our efforts have not been successful in producing crystals containing these 
guest species. 
 
 
  
                                  a                                                                       b 
Figure 6.16 (a) Molecular structure of BA-4P complex. (b) Assembly of trigonal units into 
2D acentric (36) network (benzene solvate). Hydrogen atoms are omitted for clarity. 
 
6.3.4 Crystal Structure of [Mn3O(BA)6(4-Picoline)3]+[ClO4]-C6H6. Changing the 
pyridine ligand to 4-picoline does not change the supramolecular structure as predicted 
by the analysis given above. In fact, this compound is isostructural to the pyridine 
derivative described in the previous section. The TMC units retain their acentric trigonal 
symmetry in the crystal. They are held into acentric 2D trigonal (36) networks through 
short C–H⋅⋅⋅O hydrogen bonds with ClO4- ions (Table 6.6). Again, the ClO4- ions adopt 
pseudo-octahedral geometry in which four O atoms share six apices of a pseudo-
octahedron. All the six O atoms are symmetry equivalent. The juxtaposition of benzoate 
rings again results in cavities similar to those seen in the previous structure; benzene 
molecules are trapped into these cavities with similar intermolecular contacts described in 
previous section. Figures 6.16a and b show details of BA-4P benzene solvate structure at 
the molecular and crystal level. As explained above, we tried to grow crystals of BA-4P 
containing guests that are laterally expanded. These trials, however, produced crystals in 
which dichloromethane (solvent used for the crystallization) is included within the 
cavities. 
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6.3.5 Crystal Structure of [Mn3O(BA)6(4-Picoline)3]+[ClO4]-CH2Cl2. The CH2Cl2 
solvate of BA-4P is isostructural to the benzene solvate described above. The only 
difference is that the solvent molecule is disordered (it does not possess three-fold 
symmetry) such that two Cl atoms occupy the three apices of an equilateral triangle, and 
the C atom occupies two positions situated above and below the triangle formed by the 
three Cl atoms. Figures 6.17a and b show details of BA-4PCH2Cl2 solvate structure at 
the molecular and crystal level. The ability to change the guest species without changing 
the overall structure again indicates that the guest molecules play the role of ‘space-
fillers’ and that they are not involved in structure directing intermolecular interactions.  
 
   
                       a                                                                         b             
Figure 6.17 (a) Molecular structure of BA-4P complex. (b) Assembly of trigonal units into 
2D acentric (36) network (dichloromethane solvate). Hydrogen atoms ate omitted for 
clarity. 
 
6.3.6 Crystal Structure of [Mn3O(BA)6(3-Picoline)3]+[ClO4]-C6H6. We have been able 
to grow crystals (with hexagonal morphology) of BA-3P in benzene. These crystals, 
however, diffracted poorly and X-ray data was not good enough for full structure 
determination. To date, we have been able to determine the space group and locate the 
ClO4- anions and the central Mn3O-(OOC)6 units from the available data. Further 
refinement of this structure is not possible because of poor quality of the X-ray data 
(obtained from crystals that are either twinned or display layer misalignment). A 
comparison of the unit cell parameters in Table 6.4 (and location of ClO4- anions and 
Mn3O units within the unit cell) with previous structures indicates that the BA-3P is 
isostructural to BA-Py and BA-4P. These results show that acentric 36 networks can be 
reliably generated within the family of BA-Py TMC structures by incorporating small 
substituents on the pyridyl ligands. The overall structure, however, remains 
centrosymmetric; thus, we focused our attention on changing the benzoate ligands to 
explore new types of structures.  
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6.3.7 Crystal Structure of [Mn3O(pTA)6(Py)3]+[ClO4]-: Acentric 44 and Centric 36 
Networks. Changing the benzoic acid ligands to p-toluic acid changes the structure type 
as expected from the analysis given in Section 6.3.3. In the following we describe two 
sets of structures, one belonging to centrosymmetric space groups (e.g., pTA-Py, this 
section), and the others belonging to noncentrosymmetric space groups (e.g., mTA-Py, 
next section). The similarities and differences between these networks and design 
considerations are given below. 
 
6.3.7.1 Reduction of Molecular Symmetry. This TMC perchlorate crystallizes in the 
centrosymmetric space group Pccn (P⋅21/c⋅21/c⋅2/n). The TMC unit is located on the 2-
fold axis (as opposed to be on the 6  axis as in the case of BA-Py, BA-4P, and BA-3P 
series of structures described above). That is, the TMC unit does not retain its three-fold 
molecular symmetry in the crystal. It follows then that the six acid ligands are not 
equivalent in the crystal; similarly the three pyridyl ligands are also not equivalent (see 
Figure 6.18). We can see that changing the acid ligand from BA to pTA does change the 
structure type as expected. 
 
Type-A 
Pyridine
Type-I 
Acids
Type-B 
Pyridines
Type-II 
Acids
 
Figure 6.18 Molecular structure of pTA-Py complex. Two types of acid rings (Type I and 
Type II) and two types of pyridine rings (Type A and Type B) are indicated by different 
colors. 
 
6.3.7.2 Classification of Ligands into Groups. The molecular symmetry of TMC is 
reduced in the crystal because different acid and pyridyl ligands have different packing 
preferences. Based on the analysis of this structure and a number of other TMC structures 
to be discussed below, we classified acid and pyridyl ligands into two groups each. One 
group of acids, which we call Type-I acids, contain four acid ligands; the second group, 
Type-II acids, contains the other two acid ligands. Similarly, in the case of pyridyl 
ligands ‘Type-A’ consists of one pyridyl group (that is projected along [001]), and ‘Type-
B’ consists of other two pyridyl groups. Figure 6.18 shows coloring scheme used for 
identifying different acid and pyridyl ligands in the TMC and their relative geometrical 
arrangement.  
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6.3.7.3 Acentric 44 Networks Parallel to (001). The crystal structure of pTA-Py can be 
sectioned into 44 nets (Figure 6.19) that lie parallel to (001). In these nets, each TMC has 
four neighbors, and if we consider each TMC to be a node, the smallest cycle connecting 
nearest nodes has four nodes in it. This is the reason we call the arrangement shown in 
Figure 6.19 as 44 net. Two types of intermolecular interactions (pi⋅⋅⋅pi stacking and C–
H⋅⋅⋅O hydrogen bonds) are responsible for holding the TMC units together within this 44 
net. Stacking (pi⋅⋅⋅pi) interactions between the aromatic rings of Type-II acids and Type-B 
pyridyl ligands act as the node connectors in the net (Table 6.7). In addition, the ClO4- 
ions are situated in the square-cavities formed within the 44 net; the O atoms of ClO4- 
ions are involved in the formation of C–H⋅⋅⋅O interactions with the CH groups of Type-I 
acids and Type-B pyridyl units (Table 6.6). We should note here that unlike in BA-Py, 
BA-4P, BA-3P series of structures, both acid and pyridyl CH groups form the CHO 
bonds in this structure. This may be partly due to the reduced CH acidity of pTA ligands 
(caused by the incorporation of methyl groups). An important aspect of this 44 
arrangement of TMC units is that it is noncentrosymmetric in two dimensions. Any 
acentric arrangement of octupolar units (be it octupolar at the supramolecular level or 
not) is an important step forward in the design of materials that display second order 
NLO effects. We have fully explored this 2D acentric arrangement in the design of solid 
state NLO materials that are noncentrosymmetric in three dimensions (Sections 6.3.8-
6.3.14).  
 
 
                                             a                                                                      b 
Figure 6.19 (a) Acentric arrangement of pTA-Py molecules into 44 networks perpendicular 
to the c-axis. (b) Two types of intermolecular interactions: pi⋅⋅⋅pi  stacking of Type-B 
pyridyl and Type-II acid rings (top) and C–H⋅⋅⋅O hydrogen bonds between the ClO4- anion 
and the C–H groups of Type-I acid and Type B pyridyl rings (bottom).  
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6.3.7.4 Stacking of 44 Networks – Acentric TMC Chains along [001] and Centric Pseudo-
Trigonal Layers Parallel to (220) and (1 1 0). Stacking of 44 nets along [001] completes 
the description of crystal structure of pTA-Py. Given that Pccn is a centrosymmetric 
space group, and that the 44 nets themselves are acentric, it is obvious that adjacent 44 
nets are related by an inversion center. This is, in a broad sense, correct. It is, however, 
instructive to analyze the stacking of individual TMC units along [001] (as opposed to the 
stacking of 44 nets as a whole). TMCs stacked along [001] form a chain structure 
(mediated by C–H⋅⋅⋅pi interactions between Type-A pyridyl ring and Type-II acid rings; 
see Figure 6.20) in which adjacent TMCs are 21-axis related. That is, these TMC chains 
along [001] are acentric. Thus, we can pin-point the location of inversion center in terms 
of TMC packing: adjacent TMC chains are inversion related. An analysis of 
intermolecular interactions between TMC units that are related by inversion center 
showed that there are hardly any interactions; the only possible interactions are between 
the para-CH3 groups of two of the Type-I acids and the aromatic ring of Type-A pyridyl 
ligand. The parameters for this interaction are: C⋅⋅⋅pi  = 3.67 Å and C–H⋅⋅⋅pi = 110°. (In 
general, inversion center is expected to maximize close-packing. In this structure, 
however, this statement does not hold true. The lack of maximization of close-packing 
due to inversion suggested to us that we may be able to remove the inversion center by 
suitably substituting the acid ligands.) We therefore expected that moving the CH3 group 
to the meta position would alter interchain packing; this change might as well remove the 
unwanted center of symmetry. 
 
acentric TMC 
chains along [001] adjacent chains 
are inversion related
inversion
center
C-H···pi interactions
methyl C-H···pi
interactions
3.57Å/2.66Å/141o
 
 
Figure 6.20 Trigonal centrosymmetric networks parallel to (220). The C–H⋅⋅⋅pi  interactions 
between Type-A pyridyl and Type-II acid rings lead to the formation of acentric TMC 
chains along [001]. 
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6.3.8 Structures Adopting Acentric 44 and Acentric 36 Networks. In the following 
sections we will describe structures that are designed to adopt 3D noncentrosymmetric 
packing of molecules. This design is based on the 2D acentric 44 network discussed 
above. All the structures to be discussed are crystallized in noncentrosymmetric space 
groups. We begin with the structure of mTA-Py where the CH3 group on the acid ligands 
is relocated to the meta position. We should note here that from the analysis given above, 
we need to relocate CH3 groups on only two of the acid ligands. Such an exercise, 
however, would remove the octupolar symmetry from the TMC unit, and is also 
synthetically demanding. 
 
          
                                   a                                                   b  
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                                                                   c 
Figure 6.21 (a) Molecular structure of mTA-Py complex. Acid rings are colored dark gray 
(Type I) and light gray (Type II), and pyridines rings are colored blue (Type A) and light 
blue (Type B). (b) and (c) Assembly of TMCs in the crystal into acentric 44  [parallel to 
(001)] and 36 networks [parallel to (220)] respectively. 
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6.3.9 Crystal Structure of [Mn3O(mTA)6(Py)3]+[ClO4]-. This TMC crystallizes in the 
noncentrosymmetric space group P21212. As in pTA-Py, the TMC units are located on 
the 2-fold axis along c-axis. Thus, the TMC does not retain its 3-fold molecular 
symmetry in the crystal. Reduction of symmetry means that all acid and pyridyl ligands 
are not equivalent in their packing patterns. As in the previous case, we classified the acid 
and pyridyl groups into Types I and II and Types A and B based on their packing 
characteristics (Figure 6.21a). Again, as in pTA-Py, TMC units are assembled into 
acentric 44 nets based on stacking interactions between Type-II acid rings and Type-B 
pyridyl rings, and C–H⋅⋅⋅O interactions between perchlorate O atoms and benzoate and 
pyridyl CH groups (Figure 6.21b, Tables 6.6 and 6.7). Until the formation of 44 nets, the 
crystal structural features are similar to those in pTA-Py, though there are significant 
differences in the molecular conformations.  
 
The difference between the pTA-Py and mTA-Py structures (in terms of centricity) is that 
adjacent 44 nets in the latter are translation related, as opposed to be inversion (as in the 
case of former). That is structure of mTA-Py is acentric in three dimensions. The 
stacking of 44 nets along [001] can be best visualized by looking at layers of molecules 
along (110) or (1 1 0). Figure 6.21c shows that the molecules are arranged into acentric 
trigonal (36) nets within these 220 layers. Again, TMCs stacked along [001] form an 
acentric chain structure (mediated by C–H⋅⋅⋅pi interactions between Type-I pyridyl ring 
and Type-II acid rings; see Figure 6.21c) in which adjacent TMCs are translation related. 
Adjacent TMC chains are related by a 21-axis (recall that in pTA-Py adjacent chains are 
inversion related); this is the difference that lies at the origin of 3D noncentrosymmetry in 
mTA-Py.  
 
It appears that moving the methyl group from para to meta positions on the acid ligands 
does remove the centrosymmetry as suggested in the previous section. In the following 
sections we will describe five other structures that are similar to mTA-Py in design and 
packing features. That is all the five structures to be discussed below are 
noncentrosymmetric, and all these are based on the acentric 44 net observed in pTA-Py 
and acentric stacking of these nets to complete the 3D structure.  
 
6.3.10 Crystal Structure of [Mn3O(pTA)6(4-Picoline)3]+[ClO4]-CH2Cl2. This TMC 
crystallizes in the noncentrosymmetric space group P212121. The asymmetric unit 
contains a full TMC molecule; though six acid ligands and three pyridyl ligands are 
symmetry independent, they can be again classified into Types I-II and Types A-B sets 
based on their packing patterns (Figure 6.22a). Figures 6.22a and b show the 44 and 36 
nets observed in this structure. Stacking and C–H⋅⋅⋅O interactions (Tables 6.6 and 6.7) 
govern the formation 44 net (only acid groups, but not pyridyl ligands, contribute to C–
H⋅⋅⋅O bonds). Replacing pyridine with 4-picoline elongates the stacking axis (c-axis) 
because it is in this direction that the Type-A pyridyl ligand is projected into the groove 
formed by Type-II acid and Type-B pyridyl ligands in the two structures discussed in 
Sections 6.3.7 and 6.3.8 (see Figure 6.21c). In pTA-Py and mTA-Py structures the Type-I 
pyridyl ligand is tightly held into this groove by short C–H⋅⋅⋅pi interactions; in the current 
pTA-4P structure, the methyl group Type-A 4-picoline ligand is projected into this 
groove, and creates some void space. Solvated CH2Cl2 guest molecules occupy this 
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space. The TMC units along [001] are now held together by a combination of interactions 
between Type-A and Type-B pyridyl ligands, and Type-II acid groups, and the guest 
molecules. The overall structure again is acentric that is built upon acentric 44 and 36 nets 
(Figures 6.22b and c).  
 
 
                                         a                                                           b            
acentric TMC 
chains along [001] adjacent chains 
are 21-axis related
(CH2Cl2)
 
                                                                    c 
Figure 6.22 (a) Crystal structure of pTA-4P complex. (b) Arrangement of TMCs into 44 
networks parallel to (001). (c) Assembly of acentric TMC chains into noncentrosymmetric 
(36) networks parallel to (220). 
 
6.3.11 Crystal Structure of [Mn3O(pTA)6(3-Picoline)3]+[ClO4]-C6H6. This TMC 
crystallizes in the noncentrosymmetric space group P212121 and has a structure that is 
very similar to pTA-4P described above. As in pTA-4P the asymmetric unit contains a 
full TMC molecule; again the acid and pyridyl groups are symmetry independent but can 
be grouped into two sets each (Figure 6.23a). Figures 6.23b and c show 44 and 36 nets in 
this structure. Tables 6.6 and 6.7 show the C–H⋅⋅⋅O and stacking parameters involved in 
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the formation of these nets. As in pTA-4P insertion of methyl group onto pyridyl ring 
creates void space along stacking axis (c-axis) and this time solvated benzene molecules 
fill this space.  
 
 
                                           a                                                       b       
 
                                                                        c 
Figure 6.23 (a) Molecular structure of pTA-3P complex. (b) and (c) Acentric 44 and 36 
networks of TMCs. 
 
6.3.12 Crystal Structure of [Mn3O(mTA)6(4-Picoline)3]+[ClO4]-. This TMC 
crystallizes in the noncentrosymmetric tetragonal space group P 4 21m. The molecule is 
located on a 2-fold axis; acid and pyridyl ligands are grouped into two sets each as before 
(Figure 6.24a). This is the first structure in which the four-fold symmetry of the 44 nets is 
fully realized. In all the structures discussed above (Sections 6.3.7-6.3.10) although the 
structures contained 44 nets, they all adopt low symmetry orthorhombic space groups. As 
far as the packing patterns are concerned this structure is similar to the acentric structures 
above: it has acentric 44 nets (parallel to ab-plane) that are stacked (along c-axis) on each 
other by translation leading to the formation of acentric 36 nets (Figures 6.24b and c). 
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This is not a fully refined structure; in two of the acid groups (Type II) the methyl groups 
are disordered. There appears to be a disordered benzene ring close to these disordered 
methyl groups; the final details of this structure are yet to be determined. 
 
 
                                         a                                                         b        
 
                                                                       c 
Figure 6.24 (a) Molecular structure of mTA-4P complex with disordered Type-A pyridyl 
ligands. (b) and (c) Assembly of TMCs into high symmetry 44 and 36 networks. 
 
6.3.13 Crystal Structure of [Mn3O(3ClBA)6(4-Picoline)3]+[ClO4]-. We have been able 
to grow thin (square-shaped) plate-like crystals of this compound and collect X-ray data 
on them. The quality of the data, however, is poor; so far we have been able to determine 
the unit cell and space group but not the full structure. This TMC, like mTA-4P, 
crystallizes in the noncentrosymmetric tetragonal space group P 4 21m. Based on the 
similarity in cell dimensions of this structure and mTA-4P (Table 6.4), and based on the 
chloro-methyl exchange rule in crystal engineering,32 we expect that this TMC has a 
structure similar to mTA-4P; that is it is 3D acentric built upon acentric 44 and 36 nets.  
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6.3.14 Crystal Structure of [Mn3O(mTA)6(3,4-Lutidine)3]+[ClO4]-. This TMC 
crystallizes in the noncentrosymmetric space group P21212. This structure is also not 
fully refined at this stage, but the positions of non-H atoms that were refined so far 
clearly indicate the overall structural details. The TMC units are located on the 2-fold 
axis along c-axis. As before, acid and pyridyl ligands can be grouped into two sets each 
(Figure 6.25a). All the pyridyl ligands (Types A and B) are disordered such that 3,4-
Lutidine rings appear as though they are 3,4,5-collidine rings; two of the acid ligands 
(Type II) are disordered such that they appear as 3,5-dimethylbenzoate rings. The 
structure is similar to the acentric structures above; it is built up on acentric 44 and 36 
nets, again through stacking and C–H⋅⋅⋅O interactions. As expected the methyl groups on 
the pyridyl rings create void space and solvated benzene molecules occupy this space.  
 
   
                                         a                                                        b              
 
                                                                       c 
Figure 6.25 (a) Disordered molecular structure of mTA-34Lu complex. (b) and (c) 
Assembly of TMCs into 44 and 36 networks. 
 
The results presented in Sections 6.3.7 to 6.3.13 clearly show that 3D 
noncentrosymmetric structures can be designed with confidence within a subset of 
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charged TMC systems. All these structures contain, consistently, acentric 44 and 36 
networks. The ability to design such a large number of acentric solids within a family of 
octupolar molecules has not been achieved so far. One additional feature to note in these 
systems is that the TMCs have complex 3D shape and adopted a range of molecular 
conformations within these acentric solids. Despite this complexity, the TMCs fit well for 
the design of predictable solid state structures. We conclude our discussion of TMCs here 
and in the following sections we will discuss two other clusters with increased nuclearity. 
 
6.4 CLUSTERS OF HIGHER NUCLEARITY 
 
During the course of TMC synthesis, we have discovered two clusters of higher 
nuclearity. These clusters were formed, unexpectedly, when we used di or triaza ligands. 
We have not yet optimized these syntheses. In the following section these clusters are 
presented along with their synthesis. 
 
6.4.1 Synthesis and Structure of Mn6(OOCR)10(CH3CN)4. A mixture of 
Mn(O2CMe)2·4H2O (2.0g, 8.15 mmol), p-toluic acid (10.1g, 74.18 mmol) and triazine 
(1.0g, 12.36 mmol) were dissolved in 25 mL of absolute EtOH. To this solution was 
added nBu4NMnO4 (1.14g, 3.15 mmol) in small portions. Immediately after adding the 
permanganate, NaClO4 (0.69g, 5.65mmol) was added in portions and the mixture was 
stirred for 1h. The product was collected by filtration and dried in vacuo. 
Recrystallization was carried out in acetonitrile and thin needle shaped crystals were 
collected after two days. The structure of this cluster is shown below. We will explore the 
geometry of this cluster to see if any extended networks can be built from it. 
 
 
Figure 6.26. Molecular structure of Mn6(OOCR)10(CH3CN)4 complex (ellipsoid mode). 
Hydrogen atoms are omitted for clarity. 
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6.4.2 Synthesis, Structure, and Magnetic Properties of Mn13-µ3O2-
µ5O6(OOCR)12(C2H5O)6. A mixture of Mn(O2CMe)2·4H2O (0.20g, 0.81 mmol), m-toluic 
acid (0.836g, 6.14 mmol) and pyrimidine (1mL, 12.6 mmol) were dissolved in 25 mL of 
absolute EtOH. To this solution was added nBu4NMnO4 (0.05g, 0.12 mmol) in small 
portions. The mixture was stirred for 1h and the product was left undisturbed overnight in 
the refrigerator. The gray product was collected by filtration and dried in vacuo. 
Recrystallization was carried out in EtOH. After ~2 weeks gold microcrystals with needle 
shapes of the desired product were obtained. 
 
Structural analysis showed that the cluster contains 13 Mn ions in three oxidation states 
and two environments. Figure 6.27a shows the core of the cluster which is made of 13 
Mn ions (one Mn4+, six Mn3+, and six Mn2+) 12 benzoate ligands, 8 oxide ligands (two in 
µ3 and six in µ5 coordination), and six ethoxide ligands. From Figure 6.27a we can see 
that the core of the cluster has cubic geometry; we call this core ‘super cube’ cluster.  
 
The most interesting aspect of this cluster is that the 12 benzoate ligands are projected 
away from the cube in an octahedral fashion. We hope to develop this cluster as an 
octahedral node from which to generate porous network with simple cubic geometry, 
much in the same way as Yaghi uses Zn4O octahedral nodes to build porous solids (see 
Figure 6.7b).25 
 
  
                               a                                                                   b 
Figure 6.27 Molecular structure of Mn13-µ3O2-µ5O6(OOCR)12(C2H5O)6 cluster. (a) Core 
of the cluster (without benzoate and ethyl groups) showing the ‘super cube’. (b) Full 
structure of the cluster showing the octahedral disposition of the twelve benzoate rings. 
Hydrogen atoms are omitted for clarity.  
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6.5 SUMMARY AND CONCLUSION 
 
Crystallographic data presented above show that we are able to synthesize octupolar 
molecular materials containing Mn-carboxylate clusters. By changing the acid and 
pyridine derivatives we can design 3D noncentrosymmetric arrangements of charged 
TMCs in solid state. To date we have collected X-ray data, refined and analyzed 
structures only of charged TMCs. Future work should be focused on crystal growth, X-
ray data collection, structure refinement and analysis of remaining charged and neutral 
trigonal clusters, to explore similarities and differences among these neutral and charged 
clusters. In this work, to make the TMCs we were using Mn metal, which has octahedral 
geometry. It would be also interesting to study NLO effects of TMCs made of other 
metals. Other metals that could be explored for the synthesis of the new TMCs in this 
work are: Fe, Cr, Zn, Ru, Ir, Rh and V, with those acid and pyridine derivatives that 
produced successful noncentrosymmetric materials.  
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